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Summary 
 
Carbamoyl phosphate synthetase 1 (CPS1), a 1462-residue mitochondrial 
enzyme, catalyzes the entry of ammonia into the urea cycle, which converts 
ammonia, the neurotoxic waste product of protein catabolism, into barely toxic 
urea. The urea cycle inborn error and rare disease CPS1 deficiency (CPS1D) is 
inherited with mendelian autosomal recessive inheritance, being due to CPS1 
gene mutations (>200 mutations reported), and causing life-threatening 
hyperammonemia. 
 
We have produced recombinantly human CPS1 (hCPS1) in a baculovirus/insect 
cell expression system, isolating the enzyme in active and highly purified form, 
in massive amounts. This has allowed enzyme crystallization for structural 
studies by X-ray diffraction (an off-shoot of the present studies). This hCPS1 
production system allows site-directed mutagenesis and enzyme 
characterization as catalyst (activity, kinetics) and as protein (stability, 
aggregation state, domain composition). We have revealed previously 
unexplored traits of hCPS1 such as its domain composition, the ability of 
glycerol to replace the natural and essential CPS1 activator N-acetyl-L-
glutamate (NAG), and the hCPS1 protection (chemical chaperoning) by NAG 
and by its pharmacological analog N-carbamyl-L-glutamate (NCG).  
 
We have exploited this system to explore the effects on the activity, kinetic 
parameters and stability/folding of the enzyme, and to test the disease-causing 
nature, of mutations identified in patients with CPS1 deficiency (CPS1D). 
These results, supplemented with those obtained with other non-clinical 
mutations, have provided novel information on the functions of three non-
catalytic domains of CPS1. 
 
We have introduced three CPS1D-associated mutations and one trivial 
polymorphism in the glutaminase-like domain of CPS1, supporting a stabilizing 
and an activity-enhancing function of this non-catalytic domain. Two mutations 
introduced into the bicarbonate phosphorylation domain have shed light on 
bicarbonate binding and have directly confirmed the importance of this domain 
for NAG binding to the distant (in the sequence) C-terminal CPS1 domain. The 
introduction of 18 CPS1D-associated missense mutations mapping in a 
clinically highly eloquent central non-catalytic domain have proven the disease-
causing nature of most of these mutations while showing that in most of the 
cases they trigger enzyme misfolding and/or destabilization. These results, by 
proving an important role of this domain in the structural integration of the 
multidomain CPS1 protein, have led us to call this domain the Integrating 
Domain. 
 
  
 
      
Finally, we have examined the effects of eight CPS1D-associated mutations, of 
one trivial polymorphism and of five non-clinical mutations, all of them 
mapping in the C-terminal domain of the enzyme where NAG binds, whereas 
we have re-analyzed prior results with another four clinical and five non-
clinical mutations affecting this domain. We have largely confirmed the 
pathogenic nature of the clinical mutations, predominantly because of decreased 
activity, in many cases due to hampered NAG binding. A few mutations had 
substantial negative effects on CPS1 stability/folding. Our analysis reveals that 
NAG activation begins with a movement of the final part of the β4-α4 loop of 
the NAG site. Transmission of the activating signal to the phosphorylation 
domains involves helix α4 from this domain and is possibly transmitted by the 
mutually homologous loops 1313-1332 and 778-787 (figures are residue 
numbers) belonging, respectively, to the carbamate and bicarbonate 
phosphorylation domains. These two homologous loops are called from here on 
Signal Transmission Loops.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
      
Resumen 
 
La carbamil fosfato sintetasa 1 (CPS1), una enzima mitocondrial de 1462 
residuos, cataliza la entrada del amonio en el ciclo de la urea, que convierte esta 
neurotoxina derivada del catabolismo de las proteínas en urea, que es mucho 
menos tóxica. El déficit de CPS1 (CPS1D) es un error innato del ciclo de la 
urea, una enfermedad rara con herencia mendeliana autosómica recesiva, que se 
debe a mutaciones en el gen CPS1 (>200 mutaciones descritas) y que cursa con 
hiperamonemia. 
Hemos producido CPS1 humana recombinante (hCPS1) en un sistema de 
expresión de células de insecto y baculovirus, y la hemos aislado en forma 
activa y muy pura y en cantidad elevada. Ello ha permitido la cristalización de 
la enzima para estudios estructurales de difracción de rayos-X (un trabajo 
derivado de esta tesis pero no incluido en ella). Este sistema de producción de 
hCPS1 permite la realización de mutagénesis dirigida y la caracterización de la 
enzima como catalizador (actividad, cinética) y como proteína (estabilidad, 
estado de agregación y composición de dominios). Hemos revelado 
características de la hCPS1 antes no exploradas como es la composición de 
dominios, la capacidad que tiene el glicerol para reemplazar al activador natural 
y esencial de la CPS1, N-acetil-L-glutamato (NAG), y la protección de la 
hCPS1 por NAG y por su análogo farmacológico N-carbamil-L-glutamato 
(NCG) (chaperonas químicas). 
Hemos utilizado este sistema para explorar los efectos en la actividad, los 
parámetros cinéticos y la estabilidad/plegamiento de la enzima, y para 
comprobar la naturaleza patogénica de mutaciones identificadas en pacientes 
con CPS1D. Estos resultados, junto con los obtenidos con otras mutaciones no 
clínicas, han aportado información novedosa sobre tres de los dominios no 
catalíticos de la CPS1. 
Las observaciones realizadas tras introducir en el dominio de tipo glutaminasa 
de la enzima tres mutaciones asociadas a CPS1D y un polimorfismo trivial, 
apoyan la contribución de este dominio no catalítico a la estabilidad y a 
aumentar la actividad de la enzima. Dos mutaciones introducidas en el dominio 
de fosforilación de bicarbonato han arrojado algo de luz sobre el modo de unión 
del bicarbonato (un sustrato). Los resultados de estas mutaciones también han 
confirmado la contribución de este dominio para la unión de NAG, cuyo sitio 
de unión se encuentra en el dominio C-terminal de CPS1, bastante alejado (en 
la secuencia) del dominio de fosforilación de bicarbonato. Además, hemos 
introducido 18 mutaciones de cambio de sentido asociadas a CPS1D, las cuales 
están localizadas en un dominio no catalítico, central y de elevada elocuencia 
clínica. Estos resultados han demostrado la naturaleza patogénica de estas 
mutaciones, ya que en la mayoría de los casos estas mutaciones producen un 
mal plegamiento o/y desestabilización de la enzima. Debido a que estos 
resultados han puesto de manifiesto el importante papel de este dominio en la 
  
 
      
integración estructural de la proteína multidominio CPS1, lo hemos llamado 
Dominio Integrador. 
Finalmente, hemos examinado los efectos de ocho mutaciones asociadas a 
CPS1D, de un polimorfismo trivial y de cinco mutaciones no clínicas, todas 
ellas localizadas en el dominio C-terminal de la enzima, donde se une NAG. 
Además, hemos reanalizado resultados anteriores con otras cuatro mutaciones 
clínicas y cinco no clínicas afectando a este dominio. Hemos confirmado el 
carácter patogénico de las mutaciones clínicas, las cuales predominantemente 
causan una disminución en la actividad enzimática, en muchos casos debida a 
que la unión de NAG se encuentra obstaculizada. Unas pocas mutaciones 
mostraron efectos negativos sustanciales en la estabilidad/plegamiento de la 
CPS1. Nuestros análisis revelan que la activación por el NAG empieza con un 
movimiento de la parte final del bucle β4-α4 del sitio de NAG. La transmisión 
de la señal activadora a los dominios de fosforilación implica a la hélice α4 de 
este dominio y posiblemente se transmite a través de los bucles homólogos 
1313-1332 y 778-787 (numeración de los residuos) pertenecientes, 
respectivamente, a los dominios de fosforilación de carbamato y bicarbonato. 
Por ello, hemos llamado a ambos bucles homólogos Bucles de Transmisión de 
la Señal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
      
Resum 
 
La carbamil fosfat sintetasa 1 (CPS1), un enzim mitocondrial de 1462 residus, 
catalitza l'entrada d'amoni en el cicle de la urea, que convertix l'amoni, producte 
neurotòxic del catabolisme de les proteïnes, en urea, una molècula molt poc 
tòxica. El dèficit de CPS1 (CPS1D) és un error innat del cicle de la urea, una 
malaltia rara amb herència mendeliana autosòmica recessiva, que es deu a 
mutacions en el gen CPS1 (>200 mutacions descrites) i que cursa amb 
hiperamonièmia. 
 
Hem produït CPS1 humana recombinant (hCPS1) en un sistema d'expressió de 
cèl·lules d'insecte i baculovirus, i l'hem aïllada en forma activa i molt pura i en 
gran quantitat. Això ha permés la cristal·lització de l'enzim per a estudis 
estructurals amb difracció de raios-X (treball no inclòs en esta tesi). Aquest 
sistema de producció de hCPS1 permet la realització de mutagènesi dirigida i la 
caracterització de l'enzim com a catalitzador (activitat, cinètica) i com a 
proteïna (estabilitat, estat d'agregació i composició de dominis). Hem revelat 
característiques de la hCPS1 no explorades abans com és la composició de 
dominis, la capacitat que té el glicerol per a reemplaçar l'activador natural i 
essencial de CPS1, N-acetil-L-glutamat (NAG), i la protecció de la hCPS1 per 
NAG i pel seu anàleg farmacològic N-carbamil-L-glutamat (NCG) (xaperones 
químiques) . 
 
Hem utilitzat aquest sistema per a explorar els efectes en l'activitat, els 
paràmetres cinètics i l'estabilitat/plegament de l'enzim, i per a comprovar la 
naturalesa patogènica de mutacions identificades en pacients amb CPS1D. 
Aquestos resultats, junt amb els obtinguts amb altres mutacions no clíniques, 
han aportat informació nova sobre tres dels dominis no catalítics de la CPS1. 
 
Les observacions, després d'introduir tres mutacions associades a CPS1D i un 
polimorfisme trivial en el domini tipus glutaminasa de CPS1, recolzen la 
contribució d'aquest domini no catalític a l'estabilitat i a l'optimització de 
l'activitat enzimàtica. Dues mutacions introduïdes en el domini de fosforilació 
de bicarbonat han esclarit el mode d'unió de bicarbonat. Els resultats d'aquestes 
mutacions també han confirmat la contribució d'aquest domini per a la unió de 
NAG, el lloc d'unió de la qual es troba en el domini C-terminal de CPS1, prou 
allunyat (en la seqüència) del domini de fosforilació de bicarbonat. A més, hem 
introduït 18 mutacions de canvi de sentit associades a CPS1D, les quals estan 
localitzades en un domini no catalític, central i d'elevada eloqüència clínica. 
Aquestos resultats han demostrat la naturalesa patogènica d'aquestes mutacions, 
ja que, en la majoria dels casos produïxen un mal plegament o/i 
desestabilització de l'enzim. Pel fet que aquestos resultats han posat de manifest 
  
 
      
l'important paper d'aquest domini en la integració estructural de la proteïna 
multidomini CPS1, l'hem anomenat Domini Integrador. 
 
Finalment, hem examinat els efectes de huit mutacions associades a CPS1D, un 
polimorfisme trivial i cinc mutacions no clíniques, totes elles localitzades en el 
domini C-terminal de l'enzim, on s'unix NAG. A més, hem reanalitzat resultats 
anteriors amb altres quatre mutacions clíniques i cinc no clíniques que afecten 
aquest domini. Hem confirmat el caràcter patogènic de les mutacions clíniques, 
les quals predominantment causen una disminució en l'activitat enzimàtica, en 
molts casos pel fet que la unió de NAG es troba obstaculitzada. Unes poques 
mutacions van mostrar efectes negatius substancials en l'estabilitat/plegament 
de CPS1. Les nostres anàlisis revelen que l'activació de NAG comença amb un 
moviment de la part final del bucle β4-α4 del lloc de NAG. La transmissió del 
senyal activadora als dominis de fosforilació involucra l'hèlix α4 d'aquest 
domini i es transmet, possiblement, a través dels bucles homòlegs 1313-1332 i 
778-787 (numeració dels residus), pertanyents, respectivament, als dominis de 
fosforilació de carbamato i bicarbonat. Per això, hem anomenat a ambdós 
bucles homòlegs Bucles de Transmissió del Senyal. 
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Non-standard Abbreviations 
 
3D: Three-dimension 
6xHis or His6-tag: 6 histidine tag 
AcNPV: Autographa californica nuclear polyhedrosis virus  
ALT: Alanine transaminase 
AMPPNP: Adenylyl-imidodiphosphate 
ARG1: Arginase type 1 
ASD: C-Terminal allosteric domain of CPS1 
ASL: Argininosuccinate lyase 
ASS: Argininosuccinate synthetase 
AST: Aspartic transaminase 
ATC: Aspartate transcarbamylase  
attTn7: Target site of the Tn7 transposon 
BPSD: Bicarbonate phosphorylation domain of CPS1 
CAD: Multifunctional polypeptide that catalyzes the initial three steps of 
pyrimidine biosynthesis. It is composed of CPS II, dihydroorotase and aspartate 
transcarbamylase (in this order from N-terminus to C-terminus) 
CP: Carbamoyl-phosphate 
CPS: Carbamoyl-phosphate synthetase  
CPS1: CPS devoted to making urea. It uses ammonia and is NAG-activated 
CPS1D: Deficiency of CPS1 
CPSII: CPS used for making pyrimidines in eukaryotes 
CPSIII: CPS devoted to making urea in fishes. It uses glutamine but it is 
activated by NAG. 
CPSD: Carbamate phosphorylation domain of CPS1 
Chymo: Chymotrypsin 
DHO: Dihydroorotase 
DTT and dithiothreitol: 1,4-dithio-D-threitol   
ABBREVIATIONS 
 
II 
 
 
FUM: Fumarase 
G6PDH: glucose-6-phosphate dehydrogenase 
GDH: L-Glutamate dehydrogenase 
GLNase: Glutaminase 
GSD: Glutaminase-like domain of CPS1 
hCPS1 or hCPS: human CPS1 
HK: Hexokinase 
ID: Integrating domain, a central domain of CPSs 
ISD: Most N-terminal domain of CPS1 
Ka: For hyperbolic activation, concentration of the activator that causes half-
maximal activation 
Kana: Kanamycin 
LacZ α: Gene for α peptide of LacZ 
LDH: Lactate dehydrogenase 
MDH: Malate dehydrogenase 
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OMIM or MIM:  Online Mendelian Inheritance in Man, the online version of 
the McKusick book, "Mendelian Inheritance in Man", a repertoire of genetic 
diseases and pathology-relevant human genes and gene products. It gives a 
number code to each reported genetic disease. Can be accessed freely at 
http://www.ncbi.nlm.nih.gov/omim 
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1.1 Biological context and scope of this thesis 
 
Carbamoyl-phosphate synthetases (CPSs) are complex multidomain enzymes 
[1-3] that catalyse the synthesis of carbamoyl phosphate (CP) from two 
molecules of ATP and one molecule of each bicarbonate and ammonia (Fig. 1). 
Ammonia is used as such by the enzyme that is responsible for initiating the 
urea cycle and which is the subject of this study, CPS1. However, all other 
CPSs use ammonia derived internally from glutamine, an amino acid that is 
hydrolyzed by these other types of CPS. 
 
Search for CPS sequences in the many genomes deposited in sequence 
databases reveals that CPSs are present in virtually all organisms. The wide 
species distribution of CPSs reflects the fact that carbamoyl phosphate (CP) is 
the initial precursor of pyrimidines [4-6] and arginine [6-9]. Arginine is a 
crucial amino acid. It is a key protein component, and a precursor of nitric 
oxide, creatine, polyamines, agmatine and proline (Fig. 1) [10]. Furthermore, in 
some fishes, in amphibians and mammals, arginine has a central role in urea 
production. In these last two types of vertebrates urea is synthesized to get rid 
of ammonia. By catalyzing the entry of ammonia into the urea cycle, CPS1 has 
paramount importance in these organisms for ammonia detoxification [11].  
 
 
 
 
 
 
 
This thesis work deals with human CPS1 and with its deficiency (CPS1D) 
(OMIM #237300; http://www.ncbi.nlm.nih.gov/omim). CPS1D is an autosomal 
recessive inborn error of the urea cycle, which causes hyperammonemia, 
potentially leading to death or mental retardation [12]. More than 200 CPS1D-
associated mutations have been reported in the CPS1 gene (located in 2q34). 
The majority of these mutations are missense changes (Fig. 2). In many cases, 
the disease-causing role of these missense mutations is unproven [12]. This 
situation was recently alleviated when our group reported [13] a 
baculovirus/insect cell expression system that permitted in vitro production of 
rat CPS1, opening the way for accessible site-directed mutagenesis studies with 
this enzyme [14].  
Figure 1. Roles of carbamoyl phosphate 
synthetases. Blue arrows, CPS reaction. 
Black arrows,  metabolic conversions in 
which the indicated molecules are involved. 
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The present work adapts this baculovirus/insect cell expression system to 
endow it with the ability to produce human CPS1. Recombinant human CPS1 is 
produced and characterized here, showing that it has essentially the same 
properties as human CPS1 obtained from its natural source (the liver) [15,16]. 
With the recombinant enzyme we have been able to examine properties of 
human CPS1 that had not been studied previously, such as the domain 
composition of the enzyme. Furthermore, abundant expression of recombinant 
human CPS1 has opened the way to crystallographic studies that are 
culminating in the determination of the crystal structure of the human enzyme 
(collaborative work with other group members not reported here).  
 
In the recent mutational repertory of CPS1D [12] the density of missense 
mutations was found not to be constant along the CPS1 gene and protein. A 
particularly high frequency of missense mutations was identified in a central 
domain of CPS1 having no known function. We have applied here the 
baculovirus/insect cell expression system to investigate by site-directed 
mutagenesis the effects on the functionality and stability of human CPS1 of all 
the missense mutations mapping in this central domain that were reported in 
CPS1D patients. With this approach we aimed at testing the disease-causing 
role of these mutations and also to determine the functions of this central 
domain and to clarify the reasons for the high mutational eloquence in CPS1D.  
 
We also present here a site-directed mutagenesis study of the C-terminal 
domain of human CPS1, a domain called the allosteric domain [1-3] because it 
hosts the site for the essential allosteric activator of the enzyme, N-acetyl-L-
Figure 2. The CPS1 coding sequence split into its different exons (bottom), to show the 
location of the different missense mutations (banners) recently compiled or reported in 
CPS1 deficiency [12]. The figure aims at giving a view of the abundance and 
spreading of the mutations over the entire sequence, rather than to give specific 
information on each mutation (blurred because the figure has been taken from the 
original publication [12], being a part of Fig. 1 of that publication).  
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glutamate (NAG) [13,17]. Our study includes the expression of patient-
identified and of rationally designed mutations as well as the analysis of the 
effects of already studied  mutations mapping in this domain either as a part of 
the present work (Chapter 1 of the Results) or of previous work of other group 
members with recombinant CPS1 from rat [13,14]. This study has not only 
provided insight into disease-causation but also has shed important light into 
the process of NAG activation.  
 
The Results section of this thesis is composed of three chapters corresponding 
to three manuscripts (two of them published, one under review). Since these 
manuscripts have their own introductions, this general introduction will aim at 
providing a broader context for the present work, trying to avoid repetitions and 
redundancies. 
 
 
1.2 The urea cycle and the consequences of its derangements 
 
In vertebrates, ammonia, the final nitrogenous waste product of protein and 
amino acid catabolism, is a strong neurotoxin [18,19] that has to be eliminated 
from the organism. Fishes can do it by direct dilution in the surrounding water. 
Reptiles and birds, generally having limited water access particularly during 
development, convert the waste nitrogen into uric acid, a highly insoluble 
purine derivative that precipitates out of solution. In the case of mammals the 
viviparous foetus is mainly ammonotelic (meaning excretion of ammonia) 
during development, with the mother being in charge of ammonia disposal, 
which in this case occurs by conversion to urea (ureotelism) [20,21]. 
 
Urea [22] is the diamide of carbonic acid, a simple molecule consisting of one 
atom of each carbon and oxygen, of two atoms of nitrogen and four atoms of 
hydrogen. Since the dissociation of amidic hydrogens has very high pK values, 
urea is not an acid at body pH or even at urinary pH. Given the high polarity of 
the O and N atoms and the presence of four hydrogen atoms linked to nitrogen 
atoms, it can be dissolved in water at supramolar concentrations. Consequently, 
urea can be concentrated much in the urine of mammals, which have generally 
enough water availability to prevent its crystallization there. The kidneys have 
developed urea-impermeable tubules. In this way, while most of the water 
filtered in the glomerulus is resorbed later on, the urea is concentrated in the 
urine and becomes the main nitrogenous waste product [23]. Furthermore, 
perhaps because of the non-dissociability of its hydrogens, urea is little toxic, 
and thus it is tolerable to the body at much higher concentration than ammonia 
[24].  
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Krebs, together with Henseleit, proposed eighty three years ago how ammonia 
was converted to urea in mammals, creating the concept of metabolic cycle 
(Fig. 3) [25,26]. The original (as redrawn by Krebs in 1976) and a more recent 
view [27] of this cycle are shown in Fig. 3. 
 
 
 
 
NAGS, NAG synthase; OTC, ornithine transcarbamylase; ASS, argininosuccinate 
synthetase; ASL, argininosuccinate lyase; ARG1, arginase type 1; GLNase, 
glutaminase; GDH, glutamate dehydrogenase; AST, aspartic transaminase; ALT, 
alanine  transaminase; MDH, malate dehydrogenase; LDH, lactate dehydrogenase; 
FUM, fumarase. 
Mitochondrion
Cytosol
Citrulline
Ornithine
Aspartate
Urea
ARG1
OTC
NH3 + HCO3
-
Carbamoyl-
phosphate
Glutamate
N-Acetyl-
L-glutamate
Fumarate
Argininosuccinate
Malate
+ 2 ATP
+ 1 ATP
+
Oxalacetate
Aspartate cycle
Urea cycle
Orotic acid
UMP
Citrulline
ASL
ASS
+
Glutamine
Acetyl CoA
GLNase
Urine
Arginine
NAD(P)
NAD(P)H
-Keto-
glutarate
Ornithine
GDH
Oxalacetate
CPS1
Aspartate
-Ketoglutarate Glutamate
Alanine PyruvateALT
Portal blood
NAGS
AST
+ H2O
ORNT1
ORNT1
Citrin
Carbamoyl phosphate
AST
Lactate
NADH NAD
MDH
LDH
OMP Orotidine
FUM
Suprahepatic blood
Uridine, Uracil
+ H2O
Figure  3. Early (left) and present (down) 
views of the urea cycle. The view on the left 
is as originally formulated by Krebs, in a 
drawing of this author in 1976 [26]. The 
view down (courtesy of Drs. Häberle and 
Rubio) of this cycle (orange arrows) includes 
ancillary reactions (other arrows). The 
relation with pyrimidine synthesis is shown 
also. Enzymes and transporters are shown in 
red and boxed.  
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In mammals, the urea cycle is found in complete form exclusively in 
hepatocytes, excepting the perivenous hepatocytes, which convert the ammonia 
to glutamine instead of to urea [28]. The cycle is split into cytosolic and 
intramitochondrial compartments, with the two initial steps, including the step 
of carbamoyl phosphate synthesis, being localized in the mitochondrial matrix 
(Fig. 3) [7,11].  
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Figure 4. Total liver activities of the different urea cycle enzymes (abbreviated as in 
Fig. 3) given as product synthesis per day for a 1.5 kg liver. Derived from enzyme 
activity data in homogenates of human liver biopsies [29] assayed at optimal pH and 
substrate concentrations. Note the very high activities of OTC and ARG1 (268 and 3528 
mole/day). The arrow indicates urea production per day for an intake of 60 g protein 
per day. Modified from ref. [11]. 
 
Fig. 4 shows the relative activities of the different urea cycle enzymes [29] in 
an entire human liver, given as ability to make urea per day, and compared with 
the need to make urea in an adult consuming a normal diet (containing 60g 
protein day). It can be seen that, in principle, there is considerable functional 
reserve, and that CPS1 is among the three enzymes with the lowest activity 
among all the urea cycle enzymes. Complete absence of any urea cycle enzyme, 
particularly of those catalysing the two initial steps (CPS1 and ornithine 
transcarbamylase), causes hyperammonemia, which, given the neurotoxicity of 
ammonia, soon leads to coma and death [27, 30]. Because of the considerable 
functional reserve (Fig. 4), heterozygous individuals for any urea cycle catalyst 
(except for the X-chromosome-encoded ornithine transcarbamylase) should not 
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present pathology. Furthermore, since the heterozygous mother can take care of 
disposal of the ammonia made by the foetus, the hyperammonemic phenotype 
of individuals with complete deficiency is only manifested after birth, when the 
connection with the mother is lost and the newborn has to cope with the 
challenge to dispose of ammonia to urea using his/her own urea cycle enzymes. 
 
Complete enzyme deficiency, at least of the initial two steps of the urea cycle, 
is therefore constantly associated with neonatal hyperammonemia (called "early 
onset" or "neonatal presentation") and death by approximately 72 hours after 
birth [27,30]. However, given the important functional reserve, patients with 
partial deficiencies caused by low but not zero enzyme levels or by "kinetic" 
enzyme variants having high Km values for the substrates (and also, in the case 
of CPS1, for the essential activator NAG) have in many cases enough enzyme 
activity to cope with the normal burden of ammonia detoxification, presenting 
with hyperammonemia only when the system is overloaded with ammonia, as 
in catabolic situations caused by fever and infections, trauma, surgery, delivery, 
or in peaks of protein intake [30]. In these cases the neonate may not present 
early onset hyperammonemia after birth, having a delayed course that can have 
either a late onset presentation early in life or even much later, when growth 
rate (and thus, protein generation for building the body) decreases, or even in 
adult life. Nevertheless, even in late onset cases the outcome may be equally 
dramatic as in neonatal cases, since hyperammonemic crises can be deadly or 
can cause mental retardation irrespective of the level of residual enzyme 
activity [30].  
 
Although outside the scope of this work, it is important to mention that there 
are effective therapeutic measures [30] that can be applied to patients with urea 
cycle disorders to change the natural course of the disease and even to cure it, 
rendering it essential to apply therapy promptly and aggressively. Our present 
work can be related to the diagnosis and treatment of urea cycle deficiency 
because of the following:  
 
1) Specific disease diagnosis is now based on the detection of genetic lesions 
[12], which are in many cases missense mutations. Characterization of the 
effects of these mutations may not only help decide whether a given missense 
mutation is or is not disease-causing, but can also provide insight on its severity 
and the need to be prepared for treatment in cases in which the presence of a 
given mutation in the foetus is known before delivery. 
 
2) Specific prognostic judgements associated with the approach used in our 
present work can guide therapeutic decisions. For example, the identification of 
highly severe mutations would be an indication for particularly close 
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monitoring of the patient and might help tilt the balance in the direction of, for 
example, enrolling in liver cell therapy (presently an experimental treatment) 
and/or in liver transplantation as soon as possible. 
 
3) Identification of specific traits that could suggest susceptibility to given 
therapies. In the case of CPS1D this is related only, for the moment, to N-
acetyl-L-glutamate (NAG) activation (discussed below), since there is a 
pharmacologic NAG analog and registered orphan drug, N-carbamylglutamate 
[31], that could be tested for efficiency in those patients having CPS1 mutations 
in which the affinity for NAG is decreased, such as those that are the subject of 
Chapter 3 of the Results. 
 
4) Development of CPS1-stabilizing therapies. Pharmacological chaperones for 
treating inborn errors have gained momentum after the discovery that the 
cofactor used by phenylalanine hydroxylase, tetrahydrobiopterin, can be used in 
the therapy of phenylketonuria, having been found to increase the level of the 
enzyme "in vivo" by increasing the stability of the enzyme [32]. As it will be 
shown in Chapter 1 of the Results, we provide here promising findings with 
carbamylglutamate that may herald this approach in the treatment of CPS1D. 
 
In the next two sections we will concentrate on highlighting the biological 
significance of CPS1 as well as to review our knowledge on this enzyme. 
 
 
1.3 Biological significance of CPS1 and of its allosteric regulation by NAG 
  
Human CPS1 is inactive in the absence of NAG [16]. Since rodent studies 
[33,34] indicate that the level of NAG depends on the metabolic situation, 
CPS1 can be considered a true switch for turning the urea cycle on or off 
depending on the availability of NAG.  
 
Why should the urea cycle have such a switch? The most reasonable 
explanation stems from the fact that ammonia is not only a toxin but also an 
essential life component. Although ammonia levels cannot be allowed to be too 
high, because of brain toxicity, they should not be too low either. Ammonia is 
in equilibrium with several non-essential amino acids (such as serine, 
glutamine, asparagine, glutamate and via glutamate with other amino acids) 
[35] and the levels of these amino acids would decrease with the ammonia 
level. Therefore, the activity of the urea cycle cannot be controlled exclusively 
by the availability of ammonia, because this would lead to ammonia depletion, 
and thus to drainage of amino acids and of proteins. NAG is synthesized in the 
same cells and cell compartment (the mitochondrial matrix) where CPS1 is 
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present. It is made by a dedicated enzyme that uses acetyl-CoA and L-glutamate 
[36]. Since NAG has a short t1/2 [37] and NAGS has a high Km value for 
glutamate [36], the NAG levels is a true sensor of the nitrogen load reflected in 
the level of glutamate (Fig. 5).  
Why was acetylglutamate chosen by natural selection for such role instead of 
glutamate? The answer to this question is not clear. The choosing of NAG as 
the CPS1 effector was a relatively recent occurrence, since NAG is a CPS 
activator only in animals. The CPSs from more ancient taxonomic groups 
(including bacteria, archaea and plants) are insensitive to NAG [1-9]. Actually, 
in these organisms NAG is the first committed precursor of ornithine and thus 
of arginine [8,9] (Fig. 6, left panel). Interestingly, as discussed below, the NAG 
site of CPS1 is equivalent to the site of Escherichia coli CPS for IMP [13], a 
purine nucleotide that activates this bacterial CPS [6]. Therefore, at some 
moment in the evolution towards animal arginine biosynthesis all the genes for 
the enzymes that catalyze the conversion of NAG into ornithine were lost, with 
exclusive preservation of NAG synthase, which became exclusively devoted to 
making NAG for the purpose of CPS1 activation (Fig. 6, right panel). 
Simultaneously CPS must have shifted its allosteric activator specificity from 
IMP to NAG losing the ability to be activated by ornithine (another 
characteristic of many bacterial CPSs) [6]. Further evolution also involved an 
Mitochondrion
Citrulline
Ornithine
Aspartate
Urea
ARG1
OTC
Carbamoyl-
phosphate
Glutamate
N-Acetyl-
L-glutamate
Fumarate
Argininosuccinate
+ 2 ATP
+ 1 ATP
+
Urea cycle
Citrulline
ASL
ASS
+
Acetyl CoA
Arginine
Ornithine
CPS1
NAGS
+ H2O
ORNT1
ORNT1
Amino 
acids
Proteins
NH3 + HCO3-
Figure 5. Role of NAG as a safety switch for preventing amino acid and protein depletion. 
For further details see the text. 
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increase in the on/off ratio of activities of the enzyme depending on whether is 
present or is not present, since bacterial CPSs are active in the absence of any 
effectors [6], fish CPSIII (another type of arginine-making CPS considered a 
close predecessor of CPS1) is partially dependent on the presence of NAG [38], 
whereas CPS1 has a complete dependency on this activator [16,39], 
representing an extreme case of allosteric activation [40]. 
  
L-glutamate
NAG
AcCoA
CoA
Acetylornithine
L-ornithine
H2O
Acetate
NAG-5-Pi
ATP
ADP
L-Gln 
+ 2ATP  
+ HCO3
-
CarbamPi
L-citrulline
NAGS
NAGK
Deacylase
CPS
+
-
L-arginine
+ 2ATP  
CPS1-ACTIVATING
FUNCTION
L-glutamate
NAG
AcCoA
CoA
NH3
+ HCO3
-
NAGS
CPS I
+
L-citrulline
L-arginine
L-ornithine
Urea
CarbamPi
+
BIOSYNTHETIC
FUNCTION 
 
 
Fig. 7 schematizes the structural traits and Table 1 summarizes the differential 
properties of various types of CPS. In addition to the ability to be activated by 
NAG, CPS1 differs from other types of CPS in its inability to use glutamine as 
substrate, and in its high affinity for ammonia [16,39], approximately 100-fold 
higher than that of the bacterial enzyme [6]. The second of these properties, 
unique to CPS1, is understandable as an adaptive measure because of the major 
role of CPS1 as a detoxifier of ammonia at the concentrations of this metabolite 
that prevail in portal blood. The inability of CPS1 to utilize glutamine is also 
understandable, since in the liver there are two systems that coexist to get rid of 
ammonia [28]: the high capacity but relatively low-affinity system represented 
by the urea cycle, which is present in periportal hepatocytes, and the low 
capacity/high affinity system represented by glutamine synthetase, which is 
found only in perivenous hepatocytes. It makes metabolic sense to get rid of 
ammonia in the two metabolic processes devoted to lowering ammonia levels in 
the blood entering the liver, the urea cycle and the synthesis of glutamine, 
Figure 6. Shift in the function of 
NAG from bacteria and plants (left 
panel), where it is the first 
committed intermediate in arginine 
synthesis, to mammals (right panel), 
where it activates CPS1. Blue 
arrows denote activation and red 
arrows denote feed-back inhibition. 
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ENZYME FUNCTION SUBSTRATE 
ACTIVE  
WITHOUT 
ACTIVATOR? 
ACTIVATOR INHIBITOR 
E. coli 
PYRIMIDINE 
synthesis 
ARGININE synthesis 
Glutamine 
(ammonia) 
YES 
Ornithine 
IMP 
UMP 
CPS I 
Arginine/UREA 
synthesis 
(ureotelic) 
Ammonia NO 
N-Acetyl-L-
glutamate 
--- 
CPS II 
PYRIMIDINE 
synthesis 
Glutamine 
(ammonia) 
YES PRPP UTP 
CPS III 
Arginine/UREA 
synthesis 
(ureosmotic) 
Glutamine 
(ammonia) 
YES 
N-acetyl-L-
glutamate 
--- 
 
particularly since CPS1 has developed a relatively high affinity for ammonia 
when compared with other CPSs.  
 
Table 1. Differential traits of four classical types of CPS 
 
1.4 A brief review of knowledge about CPS1 that is relevant for this work.  
 
1.4.1 Early findings. The discovery of carbamoyl phosphate synthesis was a 
consequence of the efforts to place the urea cycle on sound enzymological 
bases. Krebs and Henseleit reported the cycle on the bases of experiments with 
liver slices in which the influence of several amino acids on the production of 
urea was tested [25]. Only after nearly 20 years Grisolia and Cohen [41] 
Figure 7. The three basic structural types of CPS. CAD stands for the 
multifunctional protein that catalyses the three initial steps of pyrimidine synthesis 
in animals. The abbreviations (in addition to CPS) stand for, GLNase, glutaminase; 
DHO, dihydroorotase; ATC, aspartate transcarbamylase. Based on a drawing in 
[11]. 
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identified the actual enzymatic steps that convert ornithine to citrulline, of 
which the first was shown to depend on ATP and to produce an unstable 
compound that was initially called compound X; this compound, when mixed 
with ornithine and a mitochondrial extract yielded citrulline in an ATP-
independent way. Jones and Lipmann showed that compound X is carbamoyl 
phosphate (CP) [42], and Cohen's group identified NAG as the natural activator 
of the enzyme catalysing the synthesis of CP [43]. These authors also were the 
first to purify CPS1, from frog liver [44]. 
 
1.4.2 Initial work with pure CPSs. Using the pure frog liver enzyme, the CPS1 
reaction was proposed to involve two phosphorylation steps that were reflected 
in two slow partial reactions, one being a bicarbonate-dependent ATPase and 
the other being the synthesis of ATP from CP and ADP [45] (Scheme 1). 
  
3-STEP GLOBAL REACTION
PARTIAL REACTIONS
Bicarbonate-dependent ATPase ATP synthesis
ATP  +  HCO3
- ADP  +  -O-P-O-C-O- Pi +  H2N-C-O
- ADP  +  H2N-C-O-P-O
-
NH3 ATPO     O      O     O      
OH O-
O
(carboxyphosphate) (carbamate) (carbamoyl phosphate)
H2O
NH3 + HCO3
-
H2O
Pi + HCO3
-
ATP  +  HCO3
- ADP  +  -O-P-O-C-O-
O     O      
OH
(carboxyphosphate)
H2N-C-O
- ADP  +  H2N-C-O-P-O
-
ATP
O     O      
O-
O
(carbamate) (carbamoyl phosphate)
 
Scheme 1. Reactional steps of the CPS1 reaction (top) and partial CPS reactions 
(bottom). The partial reactions are aligned vertically with the reactional steps they are 
believed to reflect. Taken from [46]. 
 
Little later it was discovered that bacteria also use CPS for arginine and 
pyrimidine synthesis [47], which was the starting point for extensive studies 
with the bacterial enzyme, mainly led by the group of Alton Meister. For 
brevity, these early data on the bacterial enzyme will not be revised here unless 
they are directly relevant to the present work, sending the reader to a published 
review on bacterial CPS [6]. A procedure was soon reported for purification of 
rat liver CPS1 and it was proposed that NAG activation was allosteric [39], 
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whereas the kinetic mechanism of the enzyme from beef liver was clarified 
[48,49] after the appropriate equations were developed for such a complex 
reaction [50]. In the middle seventies the very high abundance of CPS1 in liver 
mitochondria (10-25% of the mitochondrial matrix protein) was discovered [51] 
(Fig. 8).  
 
 
1.4.3 Reactional mechanism. The groups where I have carried out my PhD 
work have contributed much of the significant information about CPS1 
mechanism. Studies by one of my supervisors showed that the frog liver 
enzyme makes an unstable intermediate, called "active CO2" [52], soon shown 
demonstrated also with mammalian CPS1 [53,54], believed to be 
carboxyphosphate [55], while Meister's group showed simultaneously the 
formation of carboxyphosphate with the E. coli enzyme [56]. These two groups 
proved (in the case of Dr. Rubio's group with CPS1) the existence of two 
separate sites for ATP, one for bicarbonate phosphorylation and the other for 
carbamate phosphorylation [52-54,57]. Our laboratory showed that, in the 
absence of ammonia, "active CO2" (carboxyphosphate) was formed 
intraenzymatically and that all the substrates of the reaction were bound to the 
enzyme, with no product release prior to the addition of ammonia [52-55]. The 
properties of the two sites for ATP were characterized [53-55] (Fig. 9). The 
existence of an intraenzymatic reversible reaction between ATP and 
bicarbonate that was much faster than the ATPase partial reaction was proven 
by positional isotopic exchange techniques with the rat liver [55] and the 
bacterial enzymes [59,60]. 
 
 
Figure 8. Abundance, mass and 
mitochondrial localization of CPS1. Left, 
Coomassie staining of SDS-PAGE of 
mouse liver mitochondria. The arrow 
signals the highly abundant 160-kDa 
CPS1 band. Right, rat liver  electron 
micrograph, with CPS1 immunogold 
labeling (black spots), revealing the 
mitochondrial localization of the enzyme . 
SDS-PAGE courtesy of A. García-España 
and V. Rubio. Electron micrograph 
courtesy of Dr. Erwin Knecht (Instituto de 
Investigaciones Citológicas, now Centro 
de Investigación Príncipe Felipe, 
Valencia).  
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1.4.4 Human CPS1. Studies of an American group and of my own group 
[15,16] resulted in the purification and characterization of human CPS1, 
providing the only existing detailed enzymological data on the human enzyme 
until the present work was carried out. These data are summarized in Chapter 1 
of the Results, and, therefore, we will not deal anymore with them here. 
 
1.4.5 NAG activation and domain structure. Studies from my laboratories are 
also responsible for most of the existing knowledge about NAG activation of 
CPS1. Very early on they clarified NAG binding, showing the presence of a 
single NAG site per CPS1 molecule and proving the existence of cross-talk 
between the ATP site that is used to phosphorylate bicarbonate and the NAG 
site [61]. They proved that NAG can be partially replaced as an activator by a 
number of chemically unrelated cryoprotectant agents such as glycerol or 
sucrose [62,63]. They also showed that CPS1 has trace activity in the absence 
of NAG, which is of very low magnitude because of extremely large Km values 
for ATP and for the two ionic activators of the enzyme, K+ and Mg2+ [40]. On 
the basis of these data the proposal [39] that NAG is an allosteric activator of 
CPS1 was confirmed [40]. Evidence for NAG-triggered conformational 
changes was obtained by limited proteolysis studies [46]. A kinetic mechanism 
for NAG activation was proposed [63]. 
 
Studies with the isolated small and large subunits of bacterial CPS had shown 
that the small subunit binds and cleaves the glutamine used in its reaction and 
that the large subunit carries out the entire reaction from ammonia and binds the 
Figure 9. Scheme of CPS1 charged with all its substrates except ammonia, 
summarizing the data derived from Dr. Rubio's laboratory in the early 1980s. No 
data existed at the time on any other physical property of the enzyme except that it 
was a single polypeptide of 160 kDa. Figure reproduced from [58]. 
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Figure 10. Structural model prevailing in the 1990s 
for the 120-kDa moiety of any CPS, folded as a 
pseudohomodimer of its two phosphorylation 
domains (N-terminal, pinkish, bicarbonate 
phosphorylation; more C-terminal, yellow, 
carbamate phosphorylation), with passage of 
unstable intermediates (carboxyphosphate or 
carbamate) from one to the other, in a water-
shielded way. Darker blue, C-terminal allosteric or 
regulatory domain, which hosts the sites for the 
allosteric effectors and which is the subject of 
Chapter 3 of the Results. Light blue, intervening 
domain of previously unknown function which is the 
subject of Chapter 2 of the Results and that we now 
call Integrating domain. 
 
ATPa
+
HOCOO
-
HOCOOPO3
2-
+
ADP
DOMAIN I
40 kDa
ATPb
+
H2NCOO
-
H2NCOOPO3
2-
+
ADP
DOMAIN III
40 kDa
NH3
Pi
DOMAIN II   (?)
20 kDa
DOMAIN IV
REGULATORY
20 kDa
effectors [6]. By then, limited proteolysis results of my group [64] and of 
another three groups [65-67] revealed a domain structure of CPS1 that is 
reflected in Fig. 1 of Chapter 1 of the Results. The first fine localization of a 
function in any CPS was provided by our laboratory when it showed by 
photoaffinity labeling of rat CPS1, using N-chloroacetyl-L-[14C]glutamate and 
subsequent limited proteolysis cleavage, that NAG binds in the C-terminal 
domain of CPS1 (a domain of 20 kDa) [17]. Our group also proved that this 
domain of E. coli CPS is used for binding of all its allosteric effectors [68-70], 
an information that found correspondence in similar results for the pyrimidine-
specific CPS from mammals (CPSII) [71]. Since then the C-terminal domain of 
20 kDa of any CPS is known as the allosteric domain.  
 
1.4.6 Cloning and sequencing of CPS1 cDNA and gross enzyme architecture. 
Lusty's group cloning and sequencing in the 1980's of the cDNA for E. coli 
CPS and for rat CPS1 [72-74] opened a new era in CPS studies. The sequence 
revealed that the large subunit of bacterial CPS, of 120 kDa, exhibits internal 
homology indicating that its origin involved gene duplication and tandem 
fusion events [72]. This allowed mapping of some functions in different 
domains. Using these data, the limited proteolysis data mentioned above, 
differential scanning calorimetry results [69] and other data including oxidative 
cleavage [75] and in particular cleavage with FeATP [76], our group proposed 
[68] a model for the large subunit of E.coli CPS and for the equivalent region of 
any other CPS (including CPS1) in which (Fig. 10) this region was folded as a 
pseudohomodimer of two homologous phosphorylation domains of 40 kDa, 
the more N-terminal involved in HCO3
- phosphorylation and the more C-
terminal in the phosphorylation of carbamate [1-3]. Given the reactional 
mechanism, it was inferred that the carboxyphosphate and the carbamate 
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intermediates had to be shielded from water, and, therefore, that the two 
phosphorylation centres had to be connected intraenzymatically, so that either 
the carboxyphosphate or the carbamate would be able to migrate from one to 
the other phosphorylation centre (Fig. 10). 
 
1.4.7 Crystal structure of E. coli CPS. The next large breakthrough in the CPS 
field was the determination, 18 years ago, of the crystal structure of E. coli CPS 
[77,78] (Fig. 11). This is the only CPS for which the structure has been 
determined. Our group got crystals of frog liver CPS [79] but these have never 
provided good-quality diffraction data. Up to now, ten E. coli CPS crystal 
structures of wild-type or mutant forms, in complexes with substrates and 
allosteric effectors, have been reported [Protein data bank (PDB, 
http://www.rcsb.org/pdb/home/home.do) accession numbers: 1T36, 1M6V, 
1KEE, 1C30, 1C3O, 1CS0, 1CE8, 1BXR, 1A9X and 1JDB). All these 
structures contained the activator ornithine bound to them, and therefore they 
Figure 11. E. coli carbamoyl phosphate synthetase structure. Left, detailed structure 
based on PDB 1JBD. Right, tunnel spanning the whole enzyme as drawn in [85], modified 
to locate some clinical mutations studied in [87] (represented as spheres). 
SMALL SUBUNIT
LARGE
SUBUNIT
Allosteric
domain
Nucleotide substrate
Ornithine effector
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most likely correspond exclusively to active CPS forms, providing no insight on 
how a CPS is activated by its effectors. Despite the evolutionary distance 
between E.coli CPS and CPS1, these two types of CPS share 40% sequence 
identity over their entire lengths [74], although in CPS1 the 40-kDa and the 120 
kDa moieties that correspond to the small and large subunits of E. coli CPS are 
fused into a single polypeptide. Therefore, much information from the E. coli 
CPS is of application to CPS1, and thus the main traits of this structure will be 
briefly summarized here. 
 
The structure (Fig. 11, left panel) [77,78] confirmed the domain composition 
that had been proposed for CPS1 as well as the view that the 120-kDa moiety is 
folded as a pseudohomodimer [1]. Each phosphorylation domain presented the 
ATP grasp fold that had been identified in glutathione synthetase [80], D-Ala-
D-Ala ligase [81] and biotin carboxylase [82], a fold that is composed of three 
subdomains. Indeed, the connection between CPS and the biotin carboxylase 
component of biotin-dependent carboxylases such as acetyl-CoA carboxylase 
had been established already by our group, which had shown that biotin 
carboxylase makes the same carboxyphosphate intermediate that is made by 
CPS [83,84]. Also as predicted by our group, the transfer of intermediates 
between both phosphorylation centres in the two phosphorylation domains of 
40 kDa appeared to occur via a water-shielded intramolecular tunnel [85] (Fig. 
11, right panel). Actually, since in the case of bacterial CPS glutamine is the 
source of ammonia, the tunnel extended nearly 100 Å, from the glutaminase 
domain of the small subunit to the bicarbonate phosphorylation centre and from 
there to the carbamate phosphorylation domain at the opposite end of the large 
subunit (Fig. 11, right panel). It was inferred that the ammonia generated from 
the glutamine travels to the bicarbonate phosphorylation site via the first half-
tunnel, to react with the carboxyphosphate that is waiting for it, making the 
carbamate, that then travels to the second active site, where it is phosphorylated 
by a second MgATP molecule, giving carbamoyl phosphate [86]. 
 
Since our group had found that ADP and phosphate are only released when 
ammonia has reacted [52-54], the two phosphorylation sites must have some 
type of interconnection that permits release of their product cargo only when 
carbamoyl phosphate is released. Such coordination was illustrated best by a 
clinical mutant of the carbamate phosphorylation domain that was found in a 
CPS1 deficiency patient and that when introduced at the equivalent conserved 
residue in E.coli CPS abolished reaction at both phosphorylation sites [87]. 
Such mutant appeared to hamper [87] the opening of the B subdomain [88] of 
the carbamate phosphorylation domain, but, interestingly, it also appeared to 
prevent the opening of the B subdomain of the bicarbonate phosphorylation 
domain, indicating that this opening is concerted by as yet unknown 
                                                         INTRODUCTION 
 
19 
 
 
mechanisms. Our present work reported in Chapter 2 of the Results suggests 
that this concerted opening is mediated by the intervening domain that links 
both phosphorylation domains (called in this work the Integrating domain). 
 
1.4.8 Crystallographic data on the structure of the C-terminal domain of human 
CPS1, and NAG site delineation. Comparison of the sequences of E. coli CPS 
with those of CPS1 rendered dubious that the allosteric domain of both CPSs 
were structurally similar, because they exhibited in this region quite low 
sequence identity [89,90]. Nevertheless, in agreement with the studies of our 
group [68-70,89,90], the allosteric effectors of E. coli CPS, IMP and UMP, 
were found in the crystal structures of E. coli CPS to bind to the allosteric 
domain [91,92], and ornithine was also found to bind there, although at the 
boundary with the carbamate phosphorylation domain [77,78]. 
 
In 2007 the crystal structure of the allosteric domain of human CPS1 lacking its 
22 more C-terminal residues, produced in vitro in the absence of the remainder 
of the protein, was deposited in the PDB as entry 2YVQ, without comments or 
associated publications, by a structural genomics consortium [93]. This 
structure (Fig. 12) proved that the allosteric domain of CPS1 has nearly an 
identical fold to that of the corresponding domain of E. coli CPS. Our group 
analyzed this structure and identified within it the NAG site [13].  
This domain (Fig. 12) is built up by a central sheet of five parallel β-strands 
surrounded by a bundle of three α-helices on one side and a bundle of two α-
helices on the other side, forming the Rossmann fold seen in proteins of the 
methylglyoxal synthetase family [94]. The site identified in the flexible docking 
studies of my group within this crystal structure fitted the earlier results of the 
group concerning the binding of NAG analogues and the specificity of the 
enzyme for NAG [95], and they also fitted the results of the group's 
Figure 12. Structure of the C-
terminal domain of human CPS1 
(PDB entry 2YVQ), coloured to 
enhance visibility of the structure. 
Secondary elements are labelled. 
The pocket identified in [13] is 
shown in semi-transparent surface 
representation. A modeled NAG 
molecule bound to this pocket [13] 
is shown in sticks representation. 
Taken from [13].  
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photoaffinity labelling studies concerning the site of covalent anchoring of the 
photoactivated NAG analogue [13]. Furthermore, when these studies were 
carried out, the group had set up already the baculovirus/insect cell system for 
rat CPS1 expression, and, therefore, five putative NAG site residues were 
replaced by other residues, confirming the location of this site [13].  
 
The NAG site modeled in this crystal structure (which had no bound ligands) is 
a pocket located between the central β-sheet and two α-helices, and appeared to 
be covered by a three-residue closing lid. The location of the NAG-binding site 
is equivalent to that of the E.coli CPS activator IMP [13] (Fig. 13), indicating a 
common origin for these sites. Many of the residues which build up the 
proposed NAG-binding pocket, are conserved in all NAG-regulated enzymes 
[13].   
 
Chapter 3 of the Results represents a further development of the study of NAG 
binding to this domain, providing strong evidence that the NAG site shifts 
conformation as NAG binds to it, this likely being the initial signal for CPS1 
activation. Elements of the path for cross-talk to the catalytic domains are also 
identified in this third part of our study. 
 
1.4.9 Modelling of the CPS1 structure. The finding [13] that the structure of the 
allosteric domain of CPS1 closely resembles the structure of the allosteric 
domain of E. coli CPS despite the low sequence identity between these two 
domains supported the possibility of modelling with high fidelity the structure 
of the whole CPS1 molecule on the basis of the structure of E. coli CPS, 
Figure 13. Stereo view of the superimposed side chains (thinner sticks) of the 
residues making the IMP site (green carbons) and the proposed NAG site (black 
carbons) in E. coli CPS (PDB 1CE8) and human CPS1 (PDB 2YVQ), respectively, 
with the bound IMP and NAG molecules shown with green and black carbons 
respectively. Taken from [13]. 
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particularly since all other parts of the enzyme exhibit much higher sequence 
identity than the allosteric domain [74,96]. The group of one of my PhD 
advisers obtained such a model [97], which is virtually identical to the model 
produced with a somewhat different approach in collaborative work of my other 
adviser [12]. Both 3D models were obtained from the E.coli homologue bound 
to the non-hydrolysable ATP analogue AMPPNP (PDB file: 1BXR). In the 
present work I will use our internal group model (Fig. 14), using it as the 
context frame on which to judge and rationalize all structural inferences made 
here except those concerning the allosteric domain. Nevertheless, it should be 
remembered that, because of the presence of ornithine bound to the template 
structure used from E. coli, this model should correspond to active CPS1, since 
it is based on the active E. coli structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Structural model [97] of CPS1 used throughout the present PhD work. 
 
1.4.10 CPS1 production. Like most mitochondrial proteins that are encoded by 
nuclear genes [98], CPS1 is synthesized in the cytoplasm as a larger precursor. 
The pre-CPS1, of 1500 amino acids, contains an N-terminal 39-residue signal 
peptide that directs the protein for delivery to the mitochondrial matrix, and 
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which is cleaved off by the matrix-processing peptidase upon translocation [98-
100]. Thus far no mutations have been identified in the region encoding this 
signal peptide [12]. 
  
 
1.5 CPS1 deficiency, the CPS1 gene and its mutations. 
 
CPS1D was first reported in 1964 [101], in a mild (late onset) case. The report 
of the first case of complete deficiency (neonatal presentation) took place 10 
years later [102]. By 1976 six cases of CPS1D had been identified already 
[103]. Diagnosis was based on the finding of hyperammonemia, with low 
citrulline levels and lack of orotate excretion (orotate increases when CP 
accumulates, Fig. 3, bottom panel) [103]. Confirmatory diagnosis depended on 
enzyme activity determination in the liver, obtained by biopsy or during 
necropsy [29,103]. Intestinal biopsy was introduced later [104] as a less 
invasive means of confirmatory diagnosis. These traits, together with increased 
blood glutamine levels, have remained hallmarks of this deficiency for many 
years [105]. CPS1D was soon recognized as a genetic disease of Mendelian 
autosomal inheritance [106]. Indeed, by 1981, excepting liver transplantation, 
the main components of present-day treatment of CPS1D had been established 
already [107], consisting in protein restriction with essential amino acid 
supplementation, prevention of protein catabolism, arginine or citrulline 
supplementation, and the administration of benzoate or phenylacetate 
(nowadays replaced, when administered orally, by phenylbutyrate or by its 
glycerol triester [30,108]) as alternative pathway medications to bypass the urea 
cycle. 
 
With the description in 1981 of NAG synthase deficiency (NAGSD) [109], it 
became clear that the same clinical and biochemical picture was shared by 
CPS1D and NAGSD, with the only distinguishing element being the results of 
the assays of enzyme activity in the liver (or in intestinal mucosa in the case of 
CPS1). The fact that NAGSD can be treated with complete recovery by 
administering orally N-carbamylglutamate as substitutive therapy for the 
missing NAG [30,31] has led to the advocacy for investigating a positive 
response to the administration of carbamylglutamate as a way to differentiate 
clinically between CPS1D and NAG synthase deficiency [110]. Nevertheless, 
this may not be a perfect test for distinction between both deficiencies. Some 
kinetic or low-stability variants of CPS1 might be improved by 
carbamylglutamate because of pharmacologically-assisted saturation of the 
NAG site of CPS1 or by pharmacological chaperone effects of this drug (see 
Chapter 1 of the Results). 
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The sequence of the cDNA for the human CPS1 gene became available more 
than 20 years ago [111]. This opened the way to identification of mutations in 
the CPS1 gene, which simplified confirmatory diagnosis of CPS1D and enabled 
prenatal diagnosis (until then could only possible in foetal liver biopsies[112]). 
Thus, mutation identification is now considered the gold standard for diagnosis 
of CPS1D [27]. Nevertheless, the path to widespread genetic diagnosis of 
CPS1D has been slow, mainly because of the large size of the coding sequence 
(4503 nucleotides, including the stop codon) and the restricted distribution of 
abundant gene expression (only liver and intestinal mucosa, with some 
expression also in the pancreas [51,113]). mRNA-based diagnosis was 
progressively simplified by the use of illegitimate transcription, first in 
immortalised patient's leukocytes [114] or in patient's fibroblasts [115], and, 
more recently on phytohaemagglutinin-stimulated peripheral blood leukocytes 
[116].  
 
The report of the CPS1 gene structure [117-119] opened the way to the use of 
genomic DNA for genetic diagnosis. The gene (OMIM #608307) is localized in 
the long arm of chromosome 2, at 2q34, spanning 201425 nucleotides, with 
start and end coordinates within chromosome 2 at 211342405 and 211543830 
of the plus strand (http://www.genecards.org/cgi-bin/carddisp.pl?gene=CPS1). 
This gene is composed of 38 exons and 37 intervening introns [117-119]. 
Therefore, diagnosis using mRNA is considered less laborious than the use of 
genomic DNA for mutation identification, although this last approach might be 
alleviated in the near future with the generalization of next generation 
sequencing techniques. 
 
Now, after 50 years from the original description of CPS1D, it is clear that the 
disease is quite rare (1:50000-1:300000) [120-122]. The first summary of 
mutations identified in CPS1 patients in 24 years was published in 2011 [12]. 
Together with the mutations reported in two additional publications appearing 
after that paper [116,123], a total number of 243 CPS1D-associated genetic 
changes have been identified, generally with little recurrence of the mutations. 
As shown in Fig. 15, where the percentages of the changes corresponding to 
each type of mutation are represented, more than half of these mutations are 
missense changes. Since nonsense changes as well as most small insertions, 
deletions and splice site aberrations result in enzyme truncation, at least 1/3 of 
all the mutations should result in the lack of CPS1 protein in the liver. In fact, 
this number is even higher because a number of the missense changes also 
cause enzyme destabilization (see the Results section).  
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Figure. 15. Summary of all CPS1 mutations reported to date [12,116,123]   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 16. Density of missense mutations per CPS1 exon. The number of missense 
mutations per exon, normalized per 100 nucleotides, is plotted along the coding 
sequence, with the symbols placed at the middle point of each exon (some exon numbers 
are given). Thin line, all missense mutations. Thick line and large filled triangles, 
missense mutations that do not fall on CpG dinucleotides. Figure modified from [12] to 
include the mutations described in [116,123]. 
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The incorporation of the novel missense mutations reported in [116,123] to the 
mutational database summarized in [12] does not alter the conclusion 
formulated in [12] that the density of missense mutations along the gene varies 
with the region. Fig. 16 actualizes Fig. 2B of reference [12], highlighting the 
fact that the distribution of the mutations is highly skewed, particularly when 
the contribution of the CpG mutational hotspots is subtracted, supporting the 
existence of highly eloquent and less eloquent regions in the enzyme.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Residues hosting missense mutations localized in the structural model of 
human CPS1 that has been used here [97]. For clarity, residues have not been 
identified. They are colored as the domain where they map.  
 
INTRODUCTION 
 
26 
 
 
Fig. 17 illustrates the distribution of the missense mutations in the structural 
model of the protein, giving a 3D-view of the mutations' density in different 
domains of the enzyme. Although the size of the protein and the large number 
of mutations makes impossible a very clear view, it is evident, for example, that 
mutations are rarer towards both ends of the enzyme (in the regions 
corresponding to the small subunit of E. coli CPS and to the allosteric domain) 
than in the regions containing the catalytic machinery or than in the intervening 
domain that links both phosphorylation domains. Actually, this skewed 
distribution of mutations is one of the basis of the present work: to clarify the 
underlying reasons for the variable eloquence of the various regions and in 
particular to clarify the reasons for the high eloquence of this intervening 
domain that, after the present work, is called the Integrating domain (Chapter 2 
of the Results). 
 
 
1.6 Other roles of CPS1 in pathology. 
 
Although not the subject of the present work, it is important to briefly highlight 
that mutation-triggered CPS1 deficiency is not the only mechanism linking 
CPS1 to human pathology and that, therefore, knowledge on CPS1 may also 
have impact on other disease processes. 
 
1.6.1 Secondary hyperammonemia. One of these disease processes are the 
secondary hyperammonemias (the hyperammonemias in which the operation of 
the urea cycle is decreased secondarily to other defects external to that cycle 
[124]) since in many of them impaired CPS1 operation is the reason for the 
hyperammonemia (Fig. 18). This appears to be the case in the 
hyperammonemia of carnitine cycle defects or of fatty acid oxidation defects, in 
which the impaired cellular energy production has been proposed to reduce the 
availability of ATP for CPS1 [124]; in mitochondrial carbonic anhydrase 
deficiency [125], in which bicarbonate may not be produced fast enough to feed 
the cycle at the CPS1 level; and in the hyperammonemias of organic acidemias, 
or due to valproate or, also, to fatty acid oxidation defects, via a mechanism in 
which poor NAG production by NAGS may decrease CPS1 activity [124,126]. 
An important therapeutic consequence of this CPS1-mediated mechanism of the 
secondary hyperammonemia is that carbamylglutamate may be effective in 
treating these hyperammonemias [125,127]. It is also to be noted that carnitine 
administration restored CPS1 expression in an animal model of a carnitine 
uptake defect (juvenile visceral steatosis) that associates with hyperammonemia 
because of decreased expression of urea cycle enzymes [128], suggesting an 
additional mechanism for causation and for treatment of some types of 
secondary hyperammonemia. 
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Figure 18. Possible mechanisms of secondary hyperammonemia due to decreased 
CPS1 activity 
 
A novel aspect recently introduced in the understanding of CPS1 function and 
pathology is the realization that CPS1 is acylated at several lysines by as yet 
unclarified mechanisms that possibly depend on the acyl coenzyme A levels, 
and that it is deacylated by sirtuin 5, with claims and indirect evidences for the 
control of CPS1 (and the urea cycle) activity by the state of acylation [129,130]. 
Indeed, fatty acylation of the CPS1 active center had been reported to greatly 
affect CPS1 activity [131]. Since sirtuins are anti-aging proteins, CPS1 
acylation/deacylation was considered a link between nitrogen metabolism and 
aging [132], whereas in recent work CPS1 glutarylation was considered a key 
component of the secondary hyperammonemia of glutaric acidemia [133]. 
Clearly this is a new field that requires further exploration, and that may be 
addressed experimentally by exploiting our present expression system reported 
in Chapter 1 of the Results. 
 
1.6.2 A CPS1 polymorphism involved in vascular reactivity and in other traits 
related to pathologies. Apart from being involved in primary and secondary 
hyperammonemia, CPS1 has been  involved more recently in other pathological 
processes less clearly connected with deficient activity of the enzyme. In 
particular, the p.Thr1046 form of the CPS1 non-synonymous polymorphism 
(polymorphisms are sequence changes which do not cause evident enzyme 
deficiency) p.Thr1406Asn (designated earlier on as p.Thr1045Asn) was 
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reported [134] to be associated with lower blood concentrations of citrulline 
and higher rates of hepatic veno-occlusive disease and death than the Asn1406 
variant, in adults given high-dose chemotherapy for bone marrow 
transplantation. This polymorphism was associated with pulmonary 
hypertension and decreased plasma arginine and nitric oxide metabolites in 
neonates with respiratory distress [135], and in those developing pulmonary 
hypertension after congenital heart surgery [136], leading to trials for using 
citrulline to prevent or treat these presentations of pulmonary hypertension 
[137,138].  
 
These vascular reactivity phenotypes were rationalized on the basis of 
differences in nitric oxide production that were tentatively related to differences 
in the enzyme activity between the two polymorphs [139], given the fact that 
arginine is a precursor of nitric oxide. However, the effects on activity of the 
p.Thr1406Asn substitution appeared not to be drastic, with reports in crude 
extracts [139] of 20-30% higher activity and with pure recombinant CPS1 of up 
to 1.7-fold lower activity [140] for the Asp form. An activity effect might 
underlie the report of increased frequency of the Asp polymorphism in 
valproate-associated hyperammonemia [141,142], which would be in line with 
a decreased activity of this form of the enzyme [140]. However, a recent 
Japanese study [143] did not find an association between the p.Thr1406Asn 
polymorphism and valproate-induced hyperammonemia, although this last 
study used a pediatric cohort and defined hyperammonemia as ammonia levels 
>200 µM [143], whereas in the largest earlier study finding an association the 
threshold ammonia level was 65 µM [142].  
 
Homozygosity for the CPS1 Thr1406 variant was also associated with an 
increased risk of necrotizing enterocolitis in preterm infants [144]. This disease 
is also believed to be related to nitric oxide. However, this form of the 
polymorphism was reported not to be associated with a decreased level of 
arginine in preterm infants [145], despite the fact that the level of arginine is 
known to be decreased in preterm infants with necrotizing enterocolitis [144].  
 
With the advent of genome-wide association studies of phenotypic characters 
with genetic polymorphisms, the p.Thr1406Asp polymorphism has emerged as 
one of the determinants of the levels of homocysteine [146,147] and of 
homoarginine [148] in normal subjects, of fibrinogen in women [149], of 
creatinine [150] and of the response to albuterol in African-American children 
with severe asthma [151]. The link between these phenotypic traits and CPS1 
function is unknown or at best speculative for now.  
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1.7 Previous in vitro expression and structure-function studies on CPSs.  
 
As already indicated, Chapter 1 of the Results is devoted to the "in vitro" 
production and purification of human CPS1. We will discuss here previous 
attempts of CPS expression. Actually, once having its gene cloned, E. coli CPS 
was easily expressed in E. coli cells, having been the subject of extensive site-
directed mutagenesis studies (see for example [90,152-154]). Given the 
existence of reasonable sequence identity between the different CPSs [96], 
some of these bacterial results have been exploited to interpret the effects of a 
number of CPS1D-associated missense mutations (see for example [155]). In 
fact, work of my group [87] utilized the bacterial enzyme as a surrogate model 
for the human enzyme to explore systematically the impact of clinical 
mutations found in CPS1D on the activity of the enzyme.  
 
An eukaryotic CPS, the arginine-specific yeast enzyme, was expressed 
recombinantly in yeast and was utilized for site-directed mutagenesis studies 
focusing on basic aspects of the enzyme, without making clinical inferences 
[156,157]. Similarly, CPSII, the CPS component of the multienzymatic protein 
CAD was expressed long ago in E. coli in complete form, as its individual 
domains, or as hybrid proteins with E. coli CPS [71,158-160], and it was used 
to study the function of domains or regions of this enzyme or even of individual 
residues [159-160]. These enzymes have not been used as models for 
understanding CPS1D.  
 
Although Chinese and Korean groups claimed long ago recombinant production 
of CPS1 in cultured animal cells [161,162], the first well documented example 
of in vitro recombinant CPS1 expression and purification was provided in 2003 
by Powers-Lee group [163], for the enzyme for the american bullfrog (Rana 
catesbeina), using Schizosaccharomyces pombe as the expression host. 
Apparently large amounts (15 mg/L of yeast culture) of pure enzyme were 
obtained. This enzyme was used for site directed mutagenesis studies focusing 
on the reasons for the ammonia or glutamine specificity of different CPSs, but 
not to explore CPS1 pathology despite the 74% identity between frog and 
human CPS1s [163]. This same system was exploited by the same group to 
generate reasonable amounts (2-3 mg/L of S. pombe culture) of pure active 
human CPS1 [140,165], as reported months before our laboratory published the 
recombinant production of rat CPS1 in baculovirus/insect cells [13]. The S. 
pombe production system was used to study the impact on enzyme functionality 
of the p.Thr1406Asn polymorphism discussed in the previous section, as well a 
to try to clarify the role of the N-terminal region of the enzyme, which was 
deleted [140]; and to clarify the role of two proximate cysteines classically 
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considered essential for CPS1 activity [164]. Intriguingly, no further use has 
been reported of this system to characterize the impact in pathology of the 
mutations found in CPS1D patients. 
 
As already mentioned, in the context of characterizing the site for NAG by site-
directed mutagenesis (an objective that is completed in Chapter 3 of the Results 
of the present PhD dissertation), our group reported in 2009 [13] the production 
of the rat liver enzyme in baculovirus/insect cells. This production system was 
highly effective (10 mg of pure CPS1/L of culture), allowing to prove, by 
exploiting the high identity of rodent and human CPS1, the pathogenetic 
potential of clinical mutations found in CPS1D [14]. Since this system is 
thoroughly discussed in the next section of this introduction and in Chapter 1 of 
the Results, no further discussion of it will be made here. Indeed, Chapter 1 of 
the Results reports the production of the genuine recombinant human enzyme in 
its mature form, and, together with the two chapters following it, describes the 
use of this system to characterize the effects of clinical and experimental 
mutations of human CPS1. 
 
A weakness of all these systems mentioned thus far, including the 
baculovirus/insect cell system, is that they are not able to assess the effects of 
mutations in the non-coding regions of the CPS1 gene, or of mutations that may 
affect the splicing of the gene. Summar's group [165] has developed a tool 
based on the generation of a highly sophisticated bacterial artificial 
chromosome (BAC) that is devised to express CPS1 in SV40-immortalized 
lung fibroblasts. This expression system relies heavily on normal BAC 
replication in bacteria, episomal eukaryotic replication, antibiotic selection in 
eukaryotic cells, and the expression of green fluorescent protein. Because of the 
large size of genomic inserts allowed by BACs this system was reported to 
provide an efficient way to test genetic variants affecting both coding and 
noncoding sequences, being particularly useful for assaying mutations that 
affect RNA processing, thus being suitable to examine mutations' effects on the 
nature or the levels of the mRNA produced. 
 
As a proof of concept, this system was applied [165] to examine the mechanism 
of four putative splicing mutations (two sitting in exonic sequences and the 
other two in intronic sequences) found in CPS1D patients, locating 
experimentally two cryptic splicing sites for the two intronic mutations and 
revealing the role of nonsense-mediated decay by knocking down this process. 
The latter agrees with the previous finding of these authors in a cohort of 26 
CPS1D patients with 52 mutant alleles, that there was evidence in many cases 
of nonsense-mediated decay in those patients carrying nonsense or frameshift 
changes or splicing defects [166]. 
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In summary, we are now endowed with a number of powerful techniques that 
permit investigating the disease-causing impact and the mechanisms of damage 
for any mutation affecting CPS1. The present work deals with one such 
instrument, the use of baculovirus-insect cell expression, to analyze the 
characteristics of the recombinant human enzyme and to investigate the kinetic 
and stability derangements introduced by CPS1D-associated mutations. We will 
deal now with these two experimental approaches utilized here, to provide some 
extra insight on them, since the treatment of these two techniques in the 
manuscripts that constitute the three chapters of the Results is brief. 
 
 
1.8 The baculovirus/insect cell expression system 
 
Baculoviruses are large rod-shaped circular DNA viruses that infect many 
different species of insects [167]. They can infect mammalian cells but they do 
not propagate therein [168]. They are used in protein expression studies because 
they make massive amounts of a single protein (polyhedrin in some types of 
baculoviruses, granulin in other types of viruses of this family), which is used 
as a matrix to include therein mature virions [167,169,170]. This is the so-
called occlusion-derived virus, which favors virus conservation in the external 
environment for extended periods, facilitating viral transmission. The larval 
form of the insect gets infected by eating material such as leaves that are 
contaminated with the occluded virus within the proteinaceous matrix. The 
matrix is dissolved in the gut and the virus is released for infection. The 
infected intestinal cells produce more virions that bud out from the cell, this 
time without being included in a polyhedrin body, infecting other cells. 
 
Baculovirus-based expression systems rely on the introduction of the gene to be 
expressed in the baculoviral genome under the control of a strong late viral 
promoter such as the polyhedrin promoter [171]. Therefore, a recombinant 
virion has to be built where the gene of interest is incorporated appropriately 
into the viral genome. Classically, this was attained by lengthy recombination 
procedures. The recombinant virus was first isolated by a series of plate 
selection steps, and was then used to infect cells or even susceptible larvae, that 
were then homogenized and tested for expression of the introduced gene [172].  
 
Luckow et al. [173] developed a faster system for generating recombinant 
viruses. This system, sold as the Bac-to-Bac commercial system [174], has been 
used here. It takes advantage of site-specific transposition by the Tn7 
transposon [175], an unusual mobile DNA segment that inserts itself at high-
frequency into a single specific site in the bacterial chromosome. In the absence 
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of this specific site, called attTn7 in E. coli, Tn7 transposes at low-frequency 
into many different sites. The presence of the attTn7 site endows the 
transposition reaction with specificity and high frequency of transposition. 
 
The Bac-to-Bac system uses the Autographa californica (a moth) nuclear 
polyhedrosis virus (AcNPV) [176]. The heterologous gene is cloned into the 
pFastBac™ (Invitrogen, Carlsbad, CA) plasmid [177], which, in its 
pFastBacHT version (Fig. 19, top right), has at the cloning site a polyhedrin 
promoter (PPH) and introduces a N-terminal His6 tag connected to the cloned 
sequence by a TEV protease cleavage site. This expression cassette ends with a 
SV40 polyadenylation signal to terminate transcription and for adding a polyA 
tail. The left and right arms of the Tn7 transposon flank the cassette. 
pFastBacHT also includes ampicillin and gentamicin resistance genes. 
 
An essential second element in this expression system is the DH10Bac™ E. coli 
strain (Invitrogen Carlsbad, CA) (Fig. 20), which hosts a baculovirus shuttle 
vector (called bacmid bMON14272) with an attTn7 target site where Tn7 will 
be inserted from pFastBac. The bacmid [173,177] hosts a mini-F replicon, 
which is a fragment of the naturally occurring F (fertility or sexual) factor of E. 
coli, that carries all the genes and sites required for replicon maintenance and 
control. This enables the complete baculovirus genome to replicate in E. coli as 
a large and stable low-copy number plasmid. This bacmid includes a kanamycin 
resistance marker for antibiotic selection. Also for selection purposes, the 
attTn7 site is located within the coding sequence for the LacZ α peptide, which, 
when expressed, provides the missing part of LacZ encoded in the bacterial 
chromosome under control of the lac promoter, resulting in blue colonies upon 
IPTG induction if the chromogenic LacZ substrate X-gal is present. However, 
transfer of Tn7 to the attTn7 site disrupts the coding sequence for the LacZ α 
peptide, and the corresponding colonies, although kanamycin resistant, are 
white on agar containing IPTG and X-gal. 
  
Recombinant bacmids are generated by transposing the Tn7 element from a 
pFastBac™ donor plasmid to the attTn7 attachment site on the bacmid. The 
enzyme transposase, required to effect this transfer, is provided in this system 
by another helper plasmid, pMON7124 (Fig. 20). This helper plasmid is carried 
also in the DH10Bac™ strain, providing in trans the Tn7 transposition function 
[178], as well as conferring tetracyclin resistance, thus endowing the cells 
carrying this plasmid with an extra antibiotic selection trait. 
 
The process used for preparation of recombinant CPS1-carrying pFastBac 
plasmid is schematized in Fig. 19 and is summarized in the next paragraphs. 
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Figure 19. CPS1 cloning in pFastBacHT A. The CPS1 insert is in green and the bp 
numbering of it use as 1 the A of the initial ATG of the pre-CPS1 coding sequence. 
Only the restriction sites used here are indicated. The same symbols, acronyms and 
color code are used throughout the figure: PPH, polyhedrin promoter (pink arrow); 
6xHis, 6 histidine tag (purplish box); TEV, Tobacco Etch Virus protease cleavage 
site (light orange box); SV40 polyA, Simian virus 40 polyadenylation signal (yellow 
box); Tn7L and Tn7R, left and right arms of the Tn7 transposon (blue boxes). 
Digestions are represented by scissors. Antibiotic resistance genes are colored grey. 
INTRODUCTION 
 
34 
 
 
The cDNA for mature human CPS1, carried in a plasmid provided by Dr. 
Marshall Summar (plasmid pcDNA3.1-hCPS1; a derivative of the pcDNA3.1 
plasmid from Invitrogen; see Chapter 1 of the Results), was introduced in a 
two-step process, from base 118 to the end of the ORF, in the cloning region of 
a variant of pFastBacHT, called pFastBacHT A [174], between the BamHI and 
EcoRI sites of this cloning region. The A variant of the plasmid was used 
because it was the one that allowed CPS1 gene insertion in frame (there are A, 
B and C versions, with B and C having one and two extra G bases, respectively, 
at the cloning site). This CPS1 cDNA-bearing vector was amplified and isolated 
from suitable E. coli cells (DH5α) by exploiting the ampicillin resistance 
provided by the plasmid. The presence of the insert and the correctness of the 
construction were checked by sequencing.  
 
Similarly, the parental bacmid was propagated in E. coli DHBac10 cells as a 
large plasmid that confers resistance to kanamycin and can complement the 
lacZ deletion present on the chromosome to form colonies that are blue (Lac+) 
in the presence of a chromogenic substrate such as X-gal and the inducer IPTG. 
 
Then (Fig. 20), the isolated plasmid carrying the cDNA for mature human 
CPS1, pFastBacHT A-hCPS1, was used for heat-shock transformation of E. 
coli DHBac10 cells. Transformed cells in which the Tn7 cassette had been 
transferred to the attTn7 site were selected by the white color of the colonies on 
LB agar having IPTG and X-gal. Selection also included gentamicin, 
kanamycin and tetracyclin, to ensure the co-presence of pFastBacHT, the 
bacmid and the helper plasmid. Individual white colonies were inoculated in 
liquid LB medium with these three antibiotics. After overnight growth, the 
bacmid was isolated from the pelleted cells by a modified [174] alkaline-SDS 
miniprep procedure [179] that avoids shearing forces to prevent cleavage of the 
large circular DNA. The presence of the insert in the isolated bacmid was 
checked by PCR, corroborating the expected size of the PCR product by 
agarose electrophoresis.  
 
Although production of the bacmid is an important step in the process towards 
protein expression, it is just a prerequisite that is still far from the final goal, the 
production of the protein product of interest. The path from bacmid to protein 
requires the conversion of the bacmid into a real virus provided with its capsid 
and being capable of infecting cells [173,174]. This is accomplished (Fig. 21) 
by introducing the bacmid via transfection into susceptible cells derived from 
an insect that is sensitive to the virus. Then the cells will produce virus particles 
hosting the gene for the desired protein under the control of the potent promoter 
for the late-expressed (in the viral life cycle) polyhedrin protein. In this way, 
the protein of interest will be produced. 
                                                         INTRODUCTION 
 
35 
 
 
H elper
Plasmid
pM ON7124
13.2 kb
Transposase
Helper 
Plasmid 
pMON7124 
13.2 kb 
Transposase  
Transposition 
 
E. coli DH10Bac 
Isolation of recombinant bacmid carrying cDNA(miniprep) 
  
 
 PCR 
Primers used 
 
Bacmid DNA 
mini-attTn7  
M13  
forward 
M 13  
reverse 
300 bp 
CPS1 cDNA 
Tn7L Tn7R 
6815 bp 
Transposed pFastBac sequence 
Recombinant 
bacmid 
carrying 
CPS1 cDNA 
Tn7R 
Ori-pUC 
AcNPV 
(viral 
genes) 
mini-F replicon 
L
a
cZ
α
 
LacZα 
bp 4503 
SV40 polyA 
Tn7L 
PPH 
C
P
S
1
 c
D
N
A
 
BamHI  
bp 580  
bp118 
E. coli DH10Bac  
H elper
Plasmid
pM ON7124
13.2 kb
T ransposase
pFastBacH T A–hCPS1
9.27 bp
bp 4503
EcoRI
SV40 polyA
T n7L
T n7R
CPS1 cDNA
BamH I
bp 580 
bp118
attT n7 
Ori-pUC
AcNPV (viral genes)
mini-F replicon
pM ON14272
(parental bacmid)
136 kb  
Transform 
attT n7 
Ori-pUC
AcNPV (viral genes)
mini-F replicon
pM ON14272
(parental bacmid)
136 kb  
pFastBacH T A–hCPS1
9.27 bp
bp 4503
EcoRI
SV40 polyA
T n7L
T n7R
CPS1 cDNA
BamH I
bp 580 
bp118
E. coli DH10Bac  
Resistance to: 
• Kanamycin 
• Tetracyclin 
• Gentamicin 
LacZ+ (blue 
colonies on X-gal, 
with IPTG) 
Resistance to: 
• Kanamycin 
• Tetracyclin 
• Gentamicin 
LacZ- (white 
colonies on X-gal, 
with IPTG) 
Growth of white colonies in liquid medium with 
kanamycin, gentamicin and tetracyclin 
 
Corroboration of the construct by PCR and 
by sequencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Recombinant bacmid generation. bMON14272 elements: attTn7, target site 
of the Tn7 trasposon; mini-F replicon, fragment of the E. coli F factor that enables E. 
coli low-copy number replication; AcNPV, Autographa californica nuclear 
polyhedrosis virus genes; LacZ α, gene for α peptide of LacZ; Ori-pUC, origin of 
replication of the pUC plasmid; Kana, Kanamycin. In pMON7124, Tetra, tetracyclin 
resistance gene; Transposase, genes for the enzymatic machinery for Tn7 transposition. 
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In practice, the process from bacmid to protein expression (Fig. 21) requires 
transfection optimization, the use of cells that grow fast and allow rapid viral 
production, and the production of large viral numbers for generating important 
amounts of the desired protein in relatively large volumes of cell cultures with 
high cell concentrations. The use of continuous insect cell lines that can be 
grown in medium without serum to improve transfection, the use of several 
culture rounds for escalation in the total number of virus particles, the titration 
of the virus produced (in our case using a fluorescent assay [180] rather than the 
classical plate assay [181]), and the optimization of the multiplicity of viral 
infection (number of virus particles used per cell to be infected) and of time of 
harvesting, are considered key factors for successful protein expression [174]. 
 
We have used in all the steps in which animal cells are utilized (Fig. 21) a 
commercial cell line from the moth Spodoptera frugiperda [182] called Sf9 
cells, which are round cells that grow well in plate and in suspension. For 
further methodological detail I will refer here to the instruction booklet [174] of 
the Bac-to-Bac system. Nevertheless, I would like to underline the need to use 
at the transfection step a medium devised for insect cells in the absence of 
proteins (Grace Medium unsupplemented, protein or protein hydrolysate-free) 
[183] and the utilization as transfecting agent the cationic 
liposome/lipocomplex-forming (with DNA) commercial Cellfectin II (Life 
Technologies) [184]. In all other culture steps a protein-containing or serum-
supplemented Grace medium can be utilized, although we have used a 
proprietary (from Gibco-Invitrogen) protein-free and serum-free medium (SF-
900 II SFM [185]), to lower the protein contamination in the final CPS1 
purification step. The use of protein-free medium made essential the addition of 
an anti-shearing polymeric compound, Pluronic F68 (a copolymer of 
polyethylene glycol and polypropylene glycol with an average mass of ~8 kDa; 
obtained from Sigma) to prevent cell breakage because of the orbital shaking. 
Nevertheless, shaking was moderate (120 rpm).     
 
Although secreted proteins expressed in the baculovirus/insect cell expression 
system can be recovered from the medium, this was not the case with CPS1, 
and therefore in the final step (Fig. 21) the cells were separated from the 
medium by centrifugation, and the protein was extracted from the cell pellet by 
gentle breaking of the cells using freezing and thawing in an appropriate buffer. 
 
A property of the presently used baculovirus system is that the initial pFastBac 
plasmid containing the insert encoding the protein can be subjected to standard 
site-directed mutagenesis procedures. The use of site-directed mutagenesis has 
been crucial in the studies reported in this PhD dissertation, and thus we will 
deal with it in the next section of this Introduction.  
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Figure 21. CPS1 production. Western blots of cell extracts (20 µg protein per well) 
were revealed with an anti-rat CPS1 rabbit antiserum (provided by our laboratory) 
followed by luminiscent detection with the anti-rabbit ECL system (GE-Helathcare). 
Coomassie-stained SDS-PAGE was 8% polyacrylamide. St, protein markers. 
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1.9 Site-directed mutagenesis 
 
Site-directed mutagenesis allows the replacement at will of a given residue of a 
protein by any other residue. In this way the role of particular residues and the 
effects of amino acid changes can be assessed [188]. This approach, heralded in 
the late seventies with phage DNA [189], was popularized in the eighties 
through the utilization of several alternative principles [190], including 
phosphorothioate-based approaches [191], as well as "cassette mutagenesis", in 
which a DNA fragment with the desired mutated sequence was introduced by 
restriction enzyme-mediated digestion and ligation of the mutated cassette 
[192]. The advent of the polymerase chain reaction (PCR) [193] led to the 
introduction of much easier PCR-mediated mutagenesis techniques (too 
numerous for discussion here) which use synthetic oligonucleotide primers in 
which the gene sequence has been modified to introduce the desired mutation 
[194].  
 
A potential source of problems of the PCR techniques is the incomplete fidelity 
of the polymerase used [195], leading to the possibility of introducing undesired 
mutations. Although this is not generally a problem in applications of PCR in 
which the bulk product is sequenced, such as the analysis of mutations in 
patient DNA, it is a potential problem in those applications in which a single 
DNA molecule is cloned, such as in PCR-mediated site-directed mutagenesis. 
 
When using a low-fidelity thermostable enzyme, such as the widely utilized 
Taq polymerase (which is fast, highly processive although not optimally 
thermostable, t½ at 95ºC, 40 min) [196] generally several transformed bacterial 
colonies are selected, sequencing the isolated plasmids, which generally gives 
at least one cloned mutant DNA without unwanted mutations. Alternatively, a 
thermostable polymerase having high fidelity (due to the exhibition of 
proofreading exonuclease activity) can be used [195,196] as in the Quickchange 
Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA) used here [197]. This 
kit was chosen because it is easy to use, it is not labor-intensive and it can use 
any double-stranded plasmid. Furthermore, the rather simple mutagenesis 
protocol used with this kit has a reputation of high efficiency. 
 
This kit uses a highly elegant approach to address the problem of selecting for 
the mutant form and against the wild-type gene, by exploiting the selectivity of 
the frequent-cutter (four nucleotide target site) restriction enzyme DpnI for a 
target DNA sequence with a methylated adenine at the cutting site [198]. Since 
PCR does not introduce methylations in the synthesized DNA, this allows 
discrimination between the cell-generated template wild-type DNA and the 
PCR-generated mutated DNA, by incorporating a DpnI digestion step.  
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The rationale behind mutagenesis with this kit is as follows (Fig. 22). Two 
mutagenic forward and reverse oligonucleotides, which are complementary 
between themselves and to the two strands of the gene in the region to be 
mutated (Fig. 22, top) are synthesized and used. They are mutagenic because 
they host the required DNA changes (generally not exceeding three bases for 
simple amino acid replacements). After a high temperature denaturation of the 
plasmid double helix, these primers are hybridized to the plasmid strands by 
lowering the temperature, and then the two strands of the whole circular 
plasmid including the cDNA that encodes the protein to be mutated are copied 
by a high fidelity DNA-directed DNA polymerase that can copy processively 
and highly faithfully relatively large templates. This last goal is attained in this 
kit by using an enzyme mixture called Pfu turbo, which includes Pyrochoccus 
furiosus (an organism that lives at nearly 100ºC) DNA polymerase [199] and a 
thermostable dUTPase added to prevent poisoning of the polymerase reaction 
by dUTP, thus improving PCR performance [200]. The time allocated for 
elongation should be sufficient to complete the copy of the entire plasmid. The 
entire cycle is repeated again 12-18 cycles (a small enough number to minimize 
the probability of introducing unwanted mutations), the mixture is left to 
anneal, DpnI is added to digest the methylated parental DNA, and, after 
completing the digestion, the DNA is used to transform any suitable cell type 
such as DH5α cells, which will seal the staggered nicks in the mutated plasmid.  
 
For application to the mutagenesis of CPS1 expressed in insect cells, we used as 
template for mutagenesis the pFastBac-CPS1 vector (see above and Fig. 22), 
consisting of 9242 bp (including the 4386 bp of the CPS1 insert), and the 
mutagenic primers indicated in the individual chapters of the Results section. 
Instead of using the complete commerical kit, we only utilized the proprietary 
Pfu turbo DNA polymerase/dUTPase mix, utilizing other reagents acquired 
separately. We did not follow strictly the kit recommendation of generating 
primers with a melting temperature >75ºC, utilizing in many cases primers with 
lower melting temperatures. This did not noticeably decrease the efficiency of 
plasmid copying in the elongation step of the cycle used (1-min 95ºC-melting, 
1-min annealing at a temperature appropriate for the plasmids used; 9-min 
elongation at 72º; this process repeated generally only 16 times), despite the 
utilization of an elongation temperature that in some cases exceeded that of 
melting of the plasmid-DNA complex. Possibly during the low-temperature 
annealing step there was enough elongation to increase the melting temperature 
above that used in the proper elongation step. Only in few cases we had to add 
2-4% dimethylsulfoxide (an additive used for long-PCR [201]) for successful 
results. In our hands, the efficiency of this system is close to the manufacturer 
claim of 80% success. We have always sequenced the entire CPS1 gene of the 
mutant plasmid, and we only found very rarely unwanted mutations. 
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Figure 22. Site-directed mutagenesis represented for a starting single plasmid 
molecule. The mutagenic primers used as an example (the sequences at the top and the 
blue and red arrows in the remainder of the figure) are the ones used to introduce the 
p.Asn355Asp mutation (Chapter 1 of the Results section). The vector is shown in full at 
the top, but is schematized as circles in the remainder, coloring green the CPS1 cDNA 
insert and using different color hues for plus and minus DNA strands. Adenine 
methylations (represented by black lines) are non-exact examples used for illustation. 
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1.10  CPS1 activity assays 
CPS1D refers to the existence of too little CPS1 activity to cope with the 
physiological needs of ammonia detoxification. This can be the consequence of 
too little active protein present in the tissue or of normal levels of an abnormal 
form of the enzyme exhibiting low specific activity (or of a combination of the 
two). Therefore, the assay of enzyme activities of the purified enzyme has been 
a key element in the present studies. I will comment here mainly the rationale 
of the enzyme activity determinations used in the present work. 
As already indicated, CPS1 catalyzes the following reaction: 
2ATP + HCO3
- + NH3                            2ADP + Pi + H2NCO2PO3H2 (CP) 
We have chosen here the utilization of optical assays that determine product 
concentration because they are simpler and less labor-intensive than procedures 
based on product isolation, such as chromatography. The choice of measuring 
optically product increase rather than to follow substrate decrease (as it could 
be done, for example, for ATP) is based on the fact that in substrate 
determination-based approaches the readings of the analyte (the substrate) are 
initially very high, decreasing the sensitivity of the assay. It is more sensitive to 
measure a product for which the concentration is essentially zero at the 
beginning of the reaction (initial velocity conditions).  
A point to remember with CPS assays is that carbamoyl phosphate is unstable, 
with a t1/2 of ~40 min at 37ºC and neutral pH [202], but with much faster 
decomposition at acidic and basic pH values [203]. This led us to choose an 
assay based on the continuous conversion of CP to citrulline, using the enzyme 
ornithine transcarbamylase (OTC) in the presence of ornithine. This is a time-
honored approach [41] that was amenable to our laboratory since OTC is 
commercially available (from Sigma) and, furthermore, since we produce from 
E. coli pure recombinant Enterococcus faecalis OTC [204]. 
Although OTC catalyzes a reversible reaction, the equilibrium is highly 
displaced in the direction of citrulline synthesis [205] and, if the reaction is 
carried out in the absence of phosphate and in the presence of a high 
concentration of ornithine (the case in our assays), conversion of CP to 
citrulline is highly favored. The presence of ornithine in the reactional assay is 
not a problem with CPS1, since, in contrast with what is the case with bacterial 
CPS [6], ornithine is not an activator of CPS1. Other advantages of including 
OTC and ornithine in the CPS1 assay are the lack of any requirements for the 
OTC reaction other than the presence of its two substrates [205], and the fact 
NAG, K+,Mg2+ 
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that the immediate conversion of CP to citrulline minimizes the risk of 
decomposition of the CP. Furthermore, with this system the concentration of 
CP is expected to be always be very low, thus approaching the zero product 
concentration requirement of initial velocity assays. 
It would be possible to monitor the CPS1 reaction with OTC coupling by 
measuring phosphate, or by citrulline assay, with stoichiometries of two moles 
of Pi released per mole of citrulline made by the coupled reactions of CPS1 and 
OTC: 
2ATP + HCO3
- + NH3                                  2ADP + Pi +  H2NCO2PO3H2 
 H2NCO2PO3H2 + L-Ornithine                    Pi +  L-Citrulline 
Total reaction: 
2ATP + HCO3
- + NH3 +  L-Ornithine                           2ADP+2Pi + L-Citrulline 
We have chosen to determine citrulline rather than Pi, at the end of a given 
period of assay time. This period can be lengthened in the OTC-coupled assay 
as much as needed, since CP is not decomposed due to its immediate 
conversion to citrulline. By measuring citrulline rather than Pi the total reaction 
is monitored, rather than risking to determine only the partial reaction of ATP 
hydrolysis. It has to be remembered that CP is the final product of the reaction, 
and thus, that it is generated only if all the reactional steps are completed. In 
contrast, Pi would be generated even if no citrulline were made, provided that 
the first step of the CPS1 reaction were operative (Scheme 1, pg. 13). Another 
reason for chosing citrulline is the existence of a highly sensitive color reaction 
for citrulline [29], which is based on the classical Archibald reaction for ureido 
compounds [206]. The sensitivity of this assay is good enough to allow 
monitoring substrate kinetics even at rather low concentrations of substrates 
without deviating too much from the initial velocity condition (permisivity of 
our assays, 25% consumption of the substrate being varied).  
The N-carbamoyl-L-glutamate (NCG) NAG analog used in some of the present 
studies is an ureido compound, and, therefore, it produces color in the 
colorimetric assay for citrulline [206]. Therefore, when we have used NCG, 
particularly for assaying enzyme kinetics for variable NCG concentrations, we 
have utilized an alternative assay based on the continuous determination of 
ADP with pyruvate kinase (PK) and lactate dehydrogenase (LDH) [39]: 
NAG, K+,Mg2+ 
CPS1 
OTC 
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2ATP + HCO3
- + NH3                                    2ADP + Pi +  H2NCO2PO3H2  (CP) 
2 [ADP + Phosphoenolpyruvate (PEP)                  ATP + Pyruvate] 
2 [Pyruvate + NADH + H+                                      L-Lactate + NAD+]  
Total reaction: 
HCO3
- + NH3 + 2 PEP + 2NADH + 2H
+ 
                                                                            Pi + CP + 2 L-Lactate +  2NAD
+ 
This assay is based on the fact that the reduced form of NADH, but not the 
oxidized form, NAD+, strongly absorbs light in the near ultraviolet [207] 
(maximum at λ = 340 nm, with a molar extinction coefficient of 6.2 × 103 Mol-1 
cm-1). Provided that there is enough phosphoenolpyruvate, this assay 
regenerates the ATP used, and, therefore, it is also highly appropriate for 
measuring substrate kinetics for ATP. It is true that this assay is not useful with 
highly crude enzyme preparations or when the sample is contaminated with 
other ATP-hydrolyzing activities. Nevertheless, this problem can be aleviated 
in the case of CPS1 activity by determining the NAG-dependent (or NCG-
dependent) ADP production, estimated as the increase in ADP production that 
is triggered by the addition of NAG or NCG. 
In any case, we have used the PK/LDH-coupled assay exclusively with the pure 
enzyme, and, therefore, the presence of spureous ATPases has not been a 
problem, even in the few cases in which we have determined the slow (~10% of 
the rate of the complete activity) bicarbonate-dependent ATPase activity [16]. 
This partial activity (see Scheme 1, pg. 13) is measured in the absence of 
ammonia, and reflects the slow hydrolysis of the carboxyphosphate formed in 
the first step of the reaction.  
In some cases, where many assays had to be carried out in parallel, we adapted 
the 340 nm wavelength assay to a multiwell plate. This enabled us to carry out 
the assay in 200 μl, using less enzyme and performing multiple assays in 
parallel. To standardize the plate assay, we measured the absorbance at 340 nm 
of increasing concentrations of NADH in both a regular spectrophotometer 
using a 1-cm pathlength cuvette and in the multiwell plate, and the results 
N(A/C)G, K+, Mg2+ 
CPS1 
K
+
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obtained indicated that the measurements done in the cuvette gave 2-fold higher 
absorbance than those done in 200 μl. We used this correlation for calculations.  
Another continuous assay, in this case based on the reduction of NADP (and 
therefore on the increase in the absorbance at 340 nm) has been utilized when 
needed for determining the partial reaction of ATP synthesis from ADP and 
carbamoyl phosphate which reflects the second phosphorylation step of the 
CPS1 reaction (Scheme 1, pg. 13). The coupling enzymes used are hexokinase 
(HK) and glucose-6-phosphate dehydrogenase (G6PDH) [208], as follows: 
ADP + NH2CO2PO3H2                          ATP + NH2CO2H (→ CO2 + NH3) 
ATP + D-glucose                  ADP + D-glucose-6-phosphate (G6P) 
G6P + NADP+                   NADPH + H+ + 6-phospho-D-glucono-1,5-lactone 
In summary, we have made extensive use of enzyme activity assays. These 
have been generally citrulline assays carried out in test tubes in which the 
citrulline produced was determined after 10-30 min at 37ºC (generally 10 min). 
However, in some cases we have determined ADP or ATP production in 
continuous spectrophotometric assays at 340 nm in 1-ml cuvettes or in 
multiwell plates. 
 
 
1.11 Study goals, contents, involved laboratories, and my role in this work. 
 
The central goals of this work are: 
 
a) To produce recombinant human CPS1 as an experimental platform for 
testing the effects of mutations and of chemical chaperoning on CPS1 
functionality and stability. 
 
b) To investigate the role on the enzyme functionality and stability of the 
intervening domain that links both phosphorylation domains in the CPS1 
sequence, and to clarify the reasons for the high eloquence of this domain in the 
database of missense mutations found in CPS1D patients. 
 
c) To investigate in detail the process of CPS1 activation by NAG by 
examining and analysing the effects of all the clinical mutations reported in the 
C-terminal allosteric domain as well as by analysing the effects of a number of 
experimental mutations introduced on rational bases. 
 
NAG, K+,Mg2+ 
CPS1 
K+, Mg2+ 
HK 
G6PDH 
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d) To assess the disease-causing role of all the mutations reported in patients of 
CPS1D that map in these two domains, and to determine the mechanism of the 
ill-effects of these mutations. 
 
The Results section is composed of the following three publications: 
 
- Chapter 1: 
Díez-Fernández C, Martinez AI, Pekkala S, Barcelona B, Perez-Arellano I, 
Guadalajara A, Summar M, Cervera J, Rubio V. 2013. Molecular 
characterization of carbamoyl-phosphate synthetase (CPS1) deficiency using 
human recombinant CPS1 as a key tool. Hum Mutat. 8:1149-1159. 
 
- Chapter 2: 
Díez-Fernández C, Hu L, Cervera J, Häberle J, Rubio V. 2014. Understanding 
carbamoyl phosphate synthetase (CPS1) deficiency by using the recombinantly 
purified human enzyme: effects of CPS1 mutations that concentrate in a central 
domain of unknown function. Mol Genet Metab. 112:123-132. 
 
- Chapter 3: 
Díez-Fernández C, Gallego J, Häberle J, Cervera J, Rubio V. Experimental 
studies on the inherited metabolic error carbamoyl phosphate synthetase 1 
deficiency shed light on the mechanism for switching on/off the urea cycle. 
Submitted to Journal of Genetics and Genomics. 
 
I will summarize briefly the contents of these three chapters: 
 
- Chapter 1 largely deals with the expression and production of the human 
enzyme and with the study of its properties. It not only confirms that the 
recombinant enzyme is a genuine representation of the normal liver enzyme, 
but it also studies previously unexplored properties of it, and even investigates 
the potentiality of chemical chaperoning it with NCG. Pilot site directed 
mutagenesis studies are carried out to show the value of this system for 
studying CPS1 deficiency. 
 
- Chapter 2 studies by site-directed mutagenesis the impact of all the CPS1D 
missense mutations described so far affecting a small CPS1 domain of 
unknown function that had been called the UFSD, and that links both 
phosphorylation domains in the enzyme sequence. This domain had been found 
to be clinically highly eloquent despite the fact that it does not host substrate-
binding or catalytic machinery. Our findings support the disease-causing role of 
the mutations reported to affect this domain, highlighting the value of the 
present expression system for ascertaining the disease-causing potential of 
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CPS1D mutations. They reveal this domain's key role for proper enzyme 
folding and for the regulatory cross-talk between NAG and phosphorylation 
sites. Our work has uncovered a paramount integrating role of this domain for 
building and for organizing the highly complex CPS1 architecture, leading us to 
call this domain the “Integrating domain” of CPS1. 
 
- Chaper 3 focuses on understanding CPS1 activation by studying or analyzing 
the impact of all the missense mutations lying on the C-terminal allosteric 
domain that have been found to date in CPS1D patients, as well as the effects of 
other experimental missense mutations affecting residues proposed to be 
involved in NAG binding or NAG activation. The analysis has included, in 
addition to the mutations introduced now, seven clinical and five experimental 
mutations that had been studied already but for which the full significance had 
not been inferred. Our present results and analysis clarify disease causation 
when appropriate, identify functionally important residues, and reveal that 
many of these mutations decrease the affinity of the enzyme for NAG, opening 
the way for NAG saturation therapy with the NAG analog and registered drug 
N-carbamyl-L-glutamate. Furthermore, we identify and delineate using 
molecular dynamics a NAG-triggered conformational change in the β4-α loop 
of the CPS1 C-terminal domain that is most likely the first event in the NAG 
activation process. Thus, we provide the first hint on the mechanism by which 
NAG can control the operation of the urea cycle. 
 
This work has been carried out in three different laboratories: from 01.09.2009 
to 31.12.2011 in the laboratory of Dr. Javier Cervera, in the Centro de 
Investigación Príncipe Felipe until the laboratory was closed; then the work 
continued from 01.01.2012 till the 31.05.2014 in the laboratory of Dr. Vicente 
Rubio, in the Instituto de Biomedicina de Valencia of the CSIC; with a short 
stay (16.11.2012-26.4.2013) in the laboratory of Dr. Johannes Häberle in the 
University Children’s Hospital in Zurich, Switzerland in the collaborative work 
that was a part of the work included in sections 2 and 3 of the Results. 
 
As the results of this work are conveyed in three multiauthor papers, it is 
important to clarify which part of the work is due to myself. My personal work 
includes my central involvement in the writing of the three papers, in the 
analyses conveyed therein, whereas I have been responsible for the entire 
experimental work of Chapters 2 and 3, excepting the molecular dynamics and 
docking studies of Chapter 2 (which were carried out by Dr. José Gallego). In 
the case of Chapter 1 I was responsible for most of the work on human enzyme 
expression, purification and characterization, but I was not responsible for the 
studies on the rat enzyme or on mutant enzyme forms except in the case of the 
p.Asn355Asp mutation, which I studied myself.  
                                                                                 RESULTS 
 
 
 
 
47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2   Results 
 
 CHAPTER 1: Molecular characterization of carbamoyl-
phosphate synthetase (CPS1) deficiency using human 
recombinant CPS1 as a key tool. 
 
 CHAPTER 2: Understanding carbamoyl phosphate 
synthetase (CPS1) deficiency by using the recombinantly 
purified human enzyme: effects of CPS1 mutations that 
concentrate in a central domain of unknown function. 
 
 CHAPTER 3: Experimental studies on the inherited 
metabolic error carbamoyl phosphate synthetase 1 
deficiency shed light on the mechanism for switching 
on/off the urea cycle 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
48 
 
 
 
 
 
 
 
 
                                                                                  RESULTS. Chapter 1 
 
   
 
 
49
 
RESULTS 
 
2.1 CHAPTER 1 
 
MOLECULAR CHARACTERIZATION OF CARBAMOYL-
PHOSPHATE SYNTHETASE (CPS1) DEFICIENCY USING 
HUMAN RECOMBINANT CPS1 AS A KEY TOOL 
 
by 
 
Carmen Díez-Fernández,
1,2†
 Ana I. Martínez,
2†
 Satu Pekkala,
2‡
 Belén 
Barcelona,
1-3
 Isabel Pérez-Arellano,
2,3
 Ana María Guadalajara,
2
 Marshall 
Summar,
4
 Javier Cervera,
1-3*†
 and Vicente Rubio
1,4*† 
 
1
Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain; 
2
Centro de 
Investigación Príncipe Felipe, Valencia, Spain; 
3
Group 739, CIBERER, ISCIII, 
Spain; 
4
Childrens National Medical Center, Washington, District of Columbia 
 
Published in: Human Mutation (2013) 34:1149-1159 
 
 
†CD-F and AIM have contributed equally to this 
work. JC and VR have contributed equally to this 
work. 
 
‡Current address: Department of Health Sciences, 
University of Jyväskylä, Finland; 
 
*Correspondence to: Vicente Rubio or Javier Cervera 
Instituto de Biomedicina de Valencia 
C/ Jaime Roig 11, Valencia-46010, Spain. 
E-mail: rubio@ibv.csic.es; 
E-mail: jcermir@gmail.com 
 
Contract grant sponsors: Fundación Alicia Koplowitz 
2011; Valencian Government (Prometeo 2009/051); 
Science Department of the Spanish Government 
(BFU2011-30407 and SAF2010-17933). CD-F was a 
FPU fellow of the Ministry of Euducation of Spain; 
AIM was a CIPF-Bancaja Fellow 
 
RESULTS. Chapter 1 
 
50 
 
 
 
 
 
 
 
 
2.1.1 Abstract: The urea cycle disease carbamoyl-phosphate synthetase 
deficiency (CPS1D) has been associated with many mutations in the CPS1 gene 
[Häberle et al. Hum Mutat 2011; 32:579-589]. The disease-causing potential of 
most of these mutations is unclear. To test the mutations effects, we have 
developed a system for recombinant expression, mutagenesis, and purification 
of human carbamoyl-phosphate synthetase 1 (CPS1), a very large, complex and 
fastidious enzyme. The kinetic and molecular properties of recombinant CPS1 
are essentially the same as for natural human CPS1. Glycerol partially replaces 
the essential activator N-acetyl-L-glutamate (NAG), opening possibilities for 
treating CPS1D due to NAG site defects. The value of our expression system 
for elucidating the effects of mutations is demonstrated with eight clinical CPS1 
mutations. Five of these mutations decreased enzyme stability, two mutations 
drastically hampered catalysis, and one vastly impaired NAG activation. In 
contrast, the polymorphisms p.Thr344Ala and p.Gly1376Ser had no detectable 
effects. Site-limited proteolysis proved the correctness of the working model for 
the human CPS1 domain architecture generally used for rationalizing the 
mutations effects. NAG and its analogue and orphan drug N-carbamoyl-L-
glutamate, protected human CPS1 against proteolytic and thermal inactivation 
in the presence of MgATP, raising hopes of treating CPS1D by chemical 
chaperoning with N-carbamoyl-L-glutamate.  
 
Key words: urea cycle; CPS1 deficiency; hyperammonemia; 
carbamylglutamate 
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2.1.2 Introduction 
 
Carbamoyl-phosphate synthetase 1 (CPS1) deficiency (CPS1D; MIM# 237300) 
is a rare autosomal recessive inborn error of the urea cycle [Häberle et al., 
2011], the cycle that detoxifies the neurotoxin ammonia produced in body 
protein catabolism. Unless promptly treated, the hyperammonemia caused by 
CPS1D can lead to encephalopathy, coma and death or mental retardation 
[Brusilow and Horwich, 2001; Häberle et al., 2012]. The time of onset and 
severity of the presentation appear related to the amount of residual activity of 
the enzyme in the liver [Shih, 1976]. 
 
Human CPS1 (hCPS1), a 1462-amino acid, 160-kDa multidomain 
mitochondrial liver and intestinal enzymatic protein, catalyzes the complex 3-
step reaction that is the first of the urea cycle [Pierson and Brien, 1980; Rubio, 
1993; Rubio et al., 1981, Pekkala et al., 2010]: 
                                   
                                      NAG  
2ATP + NH3+ HCO3
-  →    2ADP +  Pi + CP 
 
(NAG = N-acetyl-L-glutamate; essential activator of CPS1; CP = carbamoyl-
phosphate) 
 
The CPS1 gene (MIM# 608307) spans 120 kb, it maps to 2q35 [Summar et 
al., 1995], comprising 38 exons and 37 introns [Summar et al., 2003]. More 
than 230 genetic lesions have been reported in CPS1D, with little recurrence, 
since most mutations are "private" to individual families [Häberle et al., 2011], 
with about 140 of these mutations being missense changes for which the 
disease-causing role has not been proven in most cases.  
 
In an earlier study [Yefimenko et al., 2005] we attempted to infer the disease-
causing potential of missense mutations found in patients with CPS1D by 
introducing them in recombinantly expressed Escherichia coli CPS, studying 
experimentally the consequences of such introduction on the activity or the 
stability of the purified enzyme. Although useful, this approach had obvious 
drawbacks due to the limited (40%) sequence identity [Nyunoya et al., 1985] 
and the large functional differences between the bacterial and human CPSs. 
These differences include the use and the lack of use by bacterial CPS of, 
respectively, glutamine and NAG [Meister, 1989], while CPS1 cannot use 
glutamine as ammonia donor, utilizing ammonia with high affinity, and it needs 
NAG as an essential allosteric activator without which it is inactive [Rubio et 
al., 1981, 1983a]. In fact, the role of the CPS1 N-terminal 40-kDa region (Fig. 
1A), corresponding to the glutamine-splitting, small subunit of bacterial 
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Figure 1. Domain composition of human CPS1. A: Linear scheme of mature CPS1, 
highlighting four interdomain linkers that are cleaved by the indicated proteases as 
identified in rodent CPS1, with the corresponding fragments masses (in kDa) above them 
[Marshall and Fahien, 1988]. Chymo, chymotrypsin.  Trypsin(2) denotes cleavage after 
scission at the other tryptic site. The bars shaded grey schematize the 40-kDa N-terminal 
and the 120-kDa C-terminal CPS1 moieties that correspond to the small and large 
subunits of E. coli CPS, respectively. Polyclonal rabbit antibodies raised against these 
isolated moieties are called Anti-40 and Anti-120. Functional domains are shown in 
background texture and are identified. Glnase-like corresponds to the Glnase domain of 
bacterial CPS, but has no known function in CPS1. ??, unknown function. A dashed line 
separates two domains composing a proteolytic domain. (continued in the next page)  
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 CPS [Meister, 1989; Nyunoya et al., 1985] is uncertain in CPS1, and thus, the 
impact of hCPS1 mutations affecting this region cannot be inferred from E. coli 
CPS studies. Furthermore, the unique characteristics among CPSs of the NAG 
activation of CPS1 makes difficult to infer from bacterial CPS studies the 
impact of hCPS1 mutations mapping in the C-terminal 20-kDa of this enzyme, 
since this region (the allosteric or regulatory domain, Fig. 1A) hosts the site for 
NAG [Pekkala et al., 2009, Rodríguez-Aparicio et al., 1989] and must generate 
the allosteric signal that shift CPS1 from inactive to active.  
 
We now exploit our recent success in producing recombinant rodent CPS1 in a 
baculovirus/insect cell system [Pekkala et al., 2009], to develop a similar 
system for recombinant production of pure human CPS1 (rhCPS1). Although 
harboring an N-terminal His-tag to help purification, rhCPS1 is proven here to 
have the same properties and characteristics as CPS1 purified from human liver 
[Pierson and Brien, 1980; Rubio et al. 1981] and the same domain composition 
as the well-studied rodent enzyme [Evans and Balon, 1988; Marshall and 
Fahien, 1988; Powers-Lee and Corina, 1986]. We demonstrate the value of this 
expression system for testing the functional impact of missense mutations found 
in CPS1D, thus helping infer the disease-causing role of these mutations. 
Furthermore, we show that NAG and its analogue and orphan drug N-carbamyl-
L-glutamate (NCG) importantly decrease hCPS1 susceptibility to proteolytic 
attack and thermal inactivation, raising hopes that NCG might be used as a 
 
Fig. 1, cont'd: The two polymorphisms (in italic and grey background) and the eight 
clinical mutations studied here are mapped in the CPS1 polypeptide with banners. B, C 
and D: Top part, fragments generated with trypsin, elastase or chymotrypsin [Marshall 
and Fahien, 1988]. The cleavage points are identified with the ABCD notation used in 
panel A. Each tryptic fragment is called T1-T3, elastase fragments E1-E4 and the 
chymotryptic one C1. Their approximate masses and their reactivity with Anti-40 and 
Anti-120 antibodies are given. The 20 kDa C-terminal fragment is rapidly degraded 
[Marshall and Fahien, 1988] and is shown crossed. Lower parts, SDS-PAGE of 
digested recombinant human CPS1 and, for comparison, of rat liver CPS1, stained with 
Coomassie or by immunoperoxidase with Anti-40 or Anti-120 after western blotting 
(only done with the rat enzyme). Digestions of CPS1 (1.3-2 mg/ml) were at 37º, for 15-
30 min with the indicated protease (4-16 g/ml; pancreatic, from Boheringer 
Mannheim or Sigma) in 35 mM Tris-HCl pH 7.4, 9% glycerol, 1.5 mM DTT, 20 mM 
KCl and 10 mM NAG. The enzyme was preincubated at least 15 min at 37ºC prior to 
the addition of the protease. This addition was considered time zero. Fragments are 
identified in the gels as T1-T3, E1-E4 or C1. Note in (D) that while chymotrypsin 
inactivates rat and human CPS1 (see the plot), there is little decrease (2 kDa) in 
polypeptide mass (top panels), corresponding to the loss of approximately 12 residues 
from the enzyme C-terminus documented earlier for rat CPS1 [Marshall and Fahien, 
1988].  
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chemical chaperone for treating CPS1D due to misfolding-causing mutations. 
The present results have also produced novel information on the significance of 
the N-terminal and C-terminal domains of CPS1. 
 
2.1.3 Patients and methods 
 
2.1.3.1 Patients and CPS1 mutations 
 
The eight missense mutations chosen (Table 1) were reported [Eeds et al., 2006; 
Finckh et al., 1998; Kurokawa et al., 2007; Summar, 1998] in seven CPS1D 
patients with neonatal presentations, implying high disease severity. Patients 4 
and 1 (Table 1) were, respectively, homozygous or compound heterozygous for 
one or two missense mutations, whereas in patients 2 and 6 the mutation was 
detected in mRNA studies that failed to detect a second mutant allele. The other 
three patients (Table 1) carried in one allele a missense mutation and in the 
other a truncation-causing change (nonsense changes in patients 3 and 7; a 
frameshift in patient 5) that, because of the large protein region deleted, should 
cause enzyme inactivation. The PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2) [Adzhubei et al., 2010] and MutPred 
(http://mutpred.mutdb.org) [Li et al., 2009] servers assigned these mutations 
with a high probability of being pathogenic, whereas they made predictions of 
benignity for two polymorphisms causing non-synonymous amino acid 
substitutions [Finckh et al., 1998; Summar et al., 2003] that are studied also 
here as negative controls (Table 1). 
 
All the mutations dealt with here were already included in the locus-specific 
database for CPS1 (http://www.lovd.nl/CPS1). Amino acid conservation (Table 
1) was determined by ClustalW sequence alignment of either CPS1, CPSIII or 
other CPSs from 15, 6 and 270 species, respectively. 
 
2.1.3.2 Recombinant human CPS1 production 
 
Human CPS1 cDNA [Haraguchi et al., 1991] (GenBank entry NM_001875.4), 
was generated from human liver mRNA [Summar et al., 2003] as two 
complementary fragments by two RT-PCR reactions with appropriate primers. 
After sequential incorporation of these fragments into pcDNA3.1 (from 
Invitrogen), the complete CPS1 cDNA was reconstructed within this plasmid 
by exploiting a unique HindIII CPS1 site, yielding pcDNA3.1-hCPS1. Then 
(Supp. Fig. S1) a 3985 bp fragment comprising the CPS1 open reading frame 
(ORF) from base 580 onwards (base 1 is the A of the translation initiation 
codon) was excised from this plasmid by BamHI and EcoRI, and was ligated 
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into pFastBac. The ORF encoding mature CPS1 (lacking the N-terminal 
mitochondrial targeting sequence, bp 1-117) was completed by in-frame 
ligation of a PCR-generated fragment comprising bp 118-579 of the CPS1 
cDNA (primers: Cloning_F and Cloning_R, Supp. Table S1; they incorporate a 
BamHI site for cloning). This yielded pFastBac-CPS1, which encodes mature 
hCPS1 (amino acids 40-1500) preceded N-terminally by the His6-tag 
MSYYHHHHHHDYDIPTTENLYFQGAMDP. Site-directed mutagenesis of 
pFastBac-CPS1 was performed by the overlapping extension method 
Supplementary Figure S1. 
 Diagram schematizing the 
steps of the production of 
recombinant human CPS1. 
The gel (SDS-PAGE, 
Coomassie staining, the 
arrows give the positions of 
protein standards of the 
indicated polypeptide 
masses) illustrates the 
presence of abundant 
soluble CPS1 protein in the 
postcentrifugal supernatant 
of the cell extract (left 
track) and the essential 
homogeneity of the purified 
protein (right track).  
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(Quickchange kit from Stratagene) using the forward and reverse primers given 
in Supp. Table S1. The correctness of the constructs, the presence of the desired 
mutation, and the absence of unwanted mutations, were corroborated by 
sequencing. 
 
For producing rhCPS1 (Supp. Fig. S1), we used the commercial Bac-to-Bac® 
Baculovirus Expression System (Invitrogen), following the manufacturer's 
directions. In short, E. coli Max Efficiency DH10Bac cells (Invitrogen), 
transformed with pFastBac-CPS1, were grown on LB-agar containing 
50/7/10/40/100 g/ml of, respectively, kanamycin/ 
gentamycin/tetracyclin/IPTG/Bluo-Gal. Individual white colonies were 
inoculated into 5-ml LB medium with the same antibiotics, cultured overnight, 
and the bacmid was isolated. The baculovirus was produced by transfecting Sf9 
insect cells with CPS1 cDNA-carrying (proven by PCR) bacmid, using 
Cellfectin/Grace medium (5 hours, 27ºC), followed by 3-day culture (27ºC, six-
well plate) in Sf900 medium (Invitrogen) containing 0.1% Pluronic F-68, 50 
U/ml penicillin and 50 g/ml streptomycin. The culture was centrifuged, and 
the supernatant was used for baculovirus enrichment by infecting with it (1:60 
dilution) a suspension of 1.5x106 Sf9 cells/ml. After 48-hour culturing (27ºC, 
orbital shaking at 125 rpm) and centrifugation, the supernatant was used to 
inoculate (1:50 dilution) a fresh cell suspension for CPS1 production, collecting 
the cells by centrifugation after 3 days of culture as above.  
 
 
2.1.3.3 Enzyme purification 
 
Unless indicated, all steps (Supp. Fig. S1) were at 4ºC. To purify rhCPS1 (wild-
type or mutant forms), the insect cell pellet from a 50-ml culture was suspended 
in 3 ml of a lysis solution [50 mM glycyl-glycine, pH 7.4, 1 mM dithiothreitol 
(DTT), 10% glycerol, 20 mM KCl, 0.1% Triton X-100, 5 μM E-64 protease 
inhibitor and 1% of the protease inhibitor cocktail for His-tagged proteins 
(Sigma product P8849)] and was thawed (melting ice) and frozen (liquid 
nitrogen or dry CO2-acetone mixture) three times. After 10-min centrifugation 
(16,000xg) and supernatant filtration through a 0.22 m membrane, the 
supernatant was applied to a HisTrap HP 1-ml column fitted in an ÄKTA FPLC 
system (GE Healthcare) that was equilibrated with 50 mM glycyl-glycine pH 
7.4, 1 mM DTT, 10 % glycerol, 0.5 M NaCl, and 20 mM imidazole. After a 10-
ml column wash, a 15-ml linear gradient of 20-500 mM imidazole in the same 
solution was applied. The CPS1-containing fractions (monitored by SDS-
PAGE) were pooled, concentrated to 3-5 mg protein/ml by centrifugal 
ultrafiltration (100-kDa cutoff membrane, Amicon Ultra, Millipore), enriched 
with 10% extra glycerol and 1 mM extra DTT, and frozen at -80ºC.  
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Rat liver CPS1, and E. coli-expressed recombinant Enterococcus faecalis 
ornithine transcarbamylase (OTC) [Barcelona-Andrés et al., 2002] were 
purified as reported [Alonso and Rubio, 1983; Marshall and Cohen, 1972].  
 
 
2.1.3.4 Enzyme activity assays 
 
In the standard CPS1 assay, CP was converted to citrulline, which was 
measured colorimetrically [Pekkala et al., 2009]. The enzyme was incubated 10 
min at 37ºC in an assay mixture containing 50 mM glycyl-glycine pH 7.4, 70 
mM KCl, 1 mM DTT, 20 mM MgSO4, 5 mM ATP, 35 mM NH4Cl, 50 mM 
KHCO3, 10 mM NAG, 5 mM L-ornithine and 4 U/ml OTC. When the 
concentration of a substrate was varied, other substrates were kept at the 
concentrations given above (unless indicated), with MgSO4 being in 15 mM 
excess over ATP. 
 
Since NCG yields color in the citrulline assay, when testing the NCG 
concentration-dependence of CPS1 activity, we used a continuous pyruvate 
kinase/lactate dehydrogenase coupled assay in which ADP production was 
monitored as NADH oxidation at 340 nm [Guthorlein and Knappe, 1968]. The 
assay (37ºC) used the same solution as the standard assay except for the lack of 
OTC and ornithine and the inclusion of 2.5 mM phosphoenolpyruvate, 0.25 
mM NADH, 40 g/ml pyruvate kinase and 25 g/ml lactate dehydrogenase. 
 
The kinetic parameters for NAG were identical, within experimental error, in 
this assay and in the standard assay. This NADH oxidation-coupled assay, 
without NH4Cl, was used for measuring the HCO3
--dependent ATPase partial 
reaction of CPS1. For measurement of the partial reaction of ATP synthesis 
from CP and ADP, an NADP reduction-coupled assay [Yefimenko et al., 2005] 
was used, monitoring the absorbance at 340 nm in a mixture at 37ºC containing 
50 mM glycylglycine pH 7.4, 0.1 M KCl, 15 mM MgSO4, 15 mM glucose, 
0.5mM ADP, 5 mM CP, 10 mM NAG, 1 mM NADP, 1 mM DTT, 0.1 mg/ml 
hexokinase and 25 g/ml glucose-6-phosphate dehydrogenase. One CPS1 unit 
produces per minute 1 mol citrulline or 2 mol ADP. The program GraphPad 
Prism (GraphPad Software, San Diego, California) was used for curve fitting.  
 
2.1.3.5 Other techniques 
 
SDS-PAGE [Laemmli, 1970] was performed in 8% polyacrylamide gels, with 
Coomassie staining or, for cell extracts, by western blotting/immunostaining 
(ECL system, GE Healthcare), utilizing an anti-rat liver CPS1 first antibody 
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[Alonso et al., 1989]. Western blots of rat liver CPS1 protease digests (Fig. 1) 
were stained with immunoperoxidase [Alonso et al., 1989] using as first 
antibodies rabbit antisera against the electrophoretically separated [Amero et 
al., 1994] N-terminal 40-kDa or C-terminal 120-kDa moieties of rat liver CPS1 
(produced by limited elastase digestion [Marshall and Fahien, 1988]). Protein 
was determined according to [Bradford, 1976] using bovine serum albumin as 
standard. 
 
Supplementary. Table S1. Synthetic oligonucleotides used in cloning and 
site-directed mutagenesis 
Name/ 
mutation 
Direction Sequence 5´- 3´ 
Cloning_F Forward CGCATGGATCCGTCTGTCAAGGCACAGACAa 
Cloning_R Reverse TTTATTTGGATCCACAAAATCCACAGGa 
p.T344A Forward CTATGCCTTGGACAACGCTCTCCCTGCTGGCb 
p.T344A Reverse GCCAGCAGGGAGAGCGTTGTCCAAGGCATAGb 
p.N355D Forward CACTTTTTGTGGATGTCAACGATCb 
p.N355D Reverse GATCGTTGACATCCACAAAAAGTGb 
p.Y389C Forward CAATAGACACTGAGTGCCTGTTTGATTCCb 
p.Y389C Reverse GAATCAAACAGGCACTCAGTGTCTATTGGb 
p.L390R Forward CAATAGACACTGAGTACCGGTTTGATTCCb 
p.L390R Reverse GAATCAAACCGGTACTCAGTGTCTATTGGb 
p.A438P Forward CCATTGGTCAGCCTGGAGAATTTGb 
p.A438P Reverse GTAATCAAATTCTCCAGGCTGACCAATGGACb 
p.T544M Forward CATTATGGCTATGGAAGACAGGCAGCTGb 
p.T544M Reverse CTGCCTGTCTTCCATAGCCATAATGGACb 
p.G1376S Forward CCAAGATTCCTTAGTGTGGCTGAACAATTACb 
p.G1376S Reverse GTAATTGTTCAGCCACACTAAGGAATCTTGGCCb 
p.A1378T Forward CCTTGGTGTGACTGAACAATTACb 
p.A1378T Reverse GTAATTGTTCAGTCACACCAAGGAATCb 
p.L1381S Forward CTTGGTGTGGCTGAACAATCACACAATGAAGGTTTCAAGb 
p.L1381S Reverse GAAACCTTCATTGTGTGATTGTTCAGCCACACCAAGGb 
p.T1443A Forward CTTCCCAACAACAACGCTAAATTTGTCb 
p.T1443A Reverse GGACAAATTTAGCGTTGTTGTTGGGAAGb 
aUnderlining marks the BamH1 restriction sites  
bBold type indicate base substitutions to introduce the desired mutation.  
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2.1.4 Results and Discussion 
 
 
2.1.4.1 Producing human CPS1 in a baculovirus/insect cell system 
 
In the liver, CPS1 is produced as a precursor that is matured by cleavage of its 
N-terminal 38-39 amino acids upon entry to the mitochondria [Ryall et al., 
1985]. We cloned for recombinant expression the cDNA for human liver CPS1 
without the N-terminal 39 codons, which were replaced by a 28-codon N-
terminal His6-tag. This allowed testing the effects of the mutations on the 
mature form of the enzyme (the functional one in vivo). The tag simplified and 
speeded CPS1 purification, what is important, given the instability of 
mammalian CPS1 [Raijman and Jones, 1976] and its sensitivity to proteolytic 
attack [Guadalajara et al., 1983]. The CPS1 expressed here carries the more 
frequent Thr form of the p.Thr1406Asn polymorphism (rs1047891, Ensemble 
database; allelic frequencies of T/N forms, 0.7/0.3) that has been associated 
with increased frequency of some vascular pathologies possibly related to 
decreased citrulline levels and nitric oxide production (see for example 
[Pearson et al., 2001]).  
 
The procedure used (Supp. Fig. S1), optimized for highest rhCPS1 production, 
had as important elements the use of insect cells cultured for two weeks after 
unfreezing, and the infection of the cells with a nominal virus-to-cell ratio of 2 
in the final CPS1-production step, leaving 72 hours the infected cells in culture 
(27ºC, orbital shaking, 125 rev/min), in either 50 or 200 ml of medium, before 
cell harvesting. Purification was possible weeks after harvesting by freezing 
cells pellets at -80ºC. 
 
Prior studies with liver-purified hCPS1  [Pierson and Brien, 1980; Rubio et al., 
1981] and even more extensive studies with rat liver CPS1 [Alonso et al., 1992; 
Guadalajara et al., 1983; Guthöhrlein and Knappe, 1968; Marshall and Fahien, 
1985, 1988; Raijman and Jones, 1976] showed that mammalian CPS1 is highly 
instable, requiring precautions to avoid oxidation, proteolytic cleavage and 
inactivation of unknown cause but preventable by glycerol. Taking into account 
these factors, we used for cell extract preparation and in subsequent steps a 
neutral medium at 4ºC containing 10% glycerol, 1 mM DTT and a very 
extensive protease inhibitor cocktail, using a fast 3-step purification protocol 
consisting of cell disruption by freeze-thawing in 0.1% Triton X-100-containing 
CPS1-protecting solution, centrifugal clarification and 0.22 m-pore membrane 
filtration, and a final step of fast Ni-affinity column chromatography with 
imidazole gradient elution. 
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rhCPS1, which represented 10% of the soluble cell protein (Supp. Fig. S1, left 
track of the gel), was largely soluble (not illustrated) and yielded after the 
column chromatography step 15 mg per L of cell culture, of highly active 
(Table 2), homogeneous and pure enzyme as shown by the finding in SDS-
PAGE of a single band migrating as expected for its sequence-deduced mass 
(163.9 kDa). (Supp. Fig. S1, right track of the gel). 
 
Table 2. Comparison of the activity, the apparent Km values for the 
substrates and the Ka values for N-acetyl-L-glutamate (NAG) or for its 
analog N-carbamyl-L-glutamate (NCG), for recombinant or natural 
human CPS1 
 
Source 
Activity 
U/mg 
Apparent Km or Ka value (mM) 
ATP HCO3
- NH4
+ NAG NCG 
Recombinanta 1.1 0.5 4.0 1.0 0.14 2.0 
Liverb 1.5 1.1 6.7 0.8 0.10 - 
Liverc 1.5 0.3 2.2 1.3 0.15 2.0 
aPresent work. 
bPierson and Brien, 1980. 
cRubio et al., 1981.  
 
 
2.1.4.2 Recombinant human CPS1 represents well the natural liver enzyme 
 
It was important to ascertain that rhCPS1 closely represents in all its properties 
natural hCPS, particularly since, to minimize enzyme inactivation, the N-
terminal His6-tag was not removed. Similarly to liver CPS1, rhCPS1 has an 
essential requirement for NAG (Fig. 2A). Its specific activity (Table 2) is 
similar to that reported for liver-isolated human CPS1 [Pierson and Brien, 1980; 
Rubio et al., 1981]. Apparent Km values for ATP, HCO3
- and NH4
+, and the Ka 
for NAG and for the drug analogue of NAG, NCG, are also within published 
value ranges for natural hCPS1 (Table 2 and Fig. 2) [Pierson and Brien, 1980; 
Rubio et al., 1981].  
 
rhCPS1 also presents the same oligomeric state as liver-derived hCPS [Rubio et 
al., 1981]. Gel exclusion chromatography experiments (Fig. 3A) reveal highly 
similar peaks and estimated masses for the natural human enzyme and for 
rhCPS1: in both cases the apparent mass exceeds by <30% that of the 
monomer, indicating that the enzyme consists of monomers in rapid 
equilibrium with dimers, with strong predominance of the monomers. 
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2.1.4.3 Glycerol partially replaces NAG in the activation of human CPS1. 
  
We also investigated potentially crucial traits of hCPS1 that had not been 
amenable to investigation until now. Thus, we show here (Fig. 3B, right panel) 
that hrCPS1 is activated by glycerol in the absence of NAG, whereas in the 
presence of NAG is inhibited by increasing concentrations of glycerol. Similar 
observations had been made with rat liver CPS1 (Fig. 2B, left panel and 
[Britton et al., 1981; Rubio et al., 1983b]). The substantial activation attained 
with glycerol and the fact that this polyol appears to activate CPS1 without 
specifically binding to the NAG site [Rubio et al., 1983b] make conceivable the 
possibility of developing treatments for CPS1D patients with a damaged NAG 
site, in which CPS1 could be activated by compounds that do not bind to the 
NAG site.   
 
 
2.1.4.4 Limited proteolysis reveals the hCPS1 domain organization. 
 
The domain composition of hCPS1 had not been made amenable to 
investigation until now. The structure of E. coli CPS [Thoden et al., 1997] had 
revealed a multidomain organization that was anticipated [Rubio, 1993] by the 
Figure 2. Dependence of CPS1 activity on the concentrations of NAG and 
bicarbonate for non-mutated (WT) CPS1 and for the indicated mutant forms. The 
curves fitted to the data are hyperbolae for the kinetic constants given in Table 3. The 
insets expand the curves for the mutants, to demonstrate the hyperbolic kinetics 
despite the decreased activity. A: NAG varied. In the case of the p.Thr544Met mutant 
the concentration of bicarbonate was fixed at 0.5 M. B: bicarbonate varied. 
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 results of limited proteolysis and of other studies with rodent and E. coli CPSs 
[Cervera et al., 1993; Evans and Balon, 1988; Marshall and Fahien, 1988; 
Powers-Lee and Corina, 1986; Rodríguez-Aparicio et al., 1989; Rubio et al., 
1991]. Limited proteolysis studies with rodent CPS1 revealed four points of 
preferential proteolytic cleavage that appear to correspond to exposed 
the use of a Superdex 200HR (10/300) column mounted on an Äkta fast protein liquid 
chromatography system, at a flow rate of 0.5 ml/min, the application of 0.02 ml of a 3 
mg/ml solution of human recombinant CPS1 or appropriate amounts of protein 
standards, and the continuous monitoring of the optical absorption at 280 nm. Protein 
standards for this panel were (masses are given in parenthesis, in kDa) bovine 
pancreatic ribonuclease A (13.7), bovine serum albumin (66.4), yeast alcohol 
dehydrogenase dimer (73.4) and tetramer (146.8), β-amylase (223.8) and ferritin (440). 
B: Effects of the addition of glycerol on CPS1 activity in the presence or in the absence 
of 10 mM NAG as indicated (closed and open circles, respectively).  Velocities, 
measured as ADP production, are expressed as a percentage of the velocity in the 
presence of 10 mM NAG and in the absence of glycerol. Left and right panels, results 
with the rat liver enzyme and with the recombinant human enzyme, respectively.    
 
Figure 3. Recombinant human CPS1 
replicates the natural enzyme in the 
oligomeric state and the ability to be 
activated and inhibited by glycerol. A: 
Gel exclusion chromatography analysis. 
The upper lines are the semilogarithmic 
plots of the masses of marker proteins 
(closed circles) versus their elution 
volumes. Peaks of CPS1 activity (left 
panel, open symbols) or of CPS1 protein 
(peak in the right panel) are shown 
below them. The mass of CPS1, 
estimated by interpolation, is shown 
above a vertical line emerging from the 
peak. Left panel, results with the enzyme 
purified from human liver [Rubio et al., 
1981], using a conventional 0.9  56 cm 
column of Sephadex G-200 run at 23ºC. 
For further details, including the list and 
masses of standards used, see [Rubio et 
al., 1981]. Right panel, present results 
with the recombinant human enzyme 
under essentially the same conditions as 
those in [Rubio et al., 1981] except for  
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sequences linking adjacent globular domains, and which are differentially 
cleaved by elastase, trypsin and chymotrypsin [Powers-Lee and Corina, 1986; 
Marshall and Cohen, 1988] (Fig. 1). We observed limited tryptic or elastase 
digestion patterns with hrCPS1 that fully comply with the reported 
fragmentation patterns for rat liver CPS1 (Figs. 1B and C)  [Marshall and 
Fahien, 1988; Powers-Lee and Corina, 1986]. These findings support the 
existence of the same domain organization and architecture in human and rat 
CPS1, also supporting the similarity of this architecture with that of E. coli CPS 
[Rubio et al., 1991; Thoden et al., 1997]. Interestingly, as with rat liver CPS1 
[Marshall and Fahien, 1988], chymotrypsin inactivated rhCPS1 (Fig. 1D, plot) 
while decreasing very little CPS1 polypeptide size (Fig. 1D, gels), in agreement 
with prior experiments with rat liver CPS1 that showed that the enzyme is 
cleaved very close to its C-terminus [Marshall and Fahien, 1988]. 
 
 
2.1.4.5 Testing the effects of clinical CPS1D mutations on enzyme 
functionality 
 
The present results show that the properties of rhCPS1 mirror those of natural 
CPS1, supporting the use of rhCPS1 for testing the impact of clinical mutations 
on enzyme function and stability. We demonstrate this use here with eight 
missense mutations found in seven neonatal CPS1D patients (Table 1 and Fig. 
1A) [Eeds et al., 2006; Finckh et al., 1998; Kurokawa et al., 2007; Summar, 
1998] and with two trivial polymorphisms (Table 1 and Fig. 1A) [Finckh et al., 
1998; Summar et al., 2003]. Of these ten amino acid substitutions, two map in 
the bicarbonate phosphorylation domain (a catalytic domain) and are therefore 
likely to hamper activity. The other eight changes were selected because they 
map in CPS1 regions of unclear or unique function for which bacterial CPS 
would not be a good model. Thus, four of them map in the Glnase-like 
subdomain and another four in the C-terminal domain (Fig. 1A). In any case, E. 
coli CPS would not have been an optimal model for nine of these amino acid 
substitutions, since only one affected residue is strictly conserved in all CPSs 
(Table 1). 
 
As expected, the polymorphisms p.Thr344Ala (c.1030A>G) and p.Gly1376Ser 
(c.4126G>A), mapping respectively in the Glnase-like and the NAG-binding 
domains (Fig. 1A), caused no negative effects on enzyme production (Fig. 4A),  
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activity (Fig. 4C), kinetic parameters for each substrate or for NAG (Table 3), 
or on thermal stability (Fig. 4D). In contrast, two clinical mutations affecting 
respectively these same regions, p.Leu390Arg (c.1169T>G) and p.Leu1381Ser 
Figure 4. Production and properties of 
the enzyme forms with the amino acid 
substitutions studied here. A:  SDS-
PAGE (8% polyacrylamide, 
Coomassie staining) of purified human 
recombinant CPS1, either wild-type 
(WT) or carrying the indicated 
mutations. Polymorphisms are shown 
in italic script and underlined. St, 
protein markers with masses indicated 
on the side. B: Western blot of cell 
extracts (20 g protein per well) of 
Sf9 cells infected with baculoviruses 
encoding either wild-type human CPS1 
or its p.Leu390Arg or p.Leu1381Ser 
mutants. A polyclonal rabbit antiserum 
against rat liver CPS1 was used for 
immunostaining. C: Enzyme activity 
(standard assay conditions) of the 
purified wild-type or mutant human 
CPS1 forms. The bars for the wild-type 
enzyme, for the two polymorphisms 
and for the forms carrying clinical 
mutations are filled in white, 
checkerboard and black, respectively. 
Error bars give standard errors. D: 
Thermal stability of wild-type 
recombinant CPS1, and of the forms 
carrying either the polymorphisms (in 
italic and underlined), or the indicated 
clinical mutations. The enzyme, at 0.5-
1 mg/ml in a solution of 50 mM glycyl-
glycine pH 7.4, 20 mM KCl an 20% 
glycerol, was heated 15 min at the 
indicated temperature, then rapidly 
cooled to 0ºC, and its activity 
determined immediately at 37ºC. The 
horizontal dashed line marks 50% 
inactivation, whereas the vertical 
dashed lines cross the X-axis at the 
temperature at which 50% inactivation 
occurs for each enzyme form. 
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(c.4142T>C) (Fig. 1A), were clearly disease-causing, since they induced strong 
CPS1 instability as revealed by western blotting of insect cell extracts that 
showed (Fig. 4B) proteolytic digestion bands instead of the clear-cut CPS1 
band observed with the wild-type enzyme. Indeed, these two mutations, which 
replace hydrophobic residues (residues of hydrophobic nature are found at these 
positions in all known CPS sequences, Table 1) by polar residues of larger 
(p.Leu390Arg) or smaller (p.Leu1381Ser) size, were predicted by the MutPred 
server to be associated with loss of stability (Table 1). The other six mutations 
studied (Table 1) were sufficiently stable to allow purification (Fig. 4A). The 
p.Ala438Pro (c.1313G>C) and p.Thr544Met (c.1631C>T) mutations, which 
affect the bicarbonate-phosphorylation domain, and the p.Thr1443Ala 
(c.4327A>G)  mutation, which affects the C-terminal domain, greatly decreased 
enzyme activity, to undetectable or nearly undetectable values (Fig. 4C), clearly 
indicating that they are disease-causing. Although having no detectable activity 
in the assay for the complete reaction (detection limit, 1% of the activity of 
wild-type rhCPS1), the p.Ala438Pro mutant catalyzed the partial reaction of 
ATP synthesis from ADP and CP (not shown) that is the reversal of the final 
step of the CPS1 reaction (a three-step reaction: 1- bicarbonate 
phosphorylation; 2- carbamate production from carboxyphosphate and 
ammonia; and 3- carbamate phosphorylation) but, as expected from the domain 
that is affected by the mutation, it failed to catalyze the bicarbonate-dependent 
ATPase partial reaction that reflects the bicarbonate phosphorylation step 
[Metzenberg et al., 1958; Rubio et al. 1981].  
 
The large decrease in the activity of the p.Thr544Met mutant was shown to be 
due (Table 3 and Fig. 2) to the combination of a 60-fold increase in the 
apparent Km for bicarbonate, a 20-fold increase in the Ka for NAG and a 4-
fold respective decrease and increase in the apparent Vmax and Km for ammonia. 
Except the increase in the Ka
NAG, these kinetic aberrations stem from the fact 
that this mutation affects a domain that catalyzes the initial two steps of the 
reaction, involving as substrates ATP, bicarbonate (step 1) and ammonia (step 
2) [Rubio 1993; Thoden et al., 1997]. The increased Ka
NAG cannot be attributed 
to direct changes in the NAG site, which sits on another enzyme domain 
[Rodríguez-Aparicio et al. 1989], but to the hampering of the cross-talk 
between the bicarbonate phosphorylation domain and the NAG binding domain 
that results in a large increase in affinity for NAG when both ATP and 
bicarbonate are bound [Alonso and Rubio, 1983]. 
 
The decrease in enzyme activity caused by the p.Thr1443Ala mutation, (Fig. 
4C) is accounted by a nearly 200-fold increase in the Ka
NAG and by a nearly 10-
fold decrease in the apparent Vmax (Table 3 and Fig. 2A). The localization of the 
NAG-binding domain justifies these effects if the mutation hampers NAG 
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binding and the transmission of the regulatory signal from the NAG site to both 
phosphorylation domains. Indeed, the two partial reactions of the enzyme, 
which reflect the two phosphorylation steps, were undetectable in this mutant 
(results not shown). 
 
The other three mutations examined here, p.Asn355Asp (c.1063A>G) and 
p.Tyr389Cys (c.1166A>G) which affect the Glnase-like domain and coexist in 
patient 1, and p.Ala1378Thr (c.4132G>A), which maps on the NAG-binding 
domain, appear to have too little an effect on enzyme activity or on kinetic 
parameters to justify the neonatal deficiency (Fig. 4C, Table 3).  The largest 
changes observed with these mutations were a 4-fold decrease in Vmax and a 
nearly 3-fold increase in the Ka for NAG, occuring with the p.Asn355Asp 
mutation (Table 3). However, thermal inactivation assays (Fig. 4D) revealed 
that these mutations substantially decreased the thermal stability of rhCPS1, 
particularly p.Asn355Asp, which lowered 11ºC the mid-inactivation 
temperature. In contrast, the temperature dependence of enzyme inactivation 
was identical for the two polymorphisms and for the wild-type enzyme (Fig. 
4D). The combined effects of the decrease in Vmax and the modest increase in 
Ka
NAG with the p.Asn355Asp mutant, together with the decreased enzyme 
stability, may result in enzyme deficiency. This may also be the case with the 
p.Tyr389Cys mutation, which decreased 40% enzyme activity (Fig. 4C) and 
caused a substantial, although less drastic effect on thermal inactivation. 
Finally, with p.Ala1378Thr, the deficiency could be due to the combination of 
the decreased stability and a twofold increase in apparent Km for ATP (Table 3). 
The fact that these last two mutations are, respectively, only one and three 
positions away from Leu390 and Leu1381, two residues for which their 
p.Leu390Arg and p.Leu1381Ser mutations were found to cause dramatic loss of 
enzyme stability (see above), lends further support to the view that these 
mutations may hamper sufficiently enzyme stability "in vivo" to cause enzyme 
deficiency. 
 
 
2.1.4.6 Influence of the substrates and of NAG on the resistance of human 
CPS1 to proteolytic or thermal inactivation 
 
From all of the above, enzyme destabilization appears a crucial element in the 
causation of CPS1D with five of the eight missense mutations studied here 
(p.Asn355Asp, p.Tyr389Cys, p.Leu390Arg, p.Ala1378Thr and p.Leu1381Ser). 
Therefore, enzyme stabilization by ligands acting as chemical chaperones could 
be a useful future treatment of CPS1D. Similarly to the observation that 
chaperoning of phenylalanine hydroxylase by its essential cofactor 
tetrahydrobiopterin is clinically useful in phenylketonuria [Erlandsen et al., 
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2004], the CPS1 substrates and particularly the CPS1 allosteric activator NAG 
and its pharmacological deacylase-resistant analog and orphan drug NCG could 
afford some protection of CPS1. We tested the effects of these ligands on the 
sensitivity of rhCPS1 to proteolytic inactivation by elastase. These experiments 
are based on previous data on the sensitivity of the rodent liver enzyme to 
elastase and on the effects on that sensitivity of enzyme ligands [Evans & 
Balon, 1988; Guadalajara et al., 1983; Marshall & Fahien, 1988; Powers-Lee & 
Corina, 1986]. Figs. 5 A and B reveal a strong influence of NAG and NCG on 
elastase inactivation of rhCPS1. Whereas these two compounds alone 
accelerated rhCPS1 inactivation in this system (Fig. 5A), when they were added 
together with MgATP, the enzyme became nearly entirely protected against 
even very large elastase concentrations (Fig. 5B). MgATP alone did not cause 
such large protection. Similarly, the combination of MgATP and NAG or 
MgATP and NCG was highly effective in protecting the enzyme from thermal 
inactivation (Fig. 5C). In this case MgATP also substantially protected the 
enzyme, although the highest degree of protection was attained with MgATP 
together with NAG or NCG. We also showed in these experiments that glycerol 
at a concentration (20%) at which it causes maximal NAG-independent CPS1 
activation (Fig. 3D) also protected substantially the enzyme from thermal 
inactivation (Fig. 5C). Interestingly, the protecting effects of NAG/MgATP, 
NCG/MgATP, MgATP and glycerol were also patent when a mutant 
(p.Ala1378Thr) exhibiting reduced thermal stability was studied (Fig. 5D). 
 
In the matrix of liver mitochondria, where CPS1 is localized, MgATP is likely 
to be abundant under most circumstances, but NAG may not, particularly under 
conditions of protein restriction as when a urea cycle deficiency is suspected. 
Therefore, under these circumstances the administration of NCG might help 
protect the enzyme from thermal inactivation or from proteolytic degradation. 
Therefore, studies on the effects of NCG on CPS1 stability “in vivo” are 
warranted. Indeed, a genetically demonstrated CPS1D patient has been 
documented to respond to NCG administration [Williams et al., 2010].   
 
 
2.1.4.7 Final comments 
 
rhCPS1 is shown here to mirror the natural human enzyme or the rat liver 
enzyme in all aspects analyzed, including substrate and activator kinetics, 
oligomeric form, domain composition, sensitivity to proteases and protection  
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Figure 5. Effects of ligands on the inactivation of rhCPS1 by elastase or by 
heating. When indicated, NAG, NCG and ATP were added, at 10 mM 
concentrations. When ATP was added, MgSO4 was also added at a concentration 
of 20 mM. Incubations were terminated by dilution in the continuous enzyme 
activity assay, monitoring ADP production at 37ºC. Results are given as 
percentages of the activity not having undergone the corresponding proteolytic or 
heating treatment. A and B: Digestions of rhCPS1 with respective elastase 
concentrations of 10 g/ml or 50 g/ml. Other conditions were as in Fig. 1D.  C 
and D: Thermal inactivation of the wild-type or the p.Ala1378Thr mutant forms of 
rhCPS1 (both used at 0.1 mg/ml concentrations) after 15-min incubation at the 
indicated temperatures in a solution of 50 mM glycyl-glycine pH 7.4, 20 mM KCl, 
1 mM DTT with the indicated ligands or with 20% glycerol. 
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thereof  by ligands, and ability of glycerol to replace NAG as a CPS1 activator. 
Our confirmation that the domain organization is that reported for other CPSs 
supports the present structural rationalizations of the effects of missense 
changes in CPS1 [Häberle et al., 2011; Martínez et al., 2010]. Since 
recombinant production of hCPS1 permits the introduction of amino acid 
changes at will, the way is now open for testing the functional impact of 
missense mutations found in CPS1D. It would be desirable to compare the 
present system and even to complement it with the one using 
Schyzosaccharomyces pombe as the expression host of hCPS1 [Ahuja and 
Powers-Lee, 2008]. Although data on this system are very limited, the 
simultaneous use of both expression systems may prove desirable for 
maximizing the number of clinical mutants that can be tested. After all, both 
expression systems are heterologous with respect to hCPS1 and therefore the 
possibility cannot be excluded that some mutant forms can be expressed in one 
system but not in the other. 
 
With the present system, clear-cut correlations between given missense 
mutations and specific molecular phenotypes can be established, hopefully 
shedding light on the degree of severity of different mutations. Indeed, the lack 
of detectable effects of the two polymorphisms studied here, and the severity of 
the effects demonstrated for six of the eight mutations analyzed, clearly indicate 
that the experimental studies with rhCPS1 mutants expressed “in vitro” identify 
disease-causing mutations. Even with the two mutations that caused the less 
drastic effects, they triggered some negative changes on enzyme activity and/or 
stability that were not observed with the two polymorphisms. In any case, the 
extension of the present pilot study to larger series of clinical CPS1D mutations 
should permit deeper ascertaining of the sensitivity of our approach to identify 
disease-causing mutations and for estimating their actual severity. 
 
Our results shed also light on the role of the Glnase-like domain of CPS1 and 
on the reasons for its preservation despite the fact that CPS1 does not use 
glutamine [Rubio et al., 1981]. The observations that the amino acid 
substitutions p.Asn355Asp and p.Tyr398Cys, mapping in the Glnase-like 
domain of CPS1 (Fig. 1A), do not inactivate CPS1 or cause dramatic changes in 
Km values for the substrates (Table 3), agrees with the general belief that this 
domain is not directly involved in the enzyme reaction. However, these 
mutations, as well as another two mutations (p.S123F and p.H337R) introduced 
previously in the N-terminal region of rat CPS1 [Pekkala et al., 2010] resulted 
in 40-75% reduction in enzyme activity (see for the present mutations Fig. 4C). 
These results also agree with a study [Ahuja and Powers-Lee, 2008] in which 
hCPS1 lacking the entire N-terminal region exhibited a 700-fold reduction in 
enzyme activity, although the very drastic change of deleting 25% of the 
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protein molecule may render difficult the interpretation of this extreme degree 
of inactivation. In any case, the changes revealed by our present studies and by 
earlier studies with single amino acid substitutions affecting this CPS1 domain 
clearly support an activating role of this N-terminal region on CP synthesis, 
which is catalyzed by the C-terminal moiety of the enzyme [Cervera et al., 
1993; Rubio, 1993]. Such activation appears reminiscent of the one caused by 
the small subunit of E. coli CPS on the catalysis by the large subunit of the 
reaction from ammonia  [Meister, 1989]. The Glnase-like domain also stabilizes 
the enzyme, since the p.Leu390Arg, p.Asn355Asp and p.Tyr389Cys mutations 
decrease CPS1 stability. Again this role is reminiscent of the strong 
stabilization triggered in E. coli CPS upon association of the small and large 
subunits [Cervera et al., 1993]. The activation of CP synthesis, and the 
enhanced enzyme stability, may be sufficiently important advantages to warrant 
retention of the N-terminal region in CPS1. 
 
Our present findings also shed light on the roles of the C-terminal domain. We 
localized "in silico" the NAG site in the crystal structure of this domain 
[Pekkala et al., 2009], providing as experimental support for this localization 
the results of photoaffinity labelling with N-chloroacetyl-L-glutamate and of 
site-directed mutagenesis of rat liver CPS1 [Pekkala et al., 2009]. We now 
provide even more direct proof for such localization with hCPS1, the enzyme 
for which the crystal structure of the C-terminal domain was determined. Thus, 
among all the mutations studied here, the one mapping closest to the proposed 
NAG site, p.Thr1443Ala, produces by far the most drastic decrease in the 
apparent affinity for NAG (two orders of magnitude decrease) (Table 3). In our 
proposed NAG binding site [Pekkala et al., 2009], Thr1443 is close to the 
bound activator, adjacent to a residue of the NAG site and to one of the three lid 
residues that cover the bound NAG molecule (Supp. Fig. S2). The importance 
of Thr1443 for effector regulation of CPS1 is highlighted also by the 
observation that phosphorylation of the equivalent residue in hamster CPSII (a 
component of CAD, the trifunctional enzyme involved in pyrimidine 
biosynthesis), Ser1406 [Simmer et al., 1990], hampers CPSII allosteric 
regulation by its negative effector UTP [Carrey et al., 1985]. As NAG in CPS1, 
UTP binds to the C-terminal domain of CPSII [Liu et al. 1994].  
 
The present data also evidence that the C-terminal domain is an important 
determinant for CPS1 stability, since two mutations mapping in this domain, 
p.Ala1378Thr and p.Leu1381Ser, which affect the inner face of a helix from the 
outer layer of the αβα sandwich conforming this domain (Supp. Fig. S2), 
substantially or very drastically destabilized the enzyme. This important impact 
on enzyme stability clearly supports a high degree of integration of the C-
terminal domain in the CPS1 architecture. Thus, despite the multidomain 
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character of CPS1, the architecture of this enzyme would appear to be highly 
cooperative, explaining the influence of NAG binding on events that occur far 
away from the C-terminal domain, such as the activation of both 
phosphorylation domains [Rubio et al., 1983a].  
 
Supplementary Figure S2. Location in the structure of the C-terminal domain of the 
amino acids whose substitutions are studied here. The protein is in ribbon 
representation. Bound NAG [Pekkala et al., 2009] and the amino acids that are 
replaced are represented in spheres and are labeled whereas the NAG site lid residues 
W1410, F1445 and K1444 are shown in sticks representation. Green and red labeling 
correspond, respectively, to the polymorphism and to clinical mutations. NAG, and the 
amino acids forming the NAG site lid, are labeled in black. In NAG and in the 
highlighted residues, C, N and O atoms are colored yellow, blue and red, respectively. 
This figure was prepared with PyMOL (http://www.pymol.org). 
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2.2.1 Abstract: Carbamoyl phosphate synthetase 1 deficiency (CPS1D) is 
an inborn error of the urea cycle that is due to mutations in the CPS1 gene. In 
the first large repertory of mutations found in CPS1D, a small CPS1 domain of 
unknown function (called the UFSD) was found to host missense changes with 
high frequency, despite the fact that this domain does not host substrate-binding 
or catalytic machinery. We investigate here by in vitro expression studies using 
baculovirus/insect cells the reasons for the prominence of the UFSD in CPS1D, 
as well as the disease-causing roles and pathogenic mechanisms of the 
mutations affecting this domain. All but three of the 18 missense changes found 
thus far mapping in this domain in CPS1D patients drastically decreased the 
yield of pure CPS1, mainly because of decreased enzyme solubility, strongly 
suggesting misfolding as a major determinant of the mutations negative effects. 
In addition, the majority of the mutations also decreased from modestly to very 
drastically the specific activity of the fraction of the enzyme that remained 
soluble and that could be purified, apparently because they decreased Vmax. 
Substantial although not dramatic increases in Km values for the substrates or 
for N-acetyl-L-glutamate were observed for only five mutations. Similarly, 
important thermal stability decreases were observed for three mutations. The 
results indicate a disease-causing role for all the mutations, due in most cases to 
the combined effects of the low enzyme level and the decreased activity. Our 
data strongly support the value of the present expression system for ascertaining 
the disease-causing potential of CPS1 mutations, provided that the CPS1 yield 
is monitored. The observed effects of the mutations have been rationalized on 
the basis of an existing structural model of CPS1. This model shows that the 
UFSD, which is in the middle of the 1462-residue multidomain CPS1 protein, 
plays a key integrating role for creating the CPS1 multidomain architecture 
leading us to propose here a denomination of "Integrating Domain" for this 
CPS1 region. The majority of these 18 mutations distort the interaction of this 
domain with other CPS1 domains, in many cases by causing improper folding 
of structural elements of the Integrating Domain that play key roles in these 
interactions.  
 
Key words: urea cycle diseases; CPS1 deficiency; hyperammonemia; inborn 
errors; CPS 1 structure; site-directed mutagenesis 
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2.2.2 Introduction 
 
Primary CPS1 deficiency (CPS1D; MIM #237300), a recessively inherited urea 
cycle disease leading to frequently fatal hyperammonemia [1,2], is due to 
mutations in the CPS1 gene. This gene, located in 2q35 [3] and being composed 
of 38 exons and 37 introns [4-6], with 4,500 coding nucleotides, encodes a 
1500-residue proenzyme [7] that is synthesized in hepatocytes and enterocytes 
[8,9], and which, upon internalization to the mitochondrial matrix, yields after 
cleavage of its N-terminal 38 amino acids, the mature 1,462-amino acid 
multidomain (Fig. 1A) CPS1 protein [10-12] [E.C. 6.3.4.16]. 
 
CPS1 catalyzes the first step of the urea cycle (2ATP + NH3 + HCO3
- 2ADP 
+ HPO4
2- + NH2CO2PO3
2-) [13], converting ammonia to carbamoyl phosphate 
(CP), a compound that is utilized by ornithine transcarbamylase (OTC) to make 
citrulline in the second reaction of the urea cycle. The three-step CPS1 reaction 
(Fig. 1B) includes two analogous ATP-dependent phosphorylations, of 
bicarbonate and carbamate, and an intervening step of carbamate synthesis from 
carboxyphosphate and ammonia [13]. To be active, CPS1 requires the presence 
of an essential allosteric activator, N-acetyl-L-glutamate (NAG) [10,14,15], 
made by NAG synthase from glutamate and acetyl-coenzyme A [16]. The rate 
of NAG synthesis heavily depends on glutamate concentration [17], and 
therefore NAG represents a switch for CPS1 activity, which is turned off when 
glutamate levels decrease, thus preventing excessive nitrogen draining by the 
urea cycle from an already low amino acid pool [18,19]. NAG activation is a 
unique property of CPS1 (and to a lesser extent of the piscine CPS1 homologue 
CPSIII) [20], not being shared by other CPSs, all of which are active in the 
absence of effectors and are insensitive to NAG [13,21,22]. NAG activation 
involves a functionally crucial cross-talk between NAG and phosphorylation 
sites. Thus, NAG vastly increases the apparent affinity of CPS1 for ATP and 
for its ionic activators K+ and Mg2+ [15] and, conversely, ATP, K+ and Mg2+ 
greatly increase CPS1 affinity for NAG [23]. 
 
The complexities of the CPS1 reaction and regulation are backed by a 
sophisticated multidomain protein machinery [13], that is still imperfectly 
characterized, since the crystal structure of CPS1 has not been determined 
(except for its 15 kDa C-terminal domain, representing only 10% of the 
entire molecule) [24,25]. Nevertheless, a number of approaches including the 
use of limited proteolysis [26] support a domain composition for CPS1 that 
mirrors that of Escherichia coli CPS, the only CPS for which the structure is 
known [27], notwithstanding the fact that these two enzymes have very 
important differences [13,21]. These differences include the chain composition 
(a single chain in CPS1; two subunits in E. coli CPS), the already indicated  
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Figure 1. Domain composition, function and architecture of CPS1. (A) Schematic 
linear representation in the CPS1 polypeptide of the different domains. The grey-
shaded background bars schematize the 40-kDa N-terminal and the 120-kDa C-
terminal moieties of the enzyme that correspond to the small and large subunits of 
E. coli CPS, respectively. The colored bars represent the different (cont'd next page) 
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Fig. 1, cont'd: CPS1 domains as defined from sequence alignment with E. coli CPS. 
Their approximate masses, in kDa, and the domain start/end residue numbers are 
given, respectively, above and below each domain. The N-terminal mitochondrial 
targeting peptide that is removed upon internalization in the organelle is not 
represented. The domains are defined by their function (when known; ?, function 
unknown), showing below each of them the corresponding acronym (ISD, GSD, BPSD, 
UFSD, CPSD and ASD) as defined in [2]. (B) Reactional steps of the CPS1 reaction, 
shown under the domain catalyzing it, colored as the domain. The thick empty 
horizontal black arrow denotes the migration of carbamate from the bicarbonate 
phosphorylation site to the carbamate phosphorylation site. (C) Stereo view of 
structural model of C trace of human CPS1 [42]. Each domain is colored differently 
and labeled in the same color. In the UFSD, the spheres mark the residues (numbered) 
hosting extremely drastic (red) or less drastic (blue) mutations found in CPS1D 
patients. Both ATP molecules and essential K+ ions are placed in their sites by 
superimposition of the E. coli CPS structure (Protein Databank file 1BXR; [48]). (D) 
Relations of the UFSD with other domains. Two views of the domain (cartoon 
representation, in yellow) are shown, highlighting the residues hosting the mutations 
(red and blue spheres as above) illustrating that the mutations cluster at the regions of 
contact with the other domains (labeled). Only the parts of these other domains that 
contact the UFSD are shown, in surface representation, colored as in (A). In the right 
panel the ISD is shown as transparent surface to allow visualization of Ala949, which 
is clamped between the ISD, the GSD and the BPSD.  
 
differences in the requirement for NAG, and the fact that CPS1 uses ammonia 
with high efficiency and cannot utilize glutamine as an ammonia source, 
whereas bacterial CPS uses ammonia poorly but utilizes glutamine as an 
internal ammonia source. The small subunit of the bacterial enzyme binds and 
cleaves the glutamine, channeling the resulting ammonia to the large subunit, 
where the entire carbamoyl phosphate synthesis reaction from ammonia takes 
place [21]. 
 
As already mentioned, limited proteolysis and other studies support the 
similarity in domain composition and function of bacterial CPS and CPS1 (Fig. 
1A). These studies evidenced [13,26,28] that CPS1 is composed of N- and C-
terminal moieties of, respectively, 40 and 120 kDa, that correspond to the 
small and large subunits of E. coli CPS [12]. Since CPS1 uses no glutamine 
[10], no functions for the N-terminal 40-kDa moiety are known other than 
possibly some enzyme stabilization and activation [26,29]. In contrast, the 120 
kDa moiety is known to host the catalytic and NAG-regulatory machinery 
[13,21], being composed of two 60-kDa halves, each one of them consisting of 
an N-terminal 45-kDa phosphorylation domain followed by a 15 kDa domain 
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[13]. Both phosphorylation domains are homologous [12]. The one in the N-
half phosphorylates bicarbonate and the other in the C-half phosphorylates 
carbamate (Fig. 1B) [30,31]. The C-terminal 15-kDa domain (residues 1354-
1500) of the C-half (the C-terminal domain of the enzyme) binds NAG and is 
crucial for activation, having been called the allosteric domain (ASD) 
[25,26,32], not hosting substrate sites or catalytic machinery. The other 15 
kDa domain (precise mass, 17.7 kDa; residues 822-973) connects both 
phosphorylation domains and its function is unclear since it has no substrate 
sites or catalytic components, having been called unknown function subdomain 
(UFSD) [26]. Interestingly, the UFSD has been found to host missense 
mutations in CPS1D patients (Fig. 1C,D) with rather high frequency [2], 
suggesting an important and until now unclear role of this domain.  
 
CPS1D has been associated with a relatively large number of different, 
generally "private" mutations, which occur in single families with very little 
recurrence [2]. Many of the >130 missense mutations reported in CPS1D 
remain to be proven responsible for the deficiency. The fact that they appear to 
be distributed non-homogeneously among the different gene exons even after 
correcting for the presence of CpG islands, suggests that some enzyme regions 
have a more important role on enzyme stability, folding or functionality than 
other regions, and that, therefore, mutations falling on these more important 
regions have higher repercussion than those falling in less critical regions of the 
protein. The UFSD domain, particularly its C-terminal half, may be such an 
important region since the relative occurrence of missense mutations 
(normalized per 100 nucleotides) in exons 22 and 23, which encode most of the 
C-terminal half of the UFSD and which have no CpG islands, approximately 
doubles the relative frequency of these mutations for the entire coding sequence 
of the enzyme (p<0.01; 2 test) [2]. 
 
We exploit here our recent ability to produce pure mature human CPS1, either 
wild-type or with the desired mutations, in a baculovirus/insect cell system 
[26], to examine the disease-causing potential of all known UFSD missense 
mutations (n=18) found in CPS1D patients [2,4,33-37] and to clarify the role 
and importance of the UFSD. When expression was possible, we studied the 
properties of the purified mutant enzyme forms, comparing them with wild-type 
human CPS1. Our findings support the disease-causing role of the mutations 
reported to affect the UFSD, revealing a key role of the UFSD for proper 
enzyme folding and for the regulatory cross-talk between NAG and 
phosphorylation sites. 
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2.2.3 Materials and Methods  
 
2.2.3.1 Patients and CPS1 Mutations 
 
Table 1 lists 18 amino acid substitutions found in patients with CPS1D, which 
are localized in the UFSD, giving some detail on the type of the clinical 
presentation in the patients carrying these mutations. Seventeen of the 
mutations were reported already [2,4,33-37], whereas one (mutation 13) is a 
novel change identified by one of us (J.H.) in a late onset CPS1D patient. We 
also report a patient with a neonatal presentation carrying an already reported 
mutation (p.Asp914His), a mutation for which there was no clinical information 
on the previously reported patient. In contrast, the new patient was known to 
have a neonatal presentation, indicating that the mutation was probably severe. 
The missense mutations in these two new patients were initially identified by 
mRNA studies in phytohemagglutinin-stimulated lymphocytes and then were 
confirmed by studies on genomic DNA as previously reported [37]. Samples 
were obtained with full informed consent of those entitled to give it, to perform 
molecular genetic diagnostics for clinical purposes. The PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) [38] and MutPred 
(http://mutpred.mutdb.org/) servers [39] were used to assess in silico the 
disease-causing potential of the different mutations. Amino-acid conservation 
was determined by ClustalW sequence alignment of either CPS1, CPSIII or 
other CPSs from 14, 6 and 24 species, respectively.  
 
 
2.2.3.2 Production of CPS1 carrying the desired mutation 
 
The indicated mutations were introduced into pFastBac-CPS1 [26] using the 
overlapping extension method (Quickchange kit from Stratagene) and the 
forward and reverse primers given in Supp. Table S1. The correctness of the 
constructs, the presence of the desired mutation, and the absence of unwanted 
mutations were corroborated by sequencing. 
  
Human mature liver CPS1, either wild-type or carrying the desired mutation, 
with the N-terminal mitochondrial targeting sequence replaced by the 28-
residue N-terminal His6-tag, MSYYHHHHHHDYDIPTTENLYFQGAMDP, 
was expressed in a baculovirus/insect cell system and purified as previously 
described [26]. The same purification procedure (cell centrifugation, cell lysis, 
centrifugal clarification of the extract, Ni-affinity chromatography and 
centrifugal ultrafiltrative concentration [26]) was used for wild-type CPS1 and 
for the mutant enzyme forms. Protein in the final enzyme preparation was 
determined according to Bradford [40]. The CPS1 yield was determined from 
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Table S1. Synthetic oligonucleotides used for site-directed mutagenesis 
Mutation Direction Sequence 5'-3'
a
 
 
p.L843S Forward CTTAGAAAAGAGTCGTCTGAACC 
p.L843S Reverse GGTTCAGACGACTCTTTTCTAAG  
p.R850C Forward CCAAGCAGCACGTGTATCTATGCCATTG 
p.R850C Reverse CAATGGCATAGATACACGTGCTGCTTGG 
p.R850H Forward GAACCAAGCAGCACGCATATCTATGCCATTG 
p.R850H Reverse CAATGGCATAGATATGCGTGCTGCTTGGTTC 
p.T871P Forward GATTGAGAAGCTCCCATACATTG 
p.T871P Reverse CAATGTATGGGAGCTTCTCAATC 
p.K875E Forward GCTCACATACATTGACGAGTGGTTTTTG 
p.K875E Reverse CAAAAACCACTCGTCAATGTATGTGAGC 
p.G911E Forward CAAAGGAGATTGAGTTCTC 
p.G911E Reverse GAGAACTCAATCTCCTTTG 
p.G911V Forward CAAAGGAGATTGTGTTCTC 
p.G911V Reverse GAGAACACAATCTCCTTTG 
p.S913L Forward GATTGGGTTCTTAGATAA 
p.S913L Reverse TTATCTAAGAACCCAATC 
p.D914H Forward GGGTTCTCACATAAGCAGATTTC 
p.D914H Reverse GAAATCTGCTTATGTGAGAACCC  
p.D914G Forward GGGTTCTCAGGTAAGCAGATTTC 
p.D914G Reverse GAAATCTGCTTACCTGAGAACCC 
p.S918P Forward GATAAGCAGATTCCAAAATGCC 
p.S918P Reverse GGCATTTTGGAATCTGCTTATC 
p.R932T Forward CAGACAAGGGAGCTGACGTTAAAG 
p.R932T Reverse CTTTAACGTCAGCTCCCTTGTCTG 
p.I937N Forward GTTAAAGAAAAACAACCACCC 
p.I937N Reverse GGGTGGTTGTTTTTCTTTAAC 
p.A949T Forward GATACACTGGCTACAGAATAC 
p.A949T Reverse GTATTCTGTAGCCAGTGTATC 
p.L958P Forward AAACTATCCCTATGTTACCTAC 
p.L958P Reverse GTAGGTAACATAGGGATAGTTT 
p.Y959C Forward CAAACTATCTCTGTGTTACCTAC 
p.Y959C Reverse GTAGGTAACACAGAGATAGTTTG 
p.Y962C Forward CTATGTTACCTGCAATGGTC 
p.Y962C Reverse GACCATTGCAGGTAACATAG 
p.G964D Forward GTTACCTACAATGATCAGGAGC 
p.G964D Reverse GCTCCTGATCATTGTAGGTAAC 
aBold type indicates base substitutions to introduce the desired mutation 
 
the total amount of protein in the enzyme preparation and the fraction of the 
protein corresponding to pure CPS1. The latter fraction was determined 
densitometrically from the band of approximately 163 kDa observed in 
Coomassie-stained 8% polyacrylamide gels after SDS-PAGE [41]. For this 
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purpose, stained gel images were collected with a Fujifilm LAS-3000 Imager 
using transmitted white light, and the fraction of the protein migrating in the 
CPS1 band of 163 kDa was determined with the Multi Gauge quantification 
software (from Fuji Film).   
 
 
2.2.3.3 Enzyme activity assays 
 
CPS1 activity was assayed at 37ºC as carbamoyl phosphate production, 
monitored as citrulline by using OTC [26]. The standard assay mixture 
contained 50 mM glycyl-glycine pH 7.4, 70 mM KCl, 1 mM dithiothreitol, 20 
mM MgSO4, 5 mM ATP, 35 mM NH4Cl, 50 mM KHCO3, 10 mM NAG, 5 mM 
L-ornithine and 4 U/ml OTC. Specific activities refer to the pure enzyme 
(determined densitometrically, see section 2.2). When the concentration of a 
substrate was varied, other substrates were kept at the concentrations given 
above, with MgSO4 being in 20 mM excess over ATP. Data for variable 
substrate or NAG concentration were fitted to hyperbolae using the GraphPad 
Prism program (GraphPad Software, San Diego, CA). One enzyme unit makes 
1 mol citrulline per minute. Specific activities refer to pure CPS1, estimated 
by densitometry (see above). 
  
 
2.2.3.4 Other assays 
 
The thermal stability of CPS1 was monitored by incubating for 15 min at the 
specified temperature 0.5 mg protein/ml of the indicated CPS1 form (either 
wild-type or mutant), in a solution containing 50 mM glycyl-glycine pH 7.4, 2 
mM dithiothreitol, 10% glycerol, 0.5 M NaCl and 20 mM imidazole. At the end 
of the incubation the solution was rapidly cooled at 0°C and enzyme activity 
was determined immediately in the standard assay at 37ºC. 
 
Western blotting was carried out after SDS-PAGE (section 2.2) as reported [26] 
using immunoluminiscent detection (Super Signal West Pico Chemiluminiscent 
Substrate, Thermo Scientific). 
 
The previously reported [42] atomic structure model of CPS1 (based on the 
experimental crystal structure of E. coli CPS) was kindly provided by B. 
Barcelona (Instituto de Biomedicina de Valencia) and is used here for structural 
analysis of the mutations effects. Pymol (DeLano Scientific; 
http://www.pymol.org) was used for visual analysis, for structural 
superimposition and for depicting protein structures.  
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2.2.4 Results 
 
2.2.4.1 CPS1D mutations that affect the UFSD 
 
Table 1 summarizes the 17 already reported [2,4,33-37] mutations reported in 
CPS1D patients that affect the UFSD, plus one more mutation (#13) falling in 
this domain which is reported here in a late onset patient. Thirteen of these 
mutations were found in patients with neonatal or with very severe 
presentations and thus might be expected to have drastic negative effects on 
CPS1 level or activity. Only mutations 4, 13, 14, 16 and 17 were found 
exclusively in late onset patients or in patients without appropriate clinical 
information to judge about their severity. The fact that two mutations affecting 
the same residue were reported for Arg850, Gly911 and Asp914, three residues 
that are invariant among all CPSs, strongly supports a damaging role of the 
corresponding six mutations (p.Arg850Cys, p.Arg850His, p.Gly911Glu, 
p.Gly911Val, p.Asp914His, and p.Asp914Gly), in agreement with the 
predictions of the Polyphen-2 and MutPred servers (Table 1). In another patient 
with a neonatal presentation, the p.Leu843Ser and p.Lys875Glu mutations, both 
mapping in the UFSD, coexisted in the same allele [4]. Of these, the 
p.Leu843Ser mutation appears more likely to be disease-causing, because of the 
high conservation of Leu843 and because Polyphen-2 and MutPred give 
p.Leu843Ser a higher degree of probability and a higher score for having a 
damaging role than they do for p.Lys875Glu. The high residue conservation 
and the Polyphen-2 and MutPred server predictions also support the disease-
causing nature of the p.Arg932Thr and p.Leu958Pro mutations, found in 
another two patients with neonatal presentations, whereas a disease-causing role 
appears less certain for the p.Ser913Leu, p.Ser918Pro and p.Gly964Asp 
mutations, found in other neonatal patients, since the residues affected are less 
conserved and the Polyphen-2 and MutPred servers are non-unanimous in 
anticipating a disease-causing role (Table 1). The lack of unanimity in the 
predictions by both servers is possible, since they do not utilize the same traits 
[38,39] for assessing the disease-causing role of a given mutation. 
 
The mutations p.Thr871Pro, p.Ile937Asn, p.Ala949Thr, p.Tyr959Cys and 
p.Tyr962Cys, reported in CPS1D patients with late presentations or with 
unreported presentation but with patient survival (suggesting less severe 
phenotype), affect invariant or virtually invariant residues and give high 
probability scores for being damaging in the Polyphen-2 and MutPred servers. 
Since the p.Ala949Thr mutation coexists with a null allele (p.Tyr89*) in the 
patient [2], it cannot abolish enzyme activity since otherwise the patient would 
have had a neonatal presentation. In principle, the same can be said for the 
p.Ile937Asn mutation, given the fact that the other CPS1 allele found in the 
RESULTS. Chapter 2 
 
90 
 
 
same patient corresponds to a very severe splice site aberration that should lead 
to exon 27 skipping, with frameshift and truncation. Since in this patient the 
CPS1 allele hosting the p.Ile937Asn mutation also hosts a second missense 
change, p.Gly401Arg (Table 1), this second change cannot be expected to be 
highly deleterious either. In contrast, a drastic effect is likely for the 
p.Thr871Pro mutation since it coexists in the patient with the expectedly mild 
mutation (given the mildness of the substitution), p.Glu1194Asp [37].  
 
 
2.2.4.2 UFSD mutations negatively influence the yield of CPS1 
 
We previously used the baculovirus/insect cell system utilized here for 
producing twenty CPS1 forms carrying different missense changes identified in 
CPS1D patients and spread all over the CPS1 protein except the UFSD [26,43]. 
We also reported [25] the effects of another five non-CPS1D-associated but 
functionally important mutations affecting the C-terminal domain (ASD). 
Furthermore, in unpublished studies, we have monitored the effects of ten more 
mutations (nine in the ASD) of which five had been identified in patients. Only 
three among these 35 experimentally tested mutations compromised drastically 
recombinant CPS1 production ([26], and data not shown). The present UFSD 
mutations yield an entirely different picture (Fig. 2A). Recombinant production 
of CPS1 protein was virtually abolished by six mutations and it was decreased 
85-95% and ~75% by five and four mutations, respectively. Only for three of 
the eighteen mutations studied here (p.Arg850Cys, p.Arg850His and 
p.Ala949Thr) the yield of pure CPS1 was comparable to that of the wild-type 
enzyme. Interestingly, each one of the two mutations found in the same allele of 
one patient, p.Leu843Ser and p.Lys875Glu (Table 1), reduced the yield of 
CPS1 by nearly 90% (Fig. 2A), raising the possibility that their joint presence 
in the same protein molecule might reduce further CPS1 production. 
 
The low yields observed with most mutants appear to be due to poor CPS1 
polypeptide production and to gross misfolding. Thus, SDS-PAGE of the pellet 
(Fig. 2B, P) and the supernatant (Fig. 2B, S) obtained by centrifugation of the 
initial cell extract not only revealed for most mutants decreased CPS1 levels, 
but also showed that the CPS1 present tended to appear in the precipitate. 
Furthermore, a multiplicity of bands of lower molecular weight than complete 
CPS1, corresponding to CPS1 degradation products, were revealed by western 
blotting in the precipitates of these low-yield mutants (Fig. 2C). 
 
In summary, the majority of the mutations found in CPS1D patients that affect 
the UFSD appear to disturb CPS1 folding and to enhance CPS1 degradation. 
The drastic decrease in enzyme production should be disease-causing at least 
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Figure 2. Effects of UFSD 
domain mutations on CPS1 
production. WT, wild-type 
recombinant enzyme. 
Mutations are represented in 
single-letter code. 
Arrowheads signal the 
position of the CPS1 band. 
(A) Yield of pure CPS1 
protein (total protein × CPS1 
purity determined 
densitometrically from 
Coomassie-stained SDS) per 
liter of cell culture, relative to 
the mean yield of pure wild-
type CPS1 (2.7 mg/L cell 
culture). (B) Distribution of 
protein between the insoluble, 
P, and the soluble, S, 
fractions of the initial 
extracts of cells expressing 
the wild-type enzyme or the 
indicated mutants, analyzed 
by SDS-PAGE and 
Coomassie staining. The 
samples applied to each track 
correspond to identical 
volumes of original cell 
extract. (C) Western blotting 
and CPS1 immunostaining in 
the precipitates from the cell 
extracts for the indicated 
enzyme forms. (D, E) 
Coomassie-stained SDS-
PAGE of the preparations 
obtained after purification of 
the wild-type and the different 
mutant enzyme forms as 
indicated. St, protein 
markers, with masses, in kDa, 
indicated at the side.  
 
for the seven mutations that reduce enzyme production by >90% (p.Thr871Pro, 
p.Gly911Glu, p.Gly911Val, p.Asp914His, p.Asp914Gly, p.Ser918Pro and 
p.Gly964Asp; Fig. 2A). Indeed, six of these mutations were found in patients 
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with neonatal or very severe presentations, and the other mutation 
(p.Thr871Pro), although found in a late onset patient, coexisted with an 
expectedly mild second allele and is likely to have by itself a severe effect 
(Table 1). On the other hand, the two mutations found in late onset patients that 
were anticipated to be mild (see section 3.1), p.Ala949Thr and p.Ile937Asn, 
were associated with substantial or normal yield of CPS1 (Fig. 2A).  
 
 
2.2.4.3 Eight UFSD mutations strongly impair CPS1 activity 
 
Although with most mutations little soluble CPS1 was produced, we always 
carried out the complete CPS1 purification protocol, observing by SDS-PAGE 
of the final preparation, with all the mutants (Figs. 2D,E), a 163 kDa-band 
corresponding to soluble CPS1 (confirmed by western blotting, data not 
shown). However, the purity of CPS1 decreased with the yield, being <10% of 
the protein (densitometric estimation) for the mutants with the lowest yield 
(Figs. 2D,E). Despite the presence of the CPS1 band, CPS1 activity was very 
low in the final preparations of the mutants p.Thr871Pro, p.Gly911Glu, 
p.Gly911Val, p.Asp914His, p.Asp914Gly, p.Ser918Pro, p.Leu958Pro and 
p.Gly964Asp. The estimated specific activity of pure soluble CPS1 was ≤6% of 
wild-type for six of these mutations and ≤12% for the other two (Fig. 3A). 
Assuming that the mutation-induced misfolding causes similar decreases in the 
production of soluble CPS1 protein in insect cells and in the liver, the low 
yields (Fig. 2A), combined with the decreased activities (Fig. 3A), lead to an 
expectation of very low residual activities in the liver (<1% of normal for 
homozygosity) for any of these eight mutant forms. The low residual activity 
further supports the disease-causing nature of these mutations and agrees with 
their observation in neonatal or very severely affected patients (Table 1). Only 
the p.Thr871Pro mutation was observed in a late onset patient, but, as already 
indicated, the second allele in this patient was expectedly mild (p.Glu1194Asp). 
 
 
2.2.4.4 Activity and stability changes with another eight UFSD mutations 
 
Eight of the ten mutations not dealt with in section 3.3 generally were 
associated with less drastic but substantial decreases in specific activity, and/or 
with decreased thermal stability of the enzyme (Fig. 3). Among these 
mutations, p.Ile937Asn caused the largest specific activity decrease (~90% 
decrease) (Fig. 3A), which combined with the observed 75% reduction in yield 
(Fig. 2A), would result (making the already indicated assumption that the yield 
in insect cells grossly corresponds to the yield in the liver) in 3% residual 
activity for homozygosity, supporting disease-causation. Nevertheless, the role 
                                                                                  RESULTS. Chapter 2 
 
93 
 
 
of the other mutation found in the same allele (Table 1), p.Gly401Arg, remains 
to be determined, although this mutation maps in the CPS1 N-terminal region 
of unknown function (Fig. 1) which hosts few CPS1D mutations [2], and it is 
predicted by Polyphen-2 and MutPred as benign or as having little probability 
of being disease-causing (not shown). 
 
Figure 3. Enzyme 
activity (A) and 
thermal stability (B, C) 
of wild-type or mutant 
forms of CPS1. The 
activity per mg of pure 
CPS1 is expressed 
relative to the 
corresponding activity 
of the pure wild-type 
enzyme (2.3 U/mg). 
(B,C) Fraction (as 
percentage) of the 
activity remaining for 
the indicated enzyme 
form after 15-min 
heating either at 46ºC 
(B) or at the indicated 
temperatures (C). 
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In the other case (Table 1) in which the same allele carried two missense 
mutations, p.Leu843Ser and p.Lys875Glu, the first of these mutations 
decreased activity by 70% (Fig. 3A) and both mutations reduced ~90% the 
yield of CPS1, leading to the assumption of a liver activity of 3% of normal 
for a null second allele (the case in the patient carrying these mutations [2]). 
This estimate might be optimistic considering the already mentioned possibility 
that the joint presence of both mutations in the same CPS1 polypeptide chain 
could reduce even further proper folding and CPS1 production, and also 
because the p.Lys875Glu mutation substantially decreased CPS1 thermal 
stability (Fig. 3B). In summary, the data for this patient appear to account fully 
for its neonatal presentation. 
 
Decreased thermal stability appears a major determinant of the effects of the 
p.Ala949Thr and p.Tyr959Cys mutations (Figs. 3B,C), being the only important 
aberration observed for the first of these two mutations. Thus, p.Ala949Thr was 
not associated with decreased yield (Fig. 2A) or with a large specific activity 
decrease (Fig. 3A), but it lowered the half-inactivation temperature of the 
enzyme by 8ºC (Fig. 3C), bringing it down to nearly 40ºC, which is close to 
the physiological body temperature, leading to the expectation of an important 
reduction in enzyme half-life and thus of enzyme level in the tissue. 
Nevertheless, some residual activity should be expected, agreeing with the late 
onset presentation in the patient carrying this mutation (the other allele carried a 
null mutation, Table 1). A similar degree of reduction in thermal stability was 
also observed for the p.Tyr959Cys mutation (Fig. 3B,C). However, in this case 
the mutation also decreased importantly CPS1 yield (by 75%; Fig. 2A) and 
specific activity (by 70%; Fig. 3A), with the resultant final activity in the tissue 
possibly being decreased further by the accelerated thermal inactivation. The 
late onset presentation in this patient (Table 1) could be due to the residual 
activity from this mutation, together with that resulting from the mutation 
carried in the second CPS1 allele (p.Pro1462Arg), which is not inactivating 
(our own unpublished data). 
 
Although the p.Tyr962Cys mutation only reduced 50% the specific activity of 
the soluble enzyme (Fig. 3A) without substantially decreasing thermal stability 
(Fig. 3B), it decreased 75% CPS1 yield (Fig. 2A). The combination of these 
two detrimental effects might result in an activity in the tissue of ~6% of 
normal, provided that the second CPS1 allele found in the patient carrying this 
mutation (p.Ile632Arg; #17, Table 1), which affects the bicarbonate 
phosphorylation domain, is inactivating. This residual activity would explain 
that patient #17 is alive. 
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The patients with the p.Ser913Leu or p.Arg932Thr mutations had neonatal 
presentations (Table 1) that must reflect a cumulative effect of modest to drastic 
but not extreme changes in yield or specific activity of CPS1 caused by these 
mutations. Thus, the p.Ser913Leu mutation decreased CPS1 yield and specific 
activity, respectively, to 20% and 30% of normal, and the p.Arg932Thr 
mutation caused respective decreases to ~12% and 40% of normal (Figs. 2A 
and 3A). A residual liver activity of 3% of normal is conceivable for both 
mutations, if they coexist in the patients with null second CPS1 alleles. 
 
 
2.2.4.5 Km effects are the major changes associated with mutations 
affecting Arg850 
 
Changes in yield (Fig. 2A), specific activity (Fig. 3A) or thermal stability (Fig. 
3B) cannot account for the neonatal presentations observed in the two patients 
that carried mutations affecting Arg850, since for the p.Arg850His and 
p.Arg850Cys mutations thermal stability was essentially normal and the yields 
and specific activities were at least 50% and 25% of normal, respectively. 
However, since the specific activity assay used here utilizes saturating (for the 
wild-type enzyme) substrate concentrations, there might be room for Km or Ka 
effects that could have negative consequences on enzyme activity at the 
generally low substrate concentrations present in the tissue [44,45]. This is 
certainly the case for the p.Arg850Cys mutation, which exhibits 5-fold and 
3-fold increases in the Km values for ATP and bicarbonate, respectively, and, 
even more importantly, a 18-fold increase in the Ka value for NAG (Fig. 4A-
C,E,G). Similarly, in the case of the p.Arg850His mutation the Km for ATP and 
the Ka for NAG were increased 3-fold and 10-fold, respectively (Fig. 4A,B,F). 
Although these kinetic constant changes are not large enough to decrease 
importantly the activity observed in the standard assay, they can lead to drastic 
reductions in the CPS1 activity in vivo, since, for example, NAG may be far 
from saturating even for the wild-type enzyme [17-19,44,45], and thus, much 
less saturating for these mutant enzyme forms. 
 
Among the ten UFSD mutants in which CPS1 yield and activity permitted 
kinetic analysis (Figs. 4A-D), substantial Km or Ka changes were rarely 
observed. In addition to the already indicated changes in the two mutants of 
Arg850, the p.Ile937Asn mutation modestly increased the Ka value for NAG 
(Fig. 4A) and the Km for ammonia (Figs. 4D,H), and the p.Leu843Ser and 
p.Ser913Leu mutations increased the Ka for NAG (Fig. 4A). It is interesting 
that the Ka for NAG was increased in all cases that exhibited a kinetic change, 
suggesting a role of the UFSD in the cross-talk known to exist between the 
NAG site and the catalytic machinery of the enzyme [15,23]. In summary, 
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while Km or Ka changes do not appear to play a paramount role in decreasing 
enzyme  activity  with  most  UFSD  mutants,  they certainly do so with the two 
mutations affecting Arg850, for which they appear major determinants of the 
severe deficiency observed in the patients carrying these mutations. 
Figure 4.  Effects 
of UFSD 
mutations on the 
Km values of 
CPS1 for its three 
substrates and on 
the Ka value for 
NAG. (A-D) 
Histograms 
illustrating the 
changes in Km or 
Ka values for the 
indicated CPS1 
mutants and 
substrates or 
NAG, relative to 
the corresponding 
values for the 
wild-type enzyme. 
The curves on the 
right panels (E-H) 
illustrate the 
dependency of the 
reaction velocity 
on the 
concentration of 
each substrate or 
NAG for the wild-
type enzyme or 
for the indicated 
mutants. 
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2.2.4.6 UFSD mutations generally decrease Vmax of the enzyme 
 
With those mutations in which kinetic analysis was possible, it was observed 
that, except in the case of p.Lys875Glu, the mutations modestly decreased Vmax 
(Fig. 5A) in a proportion that was similar to the decrease in specific activity 
(Fig. 3A). This was to be expected if the mutations affect mainly kcat without 
producing very large Km effects, since the standard activity assay utilizes 
saturating (for the wild-type enzyme) concentrations of the substrates and of 
NAG. A plot of specific activity versus Vmax (Fig. 5B) could be reasonably 
adjusted to linear regression passing through zero. This suggests that the very 
low activity of the mutants that were very little expressed and that, therefore, 
were not amenable to kinetic analysis, could be due to a Vmax effect. Thus, the 
UFSD domain appears to influence the rate at which the enzyme catalyzes its 
complex, three-step reaction.   
  
  
Figure 5. Influence of UFSD mutations on Vmax values for CPS1 activity. (A) 
Changes in Vmax values for the different mutants, as a fraction of the value for wild-
type CPS1. (B) Plot of the specific activity for each mutant as a function of the Vmax 
for this same mutant. Relative values with respect to wild-type are given for both 
parameters. The regression line goes virtually through zero and gives a value of 
r2=0.842. 
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2.2.5 Discussion 
 
The present results validate the baculovirus/insect cell expression system [46] 
for monitoring the consequences of CPS1D mutations. Such system is already 
the standard for the same task in Gaucher's disease [47,48] and has been used 
with other diseases [49-52]. It associates the abundant expression and 
possibility of purification that characterizes E. coli expression, with a high 
compatibility with human proteins, which frequently cannot be expressed in 
bacteria [46]. In the case of Gaucher's disease, the large experience 
(exemplified in [47, 48]) attests the concordance of the results in this expression 
system with the clinical phenotype. This concordance was prospectively proven 
with two polymorphisms of methylenetetrahydrofolate reductase [50], since the 
one (p.Ala222Val) shown to have negative effects on the enzyme when using 
baculovirus/insect cells, was later on proven by epidemiological and genome-
wide association studies to be linked to increased plasma homocysteine levels 
[53]. Our experience with CPS1 also supports the faithfulness of this system in 
revealing the impact of CPS1 mutations. Thus, in our prior studies [26] two 
CPS1 polymorphisms believed to be trivial had no substantial effect on any 
CPS1 trait investigated (activity, stability, kinetic constants, gross estimation of 
yield), whereas two mutations affecting a catalytic domain and used as positive 
controls were strongly detrimental. Furthermore, the results with three CPS1D-
associated mutations affecting the glutaminase-like subdomain (GSD) (Fig. 1A) 
of unknown function and of three additional mutations affecting the allosteric 
domain (ASD, Fig. 1A) accounted for disease-causation because of impaired 
activity, stability or NAG activation. These results, which followed earlier pilot 
studies using baculovirus/insect cell-expressed rat CPS1 (a surrogate of human 
CPS1) [43], are extended now with those for 18 mutations affecting the UFSD. 
 
The present results confirm that the seventeen mutations reported earlier 
[2,4,33-37] and the one described here that affect the UFSD of CPS1 in patients 
with CPS1D are disease-causing. The observed effects of the mutations on the 
production, activity, thermal stability and kinetic constants of the recombinant 
enzyme match in most cases the severity of the clinical presentation. Our data 
illustrate in one case the fact that each one of two missense changes in the same 
allele (p.Leu843Ser and p.Lys875Glu) has a detrimental effect on the enzyme, 
raising the possibility that their combined presence in the same protein 
molecule could be even more detrimental.  
 
A clear conclusion of our studies is that, at least for this domain and with this 
eukaryotic expression system, the determination of the yield of CPS1 protein is 
a key element in judging the disease-causing role of each mutation. We clearly 
show that the abolition or the drastic decrease of CPS1 production is a crucial 
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mechanism of disease production by many missense mutations affecting the 
UFSD. Our findings point to decreased efficiency of proper folding as a key 
determinant of the poor production of the soluble protein. Although there are 
few in vitro expression studies for CPS1 [25,26,29,43], our prior investigations 
with 35 missense mutations mapping in other domains (with a predominance of 
mutations affecting the C-terminal ASD) do not highlight poor CPS1 
production as a key determining element of the effects of the mutations 
affecting these other protein regions, since only with 10% of the mutations 
was CPS1 production hampered or abolished. It therefore appears that a 
decrease in the efficiency of proper CPS1 folding is a characteristic and 
remarkable trait of CPS1D-associated mutations affecting the UFSD. Such trait 
may be the reason for the prominence of this domain in CPS1D, where 
missense mutations have been found in relatively high density [2]. 
 
The central position in the enzyme architecture and the intimate relations of the 
UFSD with other CPS1 domains [2,27,42] may account for the particular 
impact of the mutations affecting this domain on CPS1 folding. In the existing 
structural CPS1 models [2,42] based on the E. coli CPS structure [27], the 
UFSD makes very extensive contacts with both phosphorylation domains and, 
to a lesser extent, with the N-terminal moiety of the enzyme (the small subunit-
like region) (Figs. 1C,D). This L-shaped domain (Fig. S1A) which embraces 
between its two arms the C subdomain of the bicarbonate phosphorylation 
domain (Fig. S1D), is sandwiched between the small subunit-like N-terminal 
moiety and the carbamate phosphorylation domain, two domains that lie 
respectively on top and below the plane defined by this L (Fig. 1D, right panel). 
Therefore, mutation-triggered UFSD misfolding can be expected to result in 
distorted relations between these other protein domains. The CPS1D-associated 
mutations affecting this domain cluster in the regions of interaction of the 
UFSD with other domains rather than in the exposed regions (Fig. 1D) that are 
involved in intermolecular interactions [27]. Therefore, the distribution of the 
mutations does not support the possibility of an increase in the interactions 
between the UFSDs of different enzyme molecules as the cause for the 
decreased solubility observed with many of these mutants. This agrees with our 
observation with E. coli CPS that the UFSD is not involved in dimer formation 
[54], and with our finding that human CPS1 exists mainly as monomers 
[10,26].  
 
A detailed structural rationalization of the effects of the mutations studied here 
is included as Supplementary material. In summary, our results highlight a 
paramount integrating role of the UFSD for building the highly complex CPS1 
architecture, revealing the key organizing function of this domain, and 
exemplifying the importance of this core structural element despite its lack of 
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substrate binding and catalytic machinery. Interestingly, a recent in silico study 
already proposed for this domain a key structural role in CPS1 [55]. On the 
basis of such key function of this domain, which is conserved in all forms of 
CPS (including the archaeal types, in which the C-terminal moiety is split into 
two complementary regions encoded by different genes), we would propose to 
call it in the future the "Integrating Domain" of CPS1. Our data fully account 
for the important representation of this domain in the database of missense 
mutations found in CPS1D [2], revealing that the main effects of the mutations 
in this domain are to negatively affect global CPS1 folding and architecture. 
We also document for some mutations and propose for other mutations that 
they have effects of greater or lower magnitude on the Vmax of the enzyme. This 
effect could be due to gross defects on domain architecture, that, for example, 
could block the conduit of the activating allosteric NAG signal, or the tunnel 
[27] through which intermediates must flow between both phosphorylation 
centers; or it could derive from more subtle changes such as the hampering of 
the concerted opening [56,57] of the B subdomains of both phosphorylation 
domains to allow product release. Indeed, mutations in the UFSD could be in 
the signaling path between both phosphorylation centers since the UFSD 
contacts the B domain of the carbamate phosphorylation domain, which is 
believed to trigger the concerted opening [57], and it also contacts the active 
site of the bicarbonate phosphorylation domain, which is to be opened (Fig. 
1D). Similarly, the UFSD appears to be involved in the cross-talk between the 
NAG site and the catalytic centers, since some UFSD mutations increase the Ka 
for NAG. Full understanding of this involvement will have to await the 
determination of the structural mechanism of NAG activation of CPS1. 
 
 
2.2.6 Supplementary material 
 
Structural rationalization of the mutations effects. 
 
Among the 18 mutations studied here, five affect four residues at the free end of 
one arm of the L-shaped UFSD, nine map at the other end of this arm, at the 
vertex of the L, and the remaining four mutations affect the distal half of the 
other arm (Fig. S1A). The core structure of the arm that hosts the larger number 
of mutations is folded in E. coli CPS [27] and is predicted to be folded in the 
structural models of CPS1 [2, 42] as two four-helix bundles connected by a 
long helix that participates in both bundles. Five mutations affecting four 
residues map in the more N-terminal four-helix bundle (Fig. S1A,B). Of these, 
three (p.Leu843Ser, p.Thr871Pro and p.Lys875Glu) likely compromise bundle 
folding. The other two mutations (p.Arg850Cys and p.Arg850His) affect a 
protruding residue that interacts with the active center K+ loop of the adjacent 
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Supplementary Figure S1. 
Mapping of the clinical 
mutations of the UFSD 
domain in the structural 
model of CPS1. The figures 
are in cartoon representation. 
Residues that host clinical 
mutations are shown either as 
red (drastic) or blue spheres 
(less drastic), or detailing the 
side-chains (in blue-colored 
sticks). Residues are labeled 
in single letter code. CPS1 
domains and secondary 
structure elements of the 
UFSD are   labeled   (from   
N-   to  C-terminus, α1 to α7; 
and β1 to β2). (A) Mapping of 
the mutations in the 
structural model of the 
isolated UFSD.  
 (B-D) Details of the three regions of the UFSD 
that host clinical mutations, illustrating their 
relations with elements of the neighboring 
domains. In (C) the broken lines mark the ion 
pair network involving Asp914, Arg932 and 
Tyr962 that is lost when any of these three 
residues is mutated 
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bicarbonate phosphorylation domain, which sits next to this bundle (Fig. S1B), 
increasing the Km value for ATP and, in the most drastic of the two mutations, 
for bicarbonate, without importantly hampering enzyme folding. This part of 
the UFSD may be involved in the as yet structurally unclarified cross-talk 
known to exist between this ATP site and the NAG site in the ASD [15, 23], 
because both mutations affecting Arg850 as well as another mutation in this 
four-helix bundle, p.Leu843Ser, substantially increased the Ka for NAG. 
 
Six of the nine mutations at the vertex of the L (Fig. S1A,C) most likely affect 
the proper folding of the second four-helix bundle, with one (p.Ser918Pro) 
simply breaking a helix, and the other five hampering the gluing of the helices 
into the bundle either by disturbing an interhelical hydrophobic nest (the case 
for p.Ile937Asn), or by abolishing an ion pair network (the case for 
p.Asp914Gly/His, p.Arg932Thr and p.Tyr962Cys; Fig. S1C). The importance 
of the interaction of this bundle with the adjacent bicarbonate and carbamate 
phosphorylation domains is made patent by the important effects of the 
mutations p.Gly911Glu, p.Gly911Val, and p.Ser913Leu (Figs. 2A and 3A of 
the main text), which should disturb the interactions with two approximately 
parallel helices, each one from a neighboring domain. The fact that the 
p.Ser913Leu and p.Ile937Asn mutations increase the Ka for NAG (Fig. 4A of 
the main text) suggests that they are in the as yet unidentified route by which 
the cross-talk between the NAG site in the ASD and the catalytic machinery of 
the enzyme takes place.  
 
The remaining four mutations affect the other arm of the L (Fig. S1A), a C-
terminal β hairpin stem-loop terminated in a string that folds back towards the β 
strands. This hairpin is inserted as a gluing, extended element, between the 
interaction domain (ISD) and the glutaminase-like domains (GSD) of the small 
subunit-like N-terminal region (Fig. 1A of the main text) and the respective C 
and A subdomains of the bicarbonate phosphorylation and the carbamate 
phosphorylation domains (Fig. 1D of the main text, and Fig. S1D). This part of 
the UFSD is so integrated structurally with the other domains that its two β 
strands and its final string extend the central β sheet of the carbamate 
phosphorylation A subdomain, conforming with it nearly a β barrel that 
encircles one helix of this A subdomain (Fig. S1D). Two of these mutations 
should either break (p.Leu958Pro) or displace (p.Tyr959Cys) the β strand that 
continues the A subdomain β sheet, whereas another mutation falls in the C-
terminal string (p.Gly964Asp) at a point where this string glues together the 
ISD and the already mentioned helix of the C subdomain of the bicarbonate 
phosphorylation domain. The extremely drastic effects of the p.Leu958Pro and 
p.Gly964Asp mutations (Figs. 2A and 3A, main text) attest to the structural 
importance of this region for proper CPS1 domain architecture. The 
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p.Ala949Thr mutation affects a residue at the tip of the hairpin loop which was 
reported in previous modeling studies of the UFSD [55] to interact with 
Arg172, belonging to the ISD. Actually, this residue is clamped between the 
ISD, the GSD, and elements of the C subdomain of the bicarbonate 
phosphorylation domain (Fig. S1D). The major negative effect of this mutation 
was on the thermal stability of the enzyme (Figs. 3B,C, main text). The other 
mutation having a similar impact on thermal stability (p.Tyr959Cys) affects a 
nearby residue that is also involved in interactions with the ISD and with the 
same structural elements of the bicarbonate phosphorylation domain, 
suggesting that this region and these domain-domain interactions have 
particular importance for ensuring good enzyme stability. In fact, the only other 
mutation (p.Lys875Glu) shown here to affect importantly enzyme stability also 
interacts with the ISD (not shown), supporting our previous conclusion [26] that 
one major function of the ISD is to increase CPS1 stability.  
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2.3.1 Abstract: Carbamoyl phosphate synthetase 1 (CPS1) deficiency 
(CPS1D) is an inborn error of the urea cycle having autosomal (2q34) recessive 
inheritance that can cause hyperammonemia and neonatal death or mental 
retardation. We have analyzed the effects on CPS1 activity, kinetic parameters 
and enzyme stability of missense mutations reported in patients with CPS1 
deficiency that map in the 20-kDa C-terminal domain of the enzyme. This 
domain turns on or off the enzyme depending on whether the essential allosteric 
activator of CPS1, N-acetyl-L-glutamate (NAG), is bound or is not bound to it. 
To carry out the present studies we have exploited a novel system that allows 
the expression in vitro and the purification of human CPS1, thus permitting 
site-directed mutagenesis. These studies have clarified disease causation by 
individual mutations, identifying functionally important residues, and revealing 
that a number of mutations decrease the affinity of the enzyme for NAG. This 
last observation raises the possibility of using in these patients NAG site 
saturation therapy with the NAG analog and registered drug N-carbamyl-L-
glutamate. Furthermore, these data, together with additional present and prior 
site-directed mutagenesis data for other residues mapping in this domain, 
suggest an NAG-triggered conformational change in the β4-4 loop of the C-
terminal domain of this enzyme. This change might be an early event in the 
NAG activation process. Restrained molecular dynamics simulations based on 
the observed mutations effects are consistent with this proposal, providing 
further backing for this structurally plausible signaling mechanism by which 
NAG could trigger urea cycle activation via CPS1.  
 
 
Key words: Urea cycle diseases, inborn errors, hyperammonemia, site-directed 
mutagenesis; restrained molecular dynamics; allosteric regulation; carbamoyl 
phosphate synthetase 1; enzyme. 
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2.3.2 Introduction 
 
Carbamoyl phosphate synthetase 1 (CPS1) deficiency (CPS1D; OMIM 
#237300), a recessively inherited autosomal (2q34) (McReynolds et al., 1981) 
inborn error of the urea cycle (Freeman et al., 1964; Gelehrter and Snodgrass, 
1974), has an estimated incidence of 1/50000 to 1/300000 (Uchino et al., 1998; 
Summar et al., 2013). CPS1 is the entry point of ammonia, the nitrogenous 
waste product of protein catabolism, into the urea cycle (Fig. 1A). Therefore, 
CPS1 deficiency causes pure hyperammonemia (Häberle and Rubio, 2014), 
leading to encephalopathy and even death (Brusilow and Horwich, 2001), and 
to depletion of downstream urea cycle intermediates, particularly of citrulline 
(Häberle and Rubio, 2014).  
 
A large repertory of mutations affecting the CPS1 gene has been compiled from 
patients with CPS1D (Häberle et al., 2011). Over 50% of these mutations are 
missense changes spreading over the entire 1462-residue mature CPS1 
polypeptide (Nyunoya et al., 1985; Haraguchi et al., 1991). The CPS1 gene 
(OMIM #608307; 201,425 nucleotides; start/end chromosome 2 coordinates, 
211,342,405/211,543,830, plus strand, http://www.genecards.org/cgi-
bin/carddisp.pl?gene=CPS1) encompasses 4500 coding nucleotides over 38 
exons (Funghini et al., 2003; Häberle et al., 2003; Summar et al., 2003). It may 
be difficult to ascertain the responsibility of a given CPS1 missense mutation in 
causing CPS1D, particularly for mutations mapping outside the two catalytic 
domains of the enzyme (the two phosphorylation domains, Fig. 1B) which bind 
the substrates and catalyze the three-step CPS reaction (Alonso et al., 1992; 
Alonso and Rubio, 1995).  
 
Our present work deals with the analysis of the effects of CPS1D-associated 
mutations (called also from here on clinical mutations) that affect a non-
catalytic domain of human CPS1, the C-terminal domain of 20 kDa (Häberle et 
al., 2011). This domain is called the allosteric domain (abbreviated ASD) (Fig. 
1B) because it binds N-acetyl-L-glutamate (NAG) (Rodríguez-Aparicio et al., 
1989; Pekkala et al., 2009), the essential allosteric activator of CPS1. Without 
NAG, CPS1 is inactive (Rubio et al., 1981, 1983), possibly reflecting the need 
to stop catalysis by the enzyme (Shigesada et al., 1978; Stewart and Walser, 
1980) before ammonia levels are too low (Fig. 1A). Too much decrease in the 
ammonia level would lead to depletion of ammonia-derived amino acids such 
as glycine, glutamate and glutamine (Bender, 2011), and possibly to protein 
catabolism. NAG is a proper effector of the CPS1 switch because its levels 
reflect the nitrogen burden manifested in the glutamate level (Fig. 1A). This is 
so because NAG has a short half-life (Morita et al., 1982) and it is made from 
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glutamate by an enzyme (NAG synthase) exhibiting a high Km for glutamate 
(Sonoda and Tatibana, 1983).  
 
Figure 1. The CPS1-NAG switch for urea cycle control. (A) Simplified view of the 
urea cycle to highlight its control at the level of CPS1. The double arrows denote 
bidirectional fluxes between the elements that are linked. Enzymes are boxed and 
abbreviated as follows: NAGS, NAG synthase; OTC, ornithine transcarbamylase; 
ASS, argininosuccinate synthetase; ASL, argininosuccinate lyase; and ARG1, 
arginase 1. ORNT 1, ornithine/citrulline antiporter. For simplicity, not all products 
of the different reactions are indicated. The intramitochondrial part of the cycle, 
which is where the switch mechanism operates, is highlighted.(Cont'd next page) 
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To explore the effects of ASD-mapping missense clinical mutations 
(abbreviated ASD clinical mutations) we utilize a novel system for production 
and mutagenesis of recombinant CPS1 that uses baculovirus and insect cells 
(Díez-Fernández et al., 2013). We had already applied this system to analyze 
the effects of some ASD missense mutations (Pekkala et al., 2010; Díez-
Fernández et al., 2013). We now extend this analysis to all the reported ASD 
clinical mutations, as well as to some mutations designed to test the role of the 
ASD (Fig. 1B, vertical lines, and Table 1). Analysis of the effects of these 
mutations has helped assess disease causality, opening the way to improved 
genetic counselling and even to individualized therapy. Furthermore, we now 
shed some light on the as yet unclarified NAG activation process, and we define 
better the NAG site. We had previously localized this site (Fig. 1C) (Pekkala et 
al., 2009) by photoaffinity labeling and by in silico docking in the deposited 
(but unpublished) crystal structure of the isolated human ASD free from NAG 
 
Fig. 1, cont'd: (B) Scheme of the mature CPS1 polypeptide (N-terminal mitochondrial 
targeting sequence removed), indicating its two moieties (top) that are homologous to 
the small and large subunits of E. coli CPS, the two halves of the large moiety (middle), 
and the domain composition (lower bar) with domain names above, domain boundaries 
given as residue numbers, and domain functions shown below (“??” means unknown 
function), including the domain localization of the three steps of the CPS1 reaction. The 
blue arrow indicates carbamate migration between both phosphorylation domains, a 
process that is unlikely to involve the integrating domain (Thoden et al., 1999). Vertical 
lines towards the C-end map CPS1D missense mutations and rationally-designed 
mutations analyzed here (listed in Table 1). The longer lines indicate that two different 
mutations affect the same residue. (C) Stereo view of the crystallographic structure of 
the allosteric domain with NAG bound as previously modeled (Pekkala et al., 2009). 
Spheres and explicitly shown amino acid side-chains mark residues hosting missense 
mutations that are discussed here, being identified by labeling (italics, residues hosting 
CPS1D-associated mutations; residues underlined are those hosting mutations studied 
experimentally here). They are colored red if the mutation decreases stability, blue if it 
increases the Ka
NAG, purple if it causes inactivation or strong kcat reduction; and orange 
for little or no effect. The R1453:D1322 ion pair is illustrated with a dotted line. Some 
ASD secondary structure elements (including the β4-4 loop) are labeled. The Cα trace 
is shown in black and NAG in sticks and colored (C, N and O atoms, yellow, blue and 
red, respectively). The indicated loops belonging to both phosphorylation domains from 
the superimposed structural model of human CPS1 (Martínez et al., 2010) are shown 
colored, with the side-chain of D1322 in sticks. (D) Hydrophobic nucleus hosting the 
three CPS1D-associated ASD mutations that destabilized CPS1. The residues forming 
this nucleus are labeled and their hydrocarbon side chains are shown in sticks 
representation and colored grey, except the three residues that host the destabilizing 
mutations, which are labeled with larger font in red, while their side-chains are colored 
yellow. Secondary structure elements are shown in cartoon representation and are also 
labeled. Figure prepared from PDB file 2YVQ. 
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(Protein Databank file 2YVQ; Xie et al., 2007). We now have found that some 
ASD mutations have effects not expected in the previously proposed NAG site. 
With the help of molecular dynamics (MD), applying restraints based on the 
site-directed mutagenesis results, we now propose a refined NAG site structure 
where a conformational change in the β4-α4 loop could be the initial signal in 
NAG activation.  
 
 
2.3.3 Results 
 
2.3.3.1 Clinical ASD domain mutations studied 
 
The twelve reported (Häberle et al., 2011) CPS1D-associated missense 
mutations mapping in the ASD are listed in Table 1A. All of them affect 
residues that are invariant or highly conserved in NAG-sensitive CPSs. Except 
for two mutations (R1371L and Y1491H), they were given unanimous 
predictions of being likely to have negative effects by two widely used 
pathogenicity prediction servers, Polyphen-2 and MutPred (Adzhubei et al., 
2010; Li et al., 2009) (Table 1A).  
 
Table 1A highlights in bold-face the clinical mutations that were studied 
experimentally here. The study begun with the expression and purification of 
each mutant form (Fig. 2A). For all purified mutants we determined the activity 
in a standard assay, the thermal stability (Fig. 2B), and the kinetic parameters 
for ATP, ammonia, bicarbonate and NAG (see Materials and Methods). All the 
velocities (Figs. 2C and 2D) are referred to one mg of the purified protein. All 
the mutants exhibited hyperbolic kinetics for the substrates and for NAG. 
Unless indicated, the kinetic parameters for the substrates were similar to those 
of wild-type CPS1 (Díez-Fernández et al., 2013). The kinetic parameters for 
NAG, relative to those for the pure recombinant wild-type enzyme (Díez-
Fernández et al., 2013), are shown in Figs. 2D and 2E. 
 
2.3.3.2 Impact of the clinical mutations on enzyme stability 
 
Unlike the case for clinical mutations mapping in the integrating domain (Díez 
Fernández et al., 2014), which drastically reduced CPS1 production in the 
present expression system, none of the five ASD clinical mutations tested here, 
(R1371L, T1391M, L1398V, P1439L and P1462R; in bold type in Table 1A) 
decreased importantly CPS1 production or purification (Fig. 2A). Only with the 
L1398V mutation there was some reduction (50%) of enzyme production and, 
correspondingly, of the purity of the final enzyme preparation (Fig. 2A). 
Nevertheless, the enzyme form carrying this mutation exhibited a decrease of 
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5 ºC in its thermal stability (Fig. 2B), relative to wild-type CPS1, suggesting 
that L1398V might cause deficiency by speeding CPS1 inactivation. Another 
two ASD mutations, A1378T and L1381S, were previously found to cause, 
respectively, thermal destabilization and abolition of CPS1 expression because 
of degradation (Díez-Fernández et al., 2013) (Table 1A). Interestingly, the 
A1378T, L1381S and L1398V mutations map  in the very crowded and highly 
hydrophobic patch between the central β sheet and the 3 layer of the domain 
(Fig. 1D) [the ASD is folded as an 3β52 sandwich (Fig. 1C) where strands 
and helices alternate, beginning with β1)]. 
 
2.3.3.3 Effects of clinical ASD mutations on CPS1 activity and on the 
kinetic parameters for NAG 
 
The R1371L, T1391M, L1398V and P1462R mutations decreased ≥80% the 
specific activity (the activity per mg of pure CPS1) of the enzyme, determined 
using a substrate-rich and NAG-rich enzyme activity assay (Fig. 2C). Of these 
mutations, P1462R caused nearly complete (97%) inactivation. Previously, the 
clinical mutations R1453W and R1453Q were found to inactivate the otherwise 
apparently well folded mutant CPS1 (Table 1A), whereas T1443A and Y1491H 
decreased by 20-fold and 4-fold, respectively, the specific activity of the 
enzyme (Pekkala et al., 2010; Díez-Fernández et al., 2013). Thus, eight among 
the twelve reported ASD clinical mutations (Häberle et al., 2011) importantly 
decrease enzyme specific activity. Of the patients carrying these activity-
decreasing mutations, those for which the clinical condition was known 
presented severe deficiency (Table 1A).  
 
The study of the NAG activation kinetics of the purified mutant proteins (Figs. 
2D and 2E) revealed that the R1371L and T1391M mutations increase by two 
orders of magnitude the NAG concentration required for half-maximal 
activation of CPS1 (Ka
NAG). The P1439L mutation also increased Ka
NAG by 15-
fold. These important decreases in the affinity of the enzyme for NAG should 
account for the clinical deficiency, given the NAG levels prevailing in the liver  
(Tuchman and Holzknecht, 1990). The same should be the case for the T1443A 
and Y1491H clinical mutations, which had been found earlier (Pekkala et al., 
2010; Díez-Fernández et al. 2013) to increase Ka
NAG 160-fold and 50-fold, 
respectively (Table 1A). Overall, in five out of the twelve ASD clinical 
mutations the Ka
NAG was importantly increased. 
 
The large decrease in the observed enzyme activity caused by the P1462R 
mutation was largely due to decreased velocity at saturation of NAG (V[NAG]=∞; 
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 Mutations studied experimentally here are highlighted in bold-type. CPSIII is the 
piscine form of CPS, which is partially dependent on NAG (Hong et al., 1994). The 
severity of the clinical mutations is based on the clinical presentation, being graded as 
severe for neonatal presentations and/or death. P1411L was considered mild because it 
coexisted with a null second CPS1 allele (Q478*) and yet the deficiency had a late 
clinical onset indicating substantial residual CPS1 activity. No clinical information was 
available for the patient with the R1371L mutation, and, therefore, its severity is 
unknown. The patient carrying the P1462R mutation is alive, but it is uncertain whether 
this is due to a mild effect of this mutation or to residual activity associated with its 
second CPS1 allele, which was the missense change Y959C. The patient carrying the 
Table 1. CPS1 allosteric domain mutations either found in CPS1 deficiency 
patients or designed to test functional features, and their effects. 
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Y1491H mutation had a late onset presentation, but the second allele was not identified, 
and therefore the possibility cannot be excluded that the residual activity was due to a 
non-diagnosed mild second allele. When reporting their occurrence in the various 
CPSs, amino acids are in low case when found with low frequency. Variable denotes 
the occurrence at a given position, in the indicated groups of CPSs, of >4 types of 
amino acids with no constant chemical characteristics (polar, apolar, charged, etc.). 
PolyPhen-2 grades the probability of a damaging effect of an amino-acid substitution, 
from higher to lower, as Probably damaging, Possibly damaging, and Benign. MutPred 
gives a g score corresponding to the probability that a given amino-acid substitution 
was deleterious/disease-associated. For further details, see Materials and Methods. 
 
aTranslation of the cDNA reference sequence NM_001875.4 (GenBank). Nucleotide 
136 in this sequence is considered +1, since it is the A of the translation initiation 
codon. 
bWhen the contact was used as a restraint for model generation, it is specified. 
cHäberle et al., 2011. 
dEeds et al., 2006. 
eDíez-Fernández et al., 2013. 
fSummar 1998. 
gUnkown when originally reported. New data gathered on the patient. 
hPekkala et al., 2010. 
iNot present in previous docking model (Pekkala et al., 2009). 
jThis residue belongs to the carbamate phosphorylation domain. It is shown here 
because of the belief that it plays a key role in the transmission of the allosteric signal 
(see text). 
kPekkala et al., 2009. 
lNAG site lid residue and H-bond to NAG -COO- in previous docking model (Pekkala 
et al., 2009). 
mNAG site lid residue in previous docking model (Pekkala et al., 2009). 
 
 
Fig. 2D), whereas the Ka
NAG remained essentially normal (Fig. 2E). Substrate 
kinetics for this mutant were normal for all substrates (not shown) except for 
ATP. Thus, the apparent Km
ATP was increased ~10-fold (Fig. 2F), which should 
not substantially decrease enzyme activity in our ATP-rich standard assay, but 
which may contribute to the deficiency in vivo. Given the lack of substrate-
binding or catalytic machinery in the ASD, the decreased V[NAG]=∞ with normal 
affinity for NAG observed for the P1462R mutant indicates that bound NAG 
elicits a poorer activation in this mutant than in wild-type CPS1. Thus, the 
transmission of the NAG signal to the catalytic domains appears to be 
hampered. This may also be the reason for the inactivation caused by the ASD 
clinical mutations R1453W and R1453Q (Pekkala et al., 2009, 2010). 
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Figure 2. Legend 
on the top of the 
opposite page. 
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2.3.3.4 The effects of ASD mutations shed further light on signal 
transmission and NAG binding  
 
We got insight on the mechanism of signal transmission from the ASD to the 
catalytic domains by introducing the non-clinical (that is, designed on rational 
bases) D1322L mutation (Table 1B; this part of the table lists rationally 
designed mutations, with those studied experimentally here highlighted in bold-
type). D1322 is a carbamate phosphorylation domain residue that is ion-paired 
to R1453 (Fig. 1C), judged from the structural model of the complete CPS1 
molecule (Martínez et al., 2010) [this model is based on the structure of 
Escherichia coli CPS, the only CPS molecule that has been structurally 
characterized in its entirety (Thoden et al., 1999); E.coli CPS is not activated by 
NAG and is active in the absence of effectors (Meister, 1989)]. If, as proposed 
above, R1453Q and R1453W inactivate CPS1 by abolishing transmission of the 
NAG signal to the catalytic domains, the D1322L mutation should also be 
inactivating. This was indeed the effect observed (Table 1B). Although the 
mutant was soluble and was expressed as abundantly as the wild-type enzyme 
and purified similarly (Fig. 3A), its activity was <1% of that of wild-type CPS1 
(Fig. 3B).  
 
We also examined the correctness of the previously proposed NAG site (Fig. 
1C) (Pekkala et al., 2009) in the light of the effects of clinical mutations studied 
here or reported recently (Pekkala et al., 2010; Díez-Fernández et al. 2013), and 
by introducing four additional non-clinical mutations designed to test specific 
Figure 2. Production, stability, activity and kinetic properties of wild-type and CPS1D-
associated mutant CPS1 forms. (A) SDS-PAGE (8% polyacrylamide, Coomassie 
staining) of purified human recombinant CPS1, either wild-type (WT) or carrying the 
indicated mutations. St, protein markers (PageRuler Prestained Protein Ladder, from 
Thermo Scientific), with masses indicated in kDa. The arrowhead signals the position of 
the CPS1 band. (B) Inactivation upon 15-min heating at the indicated temperatures of 
recombinant human CPS1, either wild-type or carrying the indicated mutations. For 
clarity, a single line was fitted to the highly similar in terms of stability R1371L, 
T1391M, P1439L and P1462R mutants. The horizontal dashed line marks 50% 
inactivation, whereas the vertical dashed lines cross the X-axis at the temperature at 
which 50% inactivation occurs for the corresponding enzyme form. (C-E) Effects of 
CPS1D-associated ASD mutations on enzyme activity (C), apparent Vmax (D), Ka
NAG  (E), 
and ATP substrate kinetics (F). For details on the assays see Materials and Methods. 
The activities and Vmax values were always referred to 1 mg of protein. Results are given 
as fractions of the corresponding mean values for wild-type CPS1 (Fernández-Díez et 
al., 2013). In (F), the curves are hyperbolae fitted with GraphPad Prism (GraphPad 
Software, San Diego, California). The value of 1 was the velocity extrapolated at infinite 
concentration of ATP for the wild-type enzyme.  
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traits of the site (Table 1B, in bold-type; and Fig. 3). The large effects on Ka
NAG 
of the N1437D, N1440D, and T1394A mutations as well as of the presently 
studied R1371L and T1391M clinical mutations (Fig. 2E) were consistent with 
 
Figure 3. Production, activity and kinetic properties of ASD mutant forms 
not identified in CPS1D. (A) SDS-PAGE (8% polyacrylamide, Coomassie 
staining) of the wild type enzyme (WT) and of the indicated mutants. St, protein 
markers (PageRuler Prestained Protein Ladder, from Thermo Scientific), with 
masses indicated in kDa. The arrowheads signal the position of the CPS1 
band. (B-D) Effects of the ASD mutations tested on enzyme activity (B), 
apparent Vmax (C), and Ka for NAG (D). Other details are as in Fig. 2.  
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the previously predicted interactions of R1371, T1391, T1394, N1437 and 
N1440 with NAG (Pekkala et al., 2009) (Fig. 4A). The 15-fold increase in the 
Ka
NAG triggered by the P1439L clinical mutation (Fig. 2E) can be accounted by 
changes in the conformation of the β4-4 loop (composed of residues 1438-
1445), to which P1439 belongs, since this loop is an important part of the 
proposed NAG site (Figs. 1C and 4A). The localization of the NAG site was 
further supported by the results obtained here with the N1449A mutant (Fig. 
3A). This mutant exhibited a 10-fold increase in the Ka
NAG (Fig. 3D), 
compatible with a predicted hydrogen bond between the N1449 side-chain and 
the NAG -carboxylate (Fig. 1C). However, surprisingly, the W1410A, 
K1444A and F1445A mutations (Fig. 3A), which would alter residues forming 
a lid in the putative NAG site in our previous model (Fig. 1C), did not trigger 
important changes in specific activity or in NAG activation kinetics (Figs. 3B-D 
and Table 1B). Furthermore, the T1443A clinical mutation was reported to 
increase Ka
NAG 160-fold (Table 1B) (Díez-Fernández et al., 2013), suggesting 
a strong interaction between the side-chain of T1443 and the bound NAG 
molecule. Such interaction was absent in our previous model for NAG binding 
(Pekkala et al., 2009) (Fig. 1C), which is based on the experimental crystal 
structure of the NAG-free ASD (Xie et al., 2007). In this structure, the side 
chain of T1443 is far from the NAG site (Figs. 1C and 4A). Altogether, these 
observations suggested that in the NAG-bound form of the ASD, the final part 
of the β4-4 loop  changed its conformation relative to the NAG-free form (Xie 
et al., 2007), placing the side chain of T1433 near NAG and altering the 
location of the neighbouring W1410, K1444 and F1445 residues, which would 
fail to interact with the ligand (Fig. 4B).  
 
 
2.3.3.5 Modeling of the NAG site 
 
To build a refined model of the NAG site of CPS1 that was consistent with the 
mutagenesis analyses, we used restrained molecular dynamics (MD) 
simulations of the CPS-NAG complex. The restraints were based on the Ka
NAG 
variations induced by the ASD mutations (Table 1) as well as on protein-NAG 
contacts deduced from previous analyses (Pekkala et al., 2009) (see Materials 
and Methods for the restraints applied and for details on the approach used). 
The MD simulations used as a starting point the experimental ASD structure 
[protein databank (PDB; www.rcsb.org) file 2YVQ] (Xie et al., 2007) together 
with the coordinates of the NAG molecule previously obtained by unrestrained 
docking (Pekkala et al., 2009). In the energy-minimized model resulting from 
the MD simulations the position of the NAG molecule was very similar to that 
proposed previously (compare Figs. 4A and 4B). The γ-COO- group of NAG 
interacts with the side chains of R1371 and T1394 in the more exposed region 
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of the binding site. The NAG N atom forms a hydrogen bond with T1391, and 
one oxygen of the -COO- group is hydrogen-bonded by the side-chains of 
N1440 and N1449. At the floor of the site, the acetamido methyl group of NAG 
is surrounded by the L1363, I1423 and I1452 hydrophobic residues (Fig. 4C), 
whereas the acetamido carbonyl establishes a hydrogen-bonding interaction 
with N1437 (Fig. 4A). The most important variation with respect to the 
previous model was a change in the conformation of the β4-α4 loop (Figs. 4A-
D), brought about by a NAG-T1443 hydrogen-bonding MD restraint based on 
the effect of the T1443A mutation (Table 1). As a result, the side chain of 
T1443 is turned inwards and forms a hydrogen bond with the other -COO- 
oxygen of NAG, whereas the side chains of the neighbouring K1444 and F1445 
residues, which blocked entry to the empty binding site in the crystallographic 
structure of the isolated domain, are oriented outwards (Fig. 4D). These 
changes agree with the limited effect on NAG activation of the K1444A and 
F1445A mutations (Table 1). 
 
To evaluate the new model of the ASD-NAG complex, we removed the NAG 
molecule and performed unrestrained docking calculations with GOLD 
(Verdonk et al., 2003). These calculations yielded total convergence (100%) of 
the NAG docked poses (20 of 20 solutions with root mean square 
conformational deviations, r.m.s.d. ≤ 0.3 Å) (Fig. 4C). These poses generated 
by docking were very close to the energy-minimized conformation obtained by 
restrained MD (average r.m.s.d. 0.57 Å). Furthermore, the docking scores were 
1.39 times superior (63.2 ± 0.5 vs. 45.5 ± 2.4) to those obtained for our previous 
model with the same methodology and scoring function (Pekkala et al., 2009). 
 
 
2.3.4 Discussion  
 
The present and earlier experimental results (Pekkala et al., 2010; Díez-
Fernández et al., 2013 and 2014) corroborate the value of the baculovirus/insect 
cell system used here for assessing the effects of CPS1D missense mutations. In 
the case of the ASD, only for one of the twelve reported clinical mutations 
(Häberle et al., 2011), P1411L, the expression studies could not ascertain the 
disease causality of the mutation (Table 1A) (Pekkala et al., 2010). Three ASD 
clinical mutations destabilized CPS1 and eight hampered or abolished enzyme 
activity (Table 1A). Therefore, decreased specific activity is a frequent 
consequence of ASD clinical mutations. In line with the presence of the NAG 
site in the ASD, a reduced affinity for NAG is also a common consequence of 
these mutations (five of the twelve clinical ASD mutations). The three clinical 
mutations that inactivated the enzyme or that decreased its activity without 
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increasing Ka
NAG may do so by blocking or hampering transmission of the NAG 
activating signal. NAG activation of CPS is both a V and a K allosteric process 
in which Vmax is increased and the Km for ATP is decreased (Rubio et al., 1983). 
This possibly explains the increase in Km
ATP associated to the inadequate NAG 
activation proposed for the near-inactivating P1462R mutation. 
 
In addition to being valuable for making genotype-phenotype correlations, the 
present expression/mutagenesis system could help guide therapy. Patients 
carrying "kinetic" mutations causing increases in Ka
NAG could benefit from N-
carbamyl-L-glutamate (NCG) administration. This deacylase-resistant NAG 
analog (Rubio and Grisolia, 1981) and registered drug could artificially help 
saturate the NAG site of these mutants. Furthermore, NCG stabilizes CPS1 
(Díez-Fernández et al., 2013), opening the way to testing whether NCG might 
be beneficial for patients with mutations causing CPS1 destabilization. These 
mutations can also be identified with the present system (Díez-Fernández et al., 
2014), although in the case of the ASD only few clinical mutations cause 
substantial destabilization. Nevertheless, these mutations reveal that the ASD 
contributes to CPS1 stability. Such contribution was already detected for the 
corresponding domain of E. coli CPS when the deletion of this domain was 
found to lower the denaturation temperature of the enzyme (Cervera et al., 
1993). The clustering of clinical destabilizing mutations in the hydrophobic 
patch between the central β sheet and the 3 layer of the ASD (Fig. 1D) 
suggests a particularly important contribution of this region to proper ASD and 
CPS1 folding.  
 
Our analysis provides some interesting information on CPS1 activation by 
NAG. In particular, a refined model has been built that is consistent with the 
effects on Ka
NAG of all available mutations. The more salient difference between 
this model and the structure of the NAG-free crystal structure of the ASD is a 
conformational change in the final part of the β4-α4 loop to accommodate NAG 
(Figs. 4A-D). The side-chains of F1445 and T1443 are those exhibiting the 
largest displacements (Figs. 4C and 4D), respectively pointing towards the 
NAG site and away from it in the NAG-free crystal form, and the reverse in the 
NAG-bound form (Fig. 4D). The interaction of T1443 and the lack of 
interaction of F1445 with NAG would explain the respective effect and absence 
of effect on Ka
NAG of the corresponding alanine mutations. This movement 
could importantly alter the relations of the NAG site with the adjacent (Figs. 1C 
and 4E) carbamate phosphorylation domain, acting as an on/off switch for this 
catalytic domain, thus possibly being the first event in the NAG activation 
process. 
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Figure 4. The NAG site, proposed 
NAG-triggered changes, and the ASD 
surface involved in the interactions 
with the carbamate phosphorylation 
domain. NAG binding to CPS1 as 
previously proposed (A) and as 
inferred here (B) on the basis of the 
analysis of all the existing site-directed 
mutagenesis data and restrained 
molecular dynamics (MD) simulations. 
(Cont'd on top of opposite page. 
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Contacts between the ASD and the carbamate phosphorylation domain 
mediated by helix 4 and strand β5 are observed in E. coli CPS (Thoden et al., 
1999) and, correspondingly, in the structural model for the entire CPS1 
(Martínez et al., 2010) (Figs. 1C and 4E). The present results suggest that these 
contacts may be essential for stabilizing the NAG-activated conformation of the 
carbamate phosphorylation domain. Since P1462 is immediately upstream of β5 
(Fig. 4E), the P1462R mutation may cause near-inactivation by altering the 
position of strand β5 relative to the carbamate phosphorylation domain. R1453 
belongs to helix 4 (Fig. 4E), and the mutations at R1453, as well as the 
mutation of D1322, the ion-pair partner of R1453 across the interdomain divide 
(Fig. 1C), may cause inactivation because the abolition of the ion pair would 
also disturb the ASD-carbamate phosphorylation domain interaction. Actually, 
D1322 belongs to a loop that is sandwiched between the ASD and another loop 
(residues 778-787) from the bicarbonate phosphorylation domain (Fig. 1C). 
Therefore, the NAG activating signal might also propagate via this conduit to 
the bicarbonate phosphorylation domain. In any case, further progress towards 
clarification of the path of the activating signal from the ASD to both catalytic 
domains may require the determination of CPS1 structures in NAG-free and 
NAG-bound forms.  
 
Figure 4 (cont'd). Some relevant residues whose participation in the site was tested by 
site-directed mutagenesis are shown in sticks representation, with hydrogen bonding to 
NAG illustrated with broken lines. (C) Stereo view of unrestrained docking of NAG to 
the hCPS1 protein structure obtained by restrained MD simulation. The 20 NAG 
binding poses (sticks with gray-colored carbon atoms) show 100% convergence. The 
amino acids side chains proposed to surround the NAG molecule are shown in thin 
sticks representation, in blue in the conformation resulting from restrained MD, 
superimposed on the conformation (in black) observed in the crystal structure of the 
NAG-free site (PDB file 2YVQ). (D) Stereo view of the superimposition of the NAG site 
in its empty form observed in the crystal structure of the isolated ASD (grey; PDB file 
2YVQ) and in the NAG bound form modelled here by restrained MD (yellow). NAG and 
some amino acid side-chains are shown in sticks representation and are labelled. Some 
secondary structure elements are shown in cartoon representation and are also 
labeled. (E) The ASD (experimental NAG-free form, PDB 2YVQ) as seen from the 
carbamate phosphorylation domain, with cyan coloring of the regions involved in the 
interactions with this last domain. Residues involved in the interactions were identified 
in the CPS1 structure model (Martínez et al., 2010) using the PISA server (Krissinel 
and Henrick, 2007) at http://www.ebi.ac.uk/pdbe/prot_int/pistart.html. Several 
secondary structure elements including helix 4, and the residues marked as red dots 
are labeled. The NAG site is identified by the bound activator. 
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2.3.5 Materials and Methods 
 
2.3.5.1 Human CPS1 production 
 
Pure recombinant human mature liver CPS1 (CPS1) production with an N-
terminal His6-tag, and site-directed mutagenesis of the pFastBac-CPS1 vector 
encoding the enzyme to yield the desired human CPS1 mutant forms were 
performed as previously described (Díez-Fernández et al., 2013) using for the 
mutations appropriate oligonucleotides (Table 2). The same purification 
procedure (cell centrifugation, lysis, centrifugal clarification, Ni-affinity 
chromatography and centrifugal ultrafiltrative concentration) proved 
appropriate for wild type and mutant enzyme forms. Purity was monitored by 
SDS-PAGE (8% polyacrylamide gels) (Laemmli, 1978) and Coomassie 
staining. Protein was determined according to Bradford (1976).  
 
Table S1. Synthetic oligonucleotides used in site-directed mutagenesis 
p.D1322L 
Forward CCCCGGTTGAGGGATGCTCTCCCCATTCTGAG 
Reverse CTCAGAATGGGGAGAGCATCCCTCAACCGGGG 
p.R1371L 
Forward CCAGCAATCATTCCTGCCAAGAT 
Reverse ATCTTGGCAGGAATGATTGCTGG 
p.T1391M 
Forward GCTGTTTGCCATGGAAGCCACATC  
Reverse GATGTGGCTTCCATGGCAAACAGC  
p.L1398V 
Forward CCACATCAGACTGGGTCAACGCC  
Reverse GGCGTTGACCCAGTCTGATGTGG  
p.W1410A 
Forward CACCCCAGTGGCAGCGCCGTCTCAAGAAGG 
Reverse CCTTCTTGAGACGGCGCTGCCACTGGGGTGGC 
p.P1439L 
Forward GTGATTAACCTTCTCAACAACAACAC 
Reverse GTGTTGTTGTTGAGAAGGTTAATCAC  
p.K1444A 
Forward CAACAACACTGCATTTGTCCATGATAATTATG 
Reverse CATAATTATCATGGACAAATGCAGTGTTGTTG 
p.F1445A 
Forward CAACAACAACACTAAAGCTGTCCATGATAATTATG   
Reverse CATAATTATCATGGACAGCTTTAGTGTTGTTGTTG    
p.N1449A 
Forward CTAAATTTGTCCATGATGCTTATGTGATTCGGAGG    
Reverse CCTCCGAATCACATAAGCATCATGGACAAATTTAG 
p.P1462R 
Forward GTGGAATCCGTCTCCTCACTAATTTTC  
Reverse GAAAATTAGTGAGGAGACGGATTCCAC 
aBold type indicates base substitutions to introduce the desired mutation 
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2.3.5.2 CPS1 activity assays 
 
Activity was determined at 37 ºC by monitoring carbamoyl phosphate 
production as citrulline (Nuzum and Snodgrass, 1976) in a 10-min ornithine 
transcarbamylase-coupled assay (Díez-Fernández et al., 2013). The standard 
assay mixture contained 50 mM glycyl-glycine pH 7.4, 70 mM KCl, 1 mM 
dithiothreitol, 20 mM MgSO4, 5 mM ATP/5mM MgCl2, 35 mM NH4Cl, 50 mM 
KHCO3, 10 mM NAG, 5 mM L-ornithine and 4 U/ml ornithine 
transcarbamylase. One enzyme unit makes 10 mol citrulline in the 10-min 
assay. Substrate kinetics and NAG activation kinetics were studied by varying 
the concentration of one substrate or of NAG while other assay components 
were kept fixed at the concentrations used in the standard reaction mixture. 
ATP was added as an equimolar mixture with MgCl2. Therefore, since 20 mM 
MgSO4 was present in the reaction mixture, Mg
2+ was always in 20 mM excess 
over ATP. Kinetic data were fitted to hyperbolae using the GraphPad Prism 
program (GraphPad Software, San Diego, CA). Values for activity and for 
V[NAG]=∞ are referred to 1 mg of protein, thus being specific activities. These 
values and Ka
NAG values are the means±SE for at least three replicate estimates. 
To better compare the magnitude of the changes in the activity and the kinetic 
constants with those reported previously, the values for these constants and for 
their standard errors have been normalized by dividing them by the 
corresponding mean values for the same parameters for wild-type CPS1 
(tabulated in Díez-Fernández et al., 2013). 
 
To monitor the thermal stability of CPS1 mutants, 0.5 mg/ml of the indicated 
enzyme form in 50 mM glycyl-glycine pH 7.4, 10% glycerol, 0.5 M NaCl, 30 
mM imidazole and 2 mM dithiothreitol were incubated 15 min at the indicated 
temperature. Then, the mixtures were rapidly cooled at 0°C and enzyme activity 
was determined immediately in the standard assay at 37ºC. Data are means±SE 
for at least duplicate assays. 
 
 
2.3.5.3 Restrained molecular dynamics (MD) and docking calculations 
 
We first used MD simulations with restraints based on the Ka
NAG variations 
induced by CPS mutations (Table 1) and on the contacts obtained in previous 
unrestrained docking runs (Pekkala et al., 2009) (see below). The calculations 
used as a starting point the PDB structure of the human CPS C-terminal domain 
(PDB file 2YVQ) (Xie et al., 2007) together with the coordinates of the NAG 
molecule previously obtained by docking and energy minimization (Pekkala et 
al., 2009). The 1415GQNPS1419 sequence missing in the crystallographic 
structure was modelled with MOE (CCG Inc.) using a method based on PDB 
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searches. The potential energy of the initial system was progressively 
minimized before subjecting the CPS-NAG complex to two MD runs of 200 ps 
and 100 ps, respectively, at 300 K. During these runs, a soft positional restraint 
was applied to all protein atoms except those of β1-α1, β2-α2, β3 and β4-α4 
residues close to the NAG binding site. The temperature of the system was 
slowly reduced to 0 K during the second half of each run, and NAG soft 
positional restraints were applied in the first simulation but eliminated in the 
second run. The following five hydrogen-bonding restraints were applied 
during the simulations, based on mutant Ka
NAG increments equal or greater than 
50-fold in Table 1 and the corresponding hydrogen-bonding contacts observed 
in unrestrained docking analyses (Pekkala et al., 2009): O NAG-HNη
R1371, 
HNNAG-Oγ
T1391, O NAG-HOγ
T1394, OAc
NAG-HNδ
N1437 and O NAG-HNδ
N1440. 
An additional O NAG-HOγ
T1443 restraint was imposed on the remaining 
O  atom of NAG on the basis of the 160-fold increase in Ka
NAG detected for 
the T1443A mutant (Table 1). Throughout these calculations we used the ff10 
force field of AMBER 8.0 (Case et al., 2005), and a generalized Born model for 
simulating an aqueous environment. The final coordinates of the hCPS-NAG 
complex were generated by minimizing the potential energy of the last MD 
snapshot. This model was evaluated by means of unrestrained docking 
calculations. These were carried out using the GOLD package (version 5.2) 
(Verdonk et al., 2003) with the GoldScore fitness function, as in the previous 
calculations (Pekkala et al., 2009).  
 
 
2.3.5.4 Other techniques 
 
The experimental crystal structure of the ASD (PDB file 2YVQ) (Xie et al., 
2007) and the corresponding models for the NAG-bound form (Pekkala et al., 
2009; and the present work) and the E. coli CPS structure-based CPS1 model 
(Martínez et al., 2010) have been used for analysis, superimpositions, and for 
structural representations, using Pymol (DeLano Scientific; 
http://www.pymol.org). Amino acid conservation was determined by ClustalW 
sequence alignment (Larkin et al., 2007) of either CPS1, CPSIII or other CPSs 
from 14, 6 and 26 species, respectively. The PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) (Adzhubei et al., 2010) and MutPred 
(http://mutpred.mutdb.org/) (Li et al., 2009) servers were used to assess in silico 
the disease-causing potential of the clinical mutations.  
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Since the main body of this PhD dissertation consists of three publications 
having their independent discussions, in this global discussion we will try to 
avoid as much as possible repetition of topics already discussed, dealing with a 
limited number of relevant and untreated issues. 
 
A point that we have not addressed in the Results section concerns the bases of 
the reported impact on vascular pathology of a widespread polymorphism, 
p.Thr1406Asn, that maps in the allosteric domain of the human enzyme [134-
139]. We have worked here with the most frequent form of this polymorphism, 
the threonine variant (rs1047891, Ensemble database; allelic frequencies of 
Thr/Asn forms, 0.7/0.3; 
http://www.ensembl.org/Homo_sapiens/Variation/Explore?db=core;r=2:210675
283-210676283;v=rs1047891;vdb=variation;vf=823866), since Powers-Lee’s 
group, using the S. pombe-expressed enzyme, only reported minor effects of the 
p.Thr1406Asn substitution: ~20% decrease in kcat and 1.2-fold, 1.7-fold and 
1.5-fold increases in the values for the Km
ATP, Km
ammonia and Ka
NAG, respectively 
[140]. Given the modesty of these changes and the large amount of extra time 
and effort needed, we decided to set aside the idea of introducing all the 
presently studied mutations in one and the other allelic forms of the enzyme for 
this polymorphism. 
 
Another question not dealt with in the Results section is the path that led us to 
utilize the baculovirus/insect cell system for expression of CPS1. We needed a 
system capable of producing large amounts of the pure human protein and that 
allowed mutations to be introduced at will. These requirements were essential 
for proper characterization of the enzyme activity and, where necessary, of the 
partial activities of the enzyme (much less active than the complete reaction). It 
was also convenient to have a highly pure enzyme preparation for determining 
the kinetic parameters of even very poorly active enzyme mutants. In addition, 
it was anticipated that a robust system was needed to be able to isolate the tiny 
fraction of the enzyme that might be anticipated to be soluble with some of the 
mutants. Another goal of these studies was crystallographic, which was also 
expected to require large amounts of highly pure protein even with the 
miniaturization and automation of present-day crystallographic techniques. 
 
Early attempts of recombinant expression in our group were carried out in Dr. 
Cervera's laboratory using cloned mature rat CPS1. E. coli, the methanol-
consuming yeast Pichia pastoris and human embryonic kidney 293T 
(HEK293T) cells were used without real success, since the expression levels of 
soluble protein were always low (unpublished results). The finding by Powers-
Lee [163] that the recombinant mature CPS1 from Rana catesbeiana could be 
expressed in Schizosaccharomyces pombe led the group of Dr. Cervera to begin 
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the process of attempting this expression in S. pombe, simultaneously with an 
attempt of using baculovirus and insect cells. The latter cells appeared 
promising: their animal nature, the strength of the promoters used and the 
reputation of having an excellent folding machinery (see for example 
http://www.embl.de/pepcore/pepcore_services/cloning/choice_expression_syste
ms) made them good (although expensive and time-consuming) candidates for 
expressing animal CPS1. Good results were obtained with this system before 
the S. pombe system was ready in our hands, and this led us to adopt 
exclusively the baculovirus/insect cell expression system.  
 
We feel that the utilization of this expression system has been rewarding 
concerning the understanding of the disease-causing role of CPS1D-associated 
mutations. Up to now our group has analyzed, either using the rat [14] or 
human recombinant CPS1 (Chapters 1-3 of the Results), 40 clinical missense 
mutations and 2 polymorphisms. While our studies proved minor or no 
differences relative to the wild-type in activity or stability of the two 
polymorphic forms, most of the clinical mutations studied revealed a disease-
causing role either because of gross misfolding, important reduction in enzyme 
stability, inactivation of the enzyme without evidence for misfolding, reduced 
kcat, or reduced apparent affinity for a substrate or for the essential CPS1 
activator NAG. In some cases several of these effects coexisted for the same 
mutant as for many mutations of the integrating domain (Chapter 2 of the 
Results). For these mutants highly decreased amounts of soluble enzyme were 
produced, indicating an unfavorable partitioning of the mutant enzyme between 
the well-folded and misfolded forms during the folding process. However, our 
observations showed also that the soluble, apparently well-folded fraction of the 
enzyme exhibited in many cases important kinetic aberrations.  
 
In any case, the overwhelming evidence extracted from our experiments is that 
most of the mutations reported in patients with CPS1D [12] that have been 
examined here were associated with important aberrations detected "in vitro", 
clearly indicating a disease-causing role. This evidence challenges our initial 
proposal that missense mutations found in patients are uncertain to have a 
disease-causing role. Since most reported missense mutations that we have 
examined "in vitro" are pathogenic, it is likely that the vast majority of all the 
mutations in the patient database are pathogenic. Indeed, evidence against their 
being polymorphisms (at least frequent polymorphisms) is growing with the 
growth of human genomes and exomes being analyzed, since otherwise it 
would be increasingly possible that they are found in homozygosis in some of 
the persons that have been fully sequenced already (see for example 
http://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&dopt=Graphics&list_uids=1
373). Nevertheless, this tentative conclusion should be nuanced by the fact that 
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only two non-catalytic domains and a small selection of mutations in other 
domains has been studied "in vitro" thus far. Dr. Rubio's laboratory, in 
collaboration with Dr. Häberle, are continuing studies in other CPS1 domains to 
try to substantiate or refute this provisional conclusion. In any case, predictions 
based on in vitro results must be prudent, given the still unknown elements that 
may be behind some still rare but nevertheless real cases of variability in the 
clinical presentation associated with the same mutant alleles, as reported for 
two splicing mutations in two cases of CPS1 deficiency [209].  
 
Apart from testing the disease-causing role of CPS1D mutations, the 
baculovirus/insect cell expression system used here enabled us to deepen into 
our understanding of the roles of CPS1 domains and of CPS1 activation by 
NAG. For example, although we have studied few mutations affecting the ~40 
kDa N-terminal region of unknown function of CPS1 (Chapter 1 of the 
Results), the results with those mutations studied here fit the lack of catalytic or 
substrate and NAG-binding function of this region. In contrast, a clear function 
of this region on enzyme stabilization and on activation of catalysis (kcat effect) 
has been documented here. The stabilizing role of this region recalls the strong 
stabilization triggered in E. coli CPS upon association of the small and large 
subunits of this bacterial enzyme [69]. The activating role of this region is also 
supported by prior studies of our laboratory [14] with the rat liver enzyme, in 
which the mutations p.Ser123Phe and p.His337Arg were found to importantly 
reduce kcat without affecting the apparent affinities for the substrates or for 
NAG. This activating role is supported also by the previous finding of Powers-
Lee’s group [140] that the removal of the entire N-terminal region of the human 
enzyme decreased 700-fold enzyme activity. With E. coli CPS it had been 
found that the occupation of the glutamine site in the small subunit of the 
enzyme (which corresponds to the N-terminal region of CPS1) activates 
catalysis by the large subunit [6], an effect that might be reminiscent of the N-
terminal region-dependent activation observed with CPS1. In summary, our 
present findings and prior observations of our laboratory and of Powers-Lee's 
group clearly exclude an absolute requirement of the N-terminal region for 
catalysis, but they provide strong reasons (stability and activation) for the 
retention by CPS1 of this N-terminal region despite the loss of the glutaminase 
activity associated to this region in all CPSs except CPS1 [1-3]. In any case, 
more experiments are required to further substantiate the role in CPS1 of the 
most N-terminal domain of this N-terminal region, since the glutaminase 
activity-attenuating function reported for this domain in the glutamine-utilizing 
CPSII [160] cannot operate in CPS1, which lacks glutaminase activity.  
 
Concerning the phosphorylation domains of CPS1, our site-directed 
mutagenesis studies have been restricted to two mutations in the bicarbonate 
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phosphorylation domain. The reason for not exploring more these two 
homologous domains is the fact that, given the identity of function of these 
domains with the corresponding domains of other CPSs [1-3], less novel 
information could be gathered from mutations mapping in these domains. 
Actually, there is a long history of mutational studies with substitutions in these 
domains of other CPSs, particularly of E. coli CPS [92,153,154,210-213]. 
Furthermore, since these domains closely resemble biotin carboxylase [82], an 
enzyme component that also catalyzes bicarbonate phosphorylation [83,84], the 
mutations introduced into this last enzyme [214,215] also provided information 
on the functions of the corresponding residues of CPS1. 
 
In any case, of the two mutations affecting the bicarbonate phosphorylation 
domain of human CPS1 that were introduced in the present studies (Chapter 1 
of the Results), p.Ala438Pro inactivated the enzyme and p.Thr544Met had 
paramount effects on the apparent Km value for bicarbonate (~60-fold increase) 
and on the Ka value for NAG (~25-fold increase),  whereas the Vmax was 
decreased ~five-fold and the Km
ATP was increased ~4-fold. These results 
suggest a primary affectation of the site for bicarbonate with a secondary effect 
on the affinity for NAG stemming from the cross-talk between the bicarbonate 
phosphorylation site and the NAG site [40,61]. Interestingly, in pioneer work 
[87], our group introduced in E.coli CPS the p.Ala126Met mutation, aiming at 
replicating in this bacterial enzyme the p.Thr544Met mutation of human CPS1. 
The observed effects were similar to those found here with the human enzyme: 
the Km values for bicarbonate and for ATP were increased 15-fold and 4-fold, 
respectively, and the Vmax was decreased, in that case 15-fold. Furthermore, 
ornithine activation of the bicarbonate phosphorylation step was hampered 
(tested at a single concentration of ornithine), an effect that may be reminiscent 
of the negative effect of p.Thr544Met on the activation by NAG of human 
CPS1.  
 
These findings with the p.Thr544Met and p.Ala126Met respective mutations of 
human and E. coli CPSs provide strong support for the utilization of E. coli 
CPS as a surrogate of human CPS1. Nevertheless, they clearly show that the 
effects of placing the same amino acid residue at a given location in the 
sequence may differ quantitatively depending on whether the enzyme is human 
CPS1 or bacterial CPS. In this work no other phosphorylation domains 
mutations have been examined for their effects on both the human and the 
bacterial enzymes. However, our group introduced [14] in rat CPS1 the human 
clinical mutations affecting the bicarbonate phosphorylation domain 
p.Thr471Asn, p.Gln678Pro and p.Pro774Leu, whereas the mutations 
corresponding to the last two of these mutations, p.Gln262Pro and p.Pro360Leu 
were introduced into the bacterial enzyme [87], studying their effects. Of these 
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mutations p.Gln678Pro and its bacterial counterpart p.Gln262Pro had as their 
major effects the dramatic destabilization of the corresponding enzymes. 
Human mutation p.Pro774Leu and the bacterial counterpart p.Pro360Leu 
dramatically decreased enzyme activity, in the first case not permitting activity 
detection, whereas in the second the detection was possible but it was heavily 
dependent on the presence of the activator ornithine. With the bacterial enzyme 
it was concluded [87] that the equilibrium between the inactive and active 
conformations of the enzyme that is displaced by ornithine towards the active 
form was heavily displaced in the mutant in the direction of the inactive 
conformation. Given the fact that CPS1 is much less active in the absence of the 
activator NAG than the E. coli enzyme in the absence of ornithine, the lack of 
activity of the rat enzyme with the mutation p.Pro774Leu might stem from a 
similar displacement of the equilibrium of the mutant CPS1 towards the 
inactive form. It is interesting that the p.Thr471Asn mutation also caused in the 
rat enzyme a large decrease in the affinity for NAG, highlighting the 
importance of the bicarbonate phosphorylation domain in the process of CPS1 
activation by NAG, leading to propose that for this mutant the cross-talk 
between the phosphorylation site of the bicarbonate phosphorylation domain 
and the NAG binding site in the C-terminal domain of CPS1 is hampered. 
Therefore, the findings concerning mutants of the bicarbonate phosphorylation 
domain of CPS1 not only stress the expected role of this domain in bicarbonate 
binding and phosphorylation, but they also show the importance of this domain 
for ensuring a good affinity of the enzyme for NAG and good NAG activation. 
In addition, the comparison of the results with the corresponding mutations in 
the bacterial and rat enzymes further supports the value of the bacterial enzyme 
as a model of human CPS1, while highlighting that quantitative differences 
should be expected even for qualitatively similar effects with one and the other 
enzyme. 
 
Concerning the carbamate phosphorylation domain, we have not introduced any 
mutation mapping therein in rat or human CPS1. However, our group 
introduced in E. coli CPS [87] three mutations, p.Val640Arg, p.Arg675Leu and 
p.Ser789Pro, that are the counterparts of the human CPS1 mutations affecting 
the carbamate phosphorylation domain p.Ile1054Arg, p.Arg1089Leu and 
p.Ser1203Pro. Of these E. coli CPS mutations, p.Ser789Pro selectively 
abolished catalysis of the carbamate phosphorylation step, whereas the other 
two mutations drastically decreased the activity for this step, also decreasing the 
affinity for the nucleotide and for carbamate (monitored as affinity for 
carbamoyl phosphate). Studies of the two partial reactions of the enzyme that 
reflect the individual steps of bicarbonate phosphorylation and carbamate 
phosphorylation showed that the p.Val640Arg mutation (and, by inference, the 
human CPS1 p.Ile1054Arg mutation) dramatically slows both phosphorylation 
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steps, leading to the conclusion [87] that this mutation, by primarily hampering 
the opening of the carbamate phosphorylation site to allow product release and 
nucleotide binding, also hampers the opening of the bicarbonate 
phosphorylation site. This supports the view (based on earlier mechanistic 
studies of the CPS1 reaction [52-55]) that this opening of both phosphorylation 
sites is a concerted process occurring simultaneously at both nucleotide sites. 
The effects of the p.Arg675Leu mutation (and of p.Arg1089Leu of human 
CPS1) points to selective near-abolition of catalysis at the carbamate 
phosphorylation site, whereas the effects of the p.Ser789Pro (and thus of 
p.Arg1089Leu of human CPS1) mutation were attributed to disturbance of the 
K+ loop of the bicarbonate phosphorylation domain, a loop that is considered 
essential for activity [77].  
 
The only mutations affecting the carbamate phosphorylation domain that were 
studied directly on the recombinant human enzyme were the p.Cys1327Ala and 
p.Cys1337Ala mutations [164], two cysteine residues that change strongly their 
accessibility and even their ability to form an intramolecular disulfide bridge 
depending on whether NAG is bound or is not bound to the enzyme [213,214].  
The p.Cys1327Ala mutation decreased 5-fold catalytic efficiency but it 
increased 7-fold the apparent affinity for NAG. This mutation was proposed to 
decrease protection of the enzyme against oxidative insults [164], something 
that could also apply to the p.Cys1327Arg mutation reported in a patient with 
CPS1D [12]. Nevertheless, the inactivating effect of the oxidation of these 
cysteines might be due to their cross-linking by a disulfide bridge [216,217], 
which probably compromises NAG activation of the enzyme (see below). 
 
Given the extensive treatment and discussion in Chapter 2 of the Results of the 
numerous mutations introduced into the Integrating domain, we will make little 
mention here of this domain. As it might have been anticipated from the central 
location of this domain, which makes extensive contacts with both 
phosphorylation domains and which also contacts the N-terminal region of the 
enzyme (see Chapter 2 of the Results), a strong integrating and stabilizing 
function has been detected for this domain. Nevertheless, although misfolding 
and/or destabilization are the major effects of mutations falling on this domain, 
being the reason for the prominence of this domain in the mutational landscape 
of CPS1D patients [12], decreased Vmax and even decreased apparent affinity 
for NAG and ATP have been observed with some of the mutations mapping 
therein. These observations suggest that this domain may be involved directly 
or indirectly in the cross-talk between the NAG site and the catalytic centers 
and in the concerting of the opening of both active centers in the two 
phosphorylation domains [87, 88]. Furthermore, this domain contacts the active 
site of the bicarbonate phosphorylation domain, which is to be opened [88].   
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Similarly, we have dealt extensively in Chapter 3 of the Results with the 20 
kDa C-terminal domain and thus we will make little mention of it here. This 
domain is known to harbor the binding sites for effectors in different CPSs 
[13,17,68-71,89-92]. The relatively low frequency of mutations mapping in this 
domain that cause misfolding possibly account for the lack of particular 
prominence of this domain in the clinical mutation landscape [12]. However, 
the frequency among the mutations affecting this domain of those that decrease 
the affinity for NAG endow this domain with particular therapeutic potential, 
rendering these mutations good candidates for using N-carbamylglutamate 
(NCG) for helping saturate in these cases the NAG site. It has to be 
remembered that, given the protein restriction that is generally applied to 
patients with urea cycle disorders [27,30], NAG levels might be low in these 
treated patients even if ammonia levels were increased. If this were the case, 
patients carrying NAG site-affecting mutations would be negatively affected by 
the low NAG levels, and in these cases NCG might be highly beneficial. 
Actually, it is to be considered whether mutations that do not affect the NAG 
site but that nevertheless increase the Ka for NAG because of the cross-talk 
between phosphorylation and allosteric domains might also benefit from NCG 
saturation therapy. 
 
An important inference resulting from the present studies concerns the 
mechanism of NAG activation of CPS1. Clearly, a movement in the β4-4 loop 
belonging to the NAG site but being at the interface with the carbamate 
phosphorylation domain appears to be a key early event in the process of 
activation (Chapter 3 of the Results and Fig. 23). A loop of the carbamate 
phosphorylation domain (residues 1318-1332) and an interacting surface of the 
allosteric domain have also been identified here as key elements in the 
transmission of the allosteric signal from this last domain to the carbamate 
phosphorylation domain. Interestingly, Cys1327 belongs to the 1318-1332 loop, 
explaining why the trapping of this loop in an inappropriate conformation due 
to disulfide bridge formation with the nearby Cys1337 might prevent activation, 
causing loss of enzyme activity [216,217]. Interestingly, a loop (residues 778-
787) of the homologous bicarbonate phosphorylation domain has been 
proposed here (Chapter 3 of the Results) as the potential receiver of the 
allosteric signal in that phosphorylation domain, with passage of the signal via 
the 1318-1332 loop of the carbamate phosphorylation domain. Clearly, we do 
not know the details of this signal transmission process, but we have identified 
some crucial elements involved in such transmission. From our data and the 
structural model for human CPS1 it can be anticipated that NAG has long-range  
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effects, with propagation of a movement in the peripheral allosteric domain  to 
both phosphorylation centers. Given the mutual homology of both 
phosphorylation domains [1,74,77], the 1318-1332 and the 778-787 loops are 
homologous loops. Thus, these two loops may be expected to have similar 
interactions with other elements of the phosphorylation domain to which each 
loop belongs. Judged from the E. coli CPS structure [77], these two loops 
contact in both phosphorylation domains with the K+ loop and with other 
elements of the nucleotide site that are key elements of the catalytic machinery 
of these domains. This gives further credence to the view that similar NAG-
Figure 23. Graphic scheme of the CPS1/NAG switch for urea cycle control. 
Structural model of human CPS1 [97] in transparent surface representation, 
with the allosteric domain in cartoon representation and shown in the NAG-
free form (gray, PDB 2YVQ) and in the modelled NAG- and ADP-bound form 
(in yellow). The bound NAG molecule and the side chains of Thr1443 and 
Arg1453 (not labelled for clarity) are shown in sticks representation. Solid 
blue arrows indicate the proposed allosteric signal transmission path, whereas 
the broken arrow indicates the β4-4 loop movement. Transmission loops are 
shown in backbone string representation and are labeled. Black empty arrows 
schematize the path of carbamate from the bicaronate phosphorylation site to 
the carbamate phosphorylation site. Green and brown denote one and the 
other phosphorylation domains. A mini urea cycle is included to symbolize the 
cycle-controlling role of the CPS1 step 
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triggered conformational changes in these two homologous loops could have 
similar effects on the corresponding phosphorylation domains. Thus, the 1318-
1332 and the 778-787 loops can be called signal transmission loops (Fig. 23). 
Since they are also found in E. coli CPS [77], they may transmit the allosteric 
signals that operate in other CPSs. The identification of these two loops paves 
the way for further site-directed mutagenesis studies for exploration of the 
signal transmission process within the catalytic parts of the enzyme molecule. 
 
Despite all the above, a picture in which the cross-talk between the NAG site 
and both phosphorylation domains occurs exclusively via the 1318-1332 and 
the 778-787 loops may be oversimplistic, given the 50-fold increase in Ka
NAG 
and ~4-fold decrease in kcat 
 caused by the p.Tyr1491His mutation [14]. This 
mutation maps nine residues upstream from the C-terminus, in a region that 
when digested in rat liver CPS1 resulted in a very important decrease in the  
 
Figure 24. Model of the most C-terminal part of the allosteric domain (in grey) and its 
modelled (on the basis of the E. coli CPS structure) relations with both catalytic 
domains (green and orange, in surface representation of the relevant parts of these 
domains) [97]. The side chains of the residues reported to be mutated in patients with 
CPS1D, T471 and Y1491 [12], are shown in blue sticks, with blue dots representation 
of its Van der Waals sphere to highlight their clamping between both phosphorylation 
domains. Note the long grey string that connects this residue to the remainder of the 
allosteric domain (not shown) to suggest that the catalytic domains may exert traction 
on this domain if, because of conformational changes, they move away from it, 
bringing with them the clamped Y1491. 
 
DISCUSSION 
 
146 
 
 
affinity for NAG [66]. It appears highly unlikely that this region, not 
represented in the crystal structure of the allosteric domain of human CPS1 
[93], directly participates in the NAG site. If similar to E. coli CPS [77], this C-
terminal part of the enzyme would project away from the allosteric domain 
body, sitting on both phosphorylation domains, with the phenolic ring of 
Tyr1491 sandwiched between them (Fig. 24). In this respect, the already 
discussed bicarbonate phosphorylation domain mutation p.Thr471Asn [12] 
affects a residue that in the structure of E. coli CPS (Thr56) belongs to a 
hydrophobic cluster that also includes Val1065, the bacterial counterpart of 
human CPS1 Tyr1491. Since, as mentioned above, the p.Thr471Asn mutation 
dramatically decreased the affinity for NAG of rat CPS1 [14], this hydrophobic 
cluster appears a clear candidate to being involved in the passage of signals 
between the bicarbonate phosphorylation domain and the enzyme C-terminus. 
In this respect it is worth remembering that NAG binding studies [61] revealed 
a strong increase in CPS1 affinity for NAG when ATP was added. Thus, ATP 
binding to the phosphorylation domains enhances NAG binding by the 
allosteric domain. Perhaps, if the C-terminal region of CPS1 anchors the 
allosteric domain on both phosphorylation domains as in E. coli CPS, this 
region could transmit signals to the core of the allosteric domain by pulling 
from it if ATP binding alters the relative disposition of the catalytic domains 
with respect to the allosteric domain. 
 
 Summarizing all our work, we have provided a relatively easy instrumental 
system for testing effects of amino acid mutation and perhaps also of amino 
acid posttranslational modifications on the catalytic and controlling functions of 
CPS1. This system, by providing very large amounts of pure human CPS1, has 
opened the way to determining the crystal structure of human CPS1, a feat that 
is presently at reach. Thus, in collaboration with my work, other group 
members (Luis Mariano Polo and Sergio de Cima) have succeeded in obtaining 
well-diffracting crystals of CPS1 grown in the presence and in the absence of 
mixtures of NAG, ADP and Mg2+ (Fig. 25). Determination of these crystal 
structures is likely to provide a highly detailed description of the process of 
NAG activation, helping answer many unclarified questions on CPS1 (for 
example, which is the reason for the high affinity of CPS1 for ammonia). I will 
be an author in the expected manuscript reporting the anticipated structural 
findings, but for reasons of time and since I will not be the main author, this 
manuscript could not be included into the present PhD dissertation. 
 
I would like to end this discussion by highlighting the future potential of the 
application of the present system to human CPS1. It may help determine the 
role of posttranslational modifications on CPS1 function and via CPS1, on urea 
cycle control. As already mentioned in the Introduction, proteomics studies are 
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expanding our view of the modifications observed in the whole human and 
animal proteome, and CPS1 has not escaped this trend, actually having been 
signalled by a number of studies [129-133] as the subject of changes having 
potentially high impact on urea cycle control and even linked to aging [129] 
and to secondary hyperammonemia [130]. Although the structure of CPS1 will 
eventually provide a reference frame for judging the potential impact of these 
modifications on human CPS1 activity and control, it would be essential to 
analyze each amino acid change in a clean system like the one used here to 
express CPS1. In a first approximation, this could be done by making amino 
acid replacements that could mimic the posttranslational modifications 
Figure 25. Left, crystals of human CPS1 without (top) and 
with (down) NAG and ADP. Right, illustration of the 
diffraction pattern (NAG/ADP form, up to 2.6 Å resolution).  
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(similarly to the substitution of phosphorylated serines by aspartate or 
glutamate) or even by exploiting new procedures for inserting in the sequence 
abnormal amino acids [218]. The long-term aim would be to reconstitute in 
vitro the whole posttranslational modifying/demodifying system, or to 
coexpress in the insect cells other elements of the modifying machinery.  
 
In addition, our work has opened a way for future personalized treatment of 
CPS1D patients. In the case of phenylketonuria, a clinically useful achievement 
was the observation of phenylalanine hydroxylase stabilization by chaperoning 
by its essential cofactor tetrahydrobiopterin [32]. Likewise, in this work we 
proved the stabilization of CPS1 by its substrates and activators NAG and NCG 
(Chapter 1 of Results). However, the possibility of finding more efficient 
pharmacological chaperones can be now approached thanks to our expression 
system, and these could eventually be used to treat CPS1D patients with 
unstabilizing mutations. In the same way, as above mentioned, CPS1D patients 
with NAG site-affecting mutations and with mutations outside the NAG-
binding domain but which are involved in the cross-talk between 
phosphorylation and allosteric domains could benefit from the commercially-
available NCG saturation therapy. However, some mutations might totally 
hamper binding of activating molecules in the NAG-binding site. In these cases, 
other activating molecules could be tested, that, like glycerol, (Chapter 1 of 
Results) activate CPS1 to some extent by unknown mechanisms that do not 
appear to involve the NAG site. As a matter of fact, this new research line has 
already been started as part of my postdoctoral work supervised by Dr. Häberle.  
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1. Recombinant human CPS1 is efficiently produced in a commercial 
baculovirus/insect cell system. The recombinant enzyme mimics 
natural CPS1 in its kinetic and molecular properties and in needing 
the essential activator N-acetyl-L-glutamate (NAG) although 
cryoprotectants can partially replace NAG. 
 
2. Limited proteolysis showed that recombinat CPS1 has the same 
domain composition as other CPSs, with interdomain hinges at 40 
kDa and 20 kDa from the enzyme N-terminus and C-terminus, 
respectively.  
 
3. This CPS1 production system is effective for testing the effects on 
the enzyme of the missense mutations found in patients with CPS1 
deficiency (CPS1D). For patients with informative genotypes 
generally there was agreement between the severity of the effects in 
vitro and the seriousness of the patient phenotype. Lack of any in 
vitro effect of two trivial polymorphisms confirmed the high value 
of this system for discriminating between disease-causing and non-
causing sequence variants of CPS1. 
 
4. A disease-causing role has been proven for the majority of the 
missense mutations identified in CPS1D patients that were tested 
with this system. Some mutations caused gross misfolding or 
markedly decreased enzyme stability, and/or they inactivated the 
enzyme or triggered kinetic aberrations such as decreased apparent 
kcat or decreased apparent affinity for one or the other of the three 
substrates or for the activator NAG.  
 
5. The effects of the tested CPS1D mutations that mapped in the N-
terminal 40-kDa region agree with the view that this region, dispite 
having become catalytically inactive, has been preserved in CPS1 
because of its stabilizing and enzyme-activating actions. 
 
6. The effects of the tested mutations mapping in the bicarbonate 
phosphorylation domain (the more N-terminal domain of the 120-
kDa C-terminal moiety of CPS1) affected bicarbonate binding 
and/or catalysis, but they also decreased the affinity for NAG, 
confirming the existence of cross-talk between the bicarbonate 
phosphorylation domain and the NAG-binding domain. 
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7. A small central domain of previously unknown function that is 
intercalated between both phosphorylation domains is concluded to 
have high mutational eloquence in CPS1D because its mutations 
frequently cause enzyme misfolding. Thus, this domain plays a 
paramount integrating role in the multidomain enzyme architecture, 
and it is called from here on the "Integrating Domain". 
 
8. The low mutational eloquence in CPS1D of the C-terminal domain 
is possibly due to the fact that mutations mapping in this domain 
rarely destabilize importantly or cause gross misfolding of CPS1. 
Some of these mutations inactivate the soluble enzyme and most of 
them decrease enzyme activity, with many mutations strongly 
decreasing the affinity for NAG. Thus, the negative effects of most 
of these mutations are largely due to interference with NAG binding 
or to hampered transmission of the activating signal to the 
phosphorylation domains of the enzyme. 
 
9. A mechanism for NAG activation based on the observation of the 
effects of missense mutations is proposed in which NAG triggers a 
movement of the β4-α4 loop of the C-terminal domain that 
drastically alters the interactions of this loop with the carbamate 
phosphorylation domain. Signal transmission involves Arg1453 
from helix α4 and Asp1322 from the 1318-1332 loop of the 
carbamate phosphorylation domain. This loop, and the homologous 
778-787 loop of the bicarbonate phosphorylation domain, are called 
here the signal transmission loops because they interact with the 
active centers of both phosphorylation domains and are proposed 
here to be the mediators of NAG activation. 
 
10. The NAG analogue and orphan drug N-carbamyl-L-glutamate 
(NCG) is proposed to be potentially useful in the treatment of CPS1 
deficiency due to mutations that decrease the affinity for NAG 
(saturation therapy) and of those that decrease enzyme stability 
(pharmacological chaperoning) since in the presence of ATP, NCG 
is found here to stabilize CPS1.  
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